Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2571484,total plasma clearance,"In this study the elimination kinetics of cilastatin in rats at doses of 5, 10, 20, 50, 100, and 200 mg/kg iv were demonstrated to be dose dependent, with total plasma clearance and non-renal clearance falling from 20.2 +/- 3.1 ml/min/kg and 17.7 +/- 3.3 ml/min/kg (mean +/- S.D.) at the 5 mg/kg dose to 11.4 +/- 1.2 ml/min/kg and 5.30 +/- 1.2 ml/min/kg, respectively, at the 200 mg/kg dose, whereas the volume of distribution of the drug remained unchanged.",Dose-dependent kinetics of cilastatin in laboratory animals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],20.2,2224,DB01597,Cilastatin
,2571484,non-renal clearance,"In this study the elimination kinetics of cilastatin in rats at doses of 5, 10, 20, 50, 100, and 200 mg/kg iv were demonstrated to be dose dependent, with total plasma clearance and non-renal clearance falling from 20.2 +/- 3.1 ml/min/kg and 17.7 +/- 3.3 ml/min/kg (mean +/- S.D.) at the 5 mg/kg dose to 11.4 +/- 1.2 ml/min/kg and 5.30 +/- 1.2 ml/min/kg, respectively, at the 200 mg/kg dose, whereas the volume of distribution of the drug remained unchanged.",Dose-dependent kinetics of cilastatin in laboratory animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],17.7,2225,DB01597,Cilastatin
,2571484,non-renal clearance,"In this study the elimination kinetics of cilastatin in rats at doses of 5, 10, 20, 50, 100, and 200 mg/kg iv were demonstrated to be dose dependent, with total plasma clearance and non-renal clearance falling from 20.2 +/- 3.1 ml/min/kg and 17.7 +/- 3.3 ml/min/kg (mean +/- S.D.) at the 5 mg/kg dose to 11.4 +/- 1.2 ml/min/kg and 5.30 +/- 1.2 ml/min/kg, respectively, at the 200 mg/kg dose, whereas the volume of distribution of the drug remained unchanged.",Dose-dependent kinetics of cilastatin in laboratory animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],5.30,2226,DB01597,Cilastatin
,2571484,fm,The fm values decreased from 0.915 at the 10 mg/kg dose to 0.626 at the 100 mg/kg dose.,Dose-dependent kinetics of cilastatin in laboratory animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),,0.915,2227,DB01597,Cilastatin
,2571484,fm,The fm values decreased from 0.915 at the 10 mg/kg dose to 0.626 at the 100 mg/kg dose.,Dose-dependent kinetics of cilastatin in laboratory animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),,0.626,2228,DB01597,Cilastatin
,2571484,renal clearance,The renal clearance of cilastatin increased from 2.50 +/- 0.40 ml/min/kg at the lowest dose to 6.10 +/- 0.50 ml/min/kg at the highest dose as the dose increased.,Dose-dependent kinetics of cilastatin in laboratory animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],2.50,2229,DB01597,Cilastatin
,2571484,renal clearance,The renal clearance of cilastatin increased from 2.50 +/- 0.40 ml/min/kg at the lowest dose to 6.10 +/- 0.50 ml/min/kg at the highest dose as the dose increased.,Dose-dependent kinetics of cilastatin in laboratory animals. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571484/),[ml] / [kg·min],6.10,2230,DB01597,Cilastatin
,3863219,half-life,"Kinetics of imipenem in plasma are less variable, and the half-life of imipenem in plasma is 1 hr.",Pharmacokinetics of imipenem and cilastatin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3863219/),h,1,3364,DB01597,Cilastatin
,3863219,plasma half-life,"When imipenem is coadministered with an equal amount of cilastatin, the amount of imipenem excreted in the urine represents 70% of the plasma clearance and the plasma half-life remains at 1 hr.",Pharmacokinetics of imipenem and cilastatin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3863219/),h,1,3365,DB01597,Cilastatin
,3863219,plasma half-life,"Whether administered alone or with imipenem, the urinary excretion of cilastatin is 70%-80% of the dose administered, and its plasma half-life is also 1 hr.",Pharmacokinetics of imipenem and cilastatin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3863219/),h,1,3366,DB01597,Cilastatin
,3480884,serum concentrations,"The serum concentrations of imipenem 0.5 h and 4 h after the end of the 40 min infusion were 53.3 (+/- 16.7) and 2.0 (+/- 0.3) mg/l, respectively.","Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480884/),mg,53.3,4494,DB01597,Cilastatin
,3480884,serum concentrations,"The serum concentrations of imipenem 0.5 h and 4 h after the end of the 40 min infusion were 53.3 (+/- 16.7) and 2.0 (+/- 0.3) mg/l, respectively.","Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480884/),mg,2.0,4495,DB01597,Cilastatin
,9420033,Total clearances,"Total clearances of imipenem and cilastatin (mean +/- standard deviations) were 122.2 +/- 28.6 and 29.2 +/- 13.7 ml/min, respectively, with hemofiltration clearances of 22.9 +/- 2.5 and 16.1 +/- 3.1 ml/min, respectively, and nonrenal, nonhemofiltration clearances of 90.8 +/- 26.3 and 13.2 +/- 13.9 ml/min, respectively.",Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420033/),[ml] / [min],122.2,5984,DB01597,Cilastatin
,9420033,Total clearances,"Total clearances of imipenem and cilastatin (mean +/- standard deviations) were 122.2 +/- 28.6 and 29.2 +/- 13.7 ml/min, respectively, with hemofiltration clearances of 22.9 +/- 2.5 and 16.1 +/- 3.1 ml/min, respectively, and nonrenal, nonhemofiltration clearances of 90.8 +/- 26.3 and 13.2 +/- 13.9 ml/min, respectively.",Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420033/),[ml] / [min],29.2,5985,DB01597,Cilastatin
,9420033,hemofiltration clearances,"Total clearances of imipenem and cilastatin (mean +/- standard deviations) were 122.2 +/- 28.6 and 29.2 +/- 13.7 ml/min, respectively, with hemofiltration clearances of 22.9 +/- 2.5 and 16.1 +/- 3.1 ml/min, respectively, and nonrenal, nonhemofiltration clearances of 90.8 +/- 26.3 and 13.2 +/- 13.9 ml/min, respectively.",Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420033/),[ml] / [min],22.9,5986,DB01597,Cilastatin
,9420033,hemofiltration clearances,"Total clearances of imipenem and cilastatin (mean +/- standard deviations) were 122.2 +/- 28.6 and 29.2 +/- 13.7 ml/min, respectively, with hemofiltration clearances of 22.9 +/- 2.5 and 16.1 +/- 3.1 ml/min, respectively, and nonrenal, nonhemofiltration clearances of 90.8 +/- 26.3 and 13.2 +/- 13.9 ml/min, respectively.",Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420033/),[ml] / [min],16.1,5987,DB01597,Cilastatin
,9420033,"nonrenal, nonhemofiltration clearances","Total clearances of imipenem and cilastatin (mean +/- standard deviations) were 122.2 +/- 28.6 and 29.2 +/- 13.7 ml/min, respectively, with hemofiltration clearances of 22.9 +/- 2.5 and 16.1 +/- 3.1 ml/min, respectively, and nonrenal, nonhemofiltration clearances of 90.8 +/- 26.3 and 13.2 +/- 13.9 ml/min, respectively.",Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420033/),[ml] / [min],90.8,5988,DB01597,Cilastatin
,9420033,"nonrenal, nonhemofiltration clearances","Total clearances of imipenem and cilastatin (mean +/- standard deviations) were 122.2 +/- 28.6 and 29.2 +/- 13.7 ml/min, respectively, with hemofiltration clearances of 22.9 +/- 2.5 and 16.1 +/- 3.1 ml/min, respectively, and nonrenal, nonhemofiltration clearances of 90.8 +/- 26.3 and 13.2 +/- 13.9 ml/min, respectively.",Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420033/),[ml] / [min],13.2,5989,DB01597,Cilastatin
,9420033,steady-state concentration,They were calculated in order to achieve an average steady-state concentration of 12 mg/liter to ensure that concentrations in plasma exceeded the MICs at which 90% of intermediately resistent bacteria are inhibited (8 mg/liter) during the majority of the dosing interval.,Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420033/),[mg] / [l],12,5990,DB01597,Cilastatin
,1510434,Serum elimination half-life,"Serum elimination half-life (1.3 h), volume of distribution (14.5 liters), and area under the curve (AUC; 27.8 micrograms.h/ml) after i.m. injection did not significantly differ from those of a comparable dose given by intravenous infusion.",Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510434/),h,1.3,6684,DB01597,Cilastatin
,1510434,volume of distribution,"Serum elimination half-life (1.3 h), volume of distribution (14.5 liters), and area under the curve (AUC; 27.8 micrograms.h/ml) after i.m. injection did not significantly differ from those of a comparable dose given by intravenous infusion.",Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510434/),l,14.5,6685,DB01597,Cilastatin
,1510434,area under the curve (AUC,"Serum elimination half-life (1.3 h), volume of distribution (14.5 liters), and area under the curve (AUC; 27.8 micrograms.h/ml) after i.m. injection did not significantly differ from those of a comparable dose given by intravenous infusion.",Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510434/),[h·μg] / [ml],27.8,6686,DB01597,Cilastatin
,1510434,Bioavailability,Bioavailability after i.m. injection was 89%.,Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510434/),%,89,6687,DB01597,Cilastatin
,1510434,AUCskin window/AUCserum ratio,"The AUCskin window/AUCserum ratio for skin window fluid after i.m. injection was 68%, indicating good penetration of the drug into skin fluid.",Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510434/),%,68,6688,DB01597,Cilastatin
,34420182,volume of distribution,"Geometric means (coefficient of variation) of the volume of distribution and clearance in individuals with normal kidney function were 15.8 (15%) L and 4.70 (27%) L/h, respectively.",Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34420182/),,15.8,8386,DB01597,Cilastatin
,34420182,clearance,"Geometric means (coefficient of variation) of the volume of distribution and clearance in individuals with normal kidney function were 15.8 (15%) L and 4.70 (27%) L/h, respectively.",Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34420182/),,4.70,8387,DB01597,Cilastatin
,34420182,clearance,"In patients with end-stage renal disease, clearance was 1.10 (24%) L/h.",Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34420182/),[l] / [h],1.10,8388,DB01597,Cilastatin
,3210304,peak levels,"In the 20 mg/kg group, peak levels were found at the end of the infusion, IPM 39.2-41.7 micrograms/ml, CS 48.1-58.8 micrograms/ml.",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),[μg] / [ml],39.2-41.7,8789,DB01597,Cilastatin
,3210304,peak levels,"In the 20 mg/kg group, peak levels were found at the end of the infusion, IPM 39.2-41.7 micrograms/ml, CS 48.1-58.8 micrograms/ml.",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),[μg] / [ml],48.1-58.8,8790,DB01597,Cilastatin
,3210304,plasma half-lives (T 1/2),"In both groups, plasma levels of IPM/CS decreased rapidly, and plasma half-lives (T 1/2) in the 20 mg/kg group were 0.9-1.2 hours (IPM) and 0.8-1.1 hours (CS).",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),h,0.9-1.2,8791,DB01597,Cilastatin
,3210304,plasma half-lives (T 1/2),"In both groups, plasma levels of IPM/CS decreased rapidly, and plasma half-lives (T 1/2) in the 20 mg/kg group were 0.9-1.2 hours (IPM) and 0.8-1.1 hours (CS).",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),h,0.8-1.1,8792,DB01597,Cilastatin
,3210304,Urinary recovery rates,"Urinary recovery rates were 17.7-28.7% (10 mg/kg), 21.1-36.9% (20 mg/kg) for IPM and 27.1-43.8% (10 mg/kg) and 21.5-76.5% (20 mg/kg) for CS.",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),%,17.7-28.7,8793,DB01597,Cilastatin
,3210304,Urinary recovery rates,"Urinary recovery rates were 17.7-28.7% (10 mg/kg), 21.1-36.9% (20 mg/kg) for IPM and 27.1-43.8% (10 mg/kg) and 21.5-76.5% (20 mg/kg) for CS.",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),%,21.1-36.9,8794,DB01597,Cilastatin
,3210304,Urinary recovery rates,"Urinary recovery rates were 17.7-28.7% (10 mg/kg), 21.1-36.9% (20 mg/kg) for IPM and 27.1-43.8% (10 mg/kg) and 21.5-76.5% (20 mg/kg) for CS.",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),%,27.1-43.8,8795,DB01597,Cilastatin
,3210304,Urinary recovery rates,"Urinary recovery rates were 17.7-28.7% (10 mg/kg), 21.1-36.9% (20 mg/kg) for IPM and 27.1-43.8% (10 mg/kg) and 21.5-76.5% (20 mg/kg) for CS.",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),%,21.5-76.5,8796,DB01597,Cilastatin
,3210304,Peak levels,"Peak levels of IPM/CS in bile were noted 1 hour after the end of infusion, and they were 3.01-12.3 micrograms/ml for IPM, and 2.5-13.1 micrograms/ml for CS.",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),[μg] / [ml],3.01-12.3,8797,DB01597,Cilastatin
,3210304,Peak levels,"Peak levels of IPM/CS in bile were noted 1 hour after the end of infusion, and they were 3.01-12.3 micrograms/ml for IPM, and 2.5-13.1 micrograms/ml for CS.",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),[μg] / [ml],2.5-13.1,8798,DB01597,Cilastatin
,3210304,Recovery rates,"Recovery rates in bile in 7 hours after the end of infusion were 0.03-0.12% (IPM), 0.01-0.12% (CS).",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),%,0.03-0.12,8799,DB01597,Cilastatin
,3210304,Recovery rates,"Recovery rates in bile in 7 hours after the end of infusion were 0.03-0.12% (IPM), 0.01-0.12% (CS).",[Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210304/),%,0.01-0.12,8800,DB01597,Cilastatin
,11786657,minimum inhibitory concentrations (MICs),"The minimum inhibitory concentrations (MICs) of CPFX, IMP and CZOP were 1.0, 1.0 and 4.0 mg/l, respectively.",Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11786657/),[mg] / [l],1.0,8826,DB01597,Cilastatin
,11786657,minimum inhibitory concentrations (MICs),"The minimum inhibitory concentrations (MICs) of CPFX, IMP and CZOP were 1.0, 1.0 and 4.0 mg/l, respectively.",Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11786657/),[mg] / [l],4.0,8827,DB01597,Cilastatin
,3859242,plasma half-lives,"The plasma half-lives of imipenem were 1.7 to 2.4 h, whereas those of cilastatin were 3.9 to 6.3 h.",Pharmacokinetics of imipenem-cilastatin in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859242/),h,1.7 to 2.4,12516,DB01597,Cilastatin
,3859242,plasma half-lives,"The plasma half-lives of imipenem were 1.7 to 2.4 h, whereas those of cilastatin were 3.9 to 6.3 h.",Pharmacokinetics of imipenem-cilastatin in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859242/),h,3.9 to 6.3,12517,DB01597,Cilastatin
,9187391,limit of detection,The limit of detection was 0.030 microg/ml.,Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9187391/),[μg] / [ml],0.030,13652,DB01597,Cilastatin
,3464783,susceptibility distribution,"The susceptibility distribution of E. coli to imipenem ranged from 0.1 to 1.56 micrograms/ml, and the peak of the distribution was at 0.1 microgram/ml.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],0.1 to 1.56,17410,DB01597,Cilastatin
,3464783,peak of the distribution,"The susceptibility distribution of E. coli to imipenem ranged from 0.1 to 1.56 micrograms/ml, and the peak of the distribution was at 0.1 microgram/ml.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],0,17411,DB01597,Cilastatin
,3464783,peak,"The peak of the susceptibility distribution of K. pneumoniae was 0.2 microgram/ml, and those of S. marcescens and Salmonella ranged from 0.2 to 1.56 micrograms/ml and from 0.1 to 0.39 microgram/ml, respectively.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],0.2,17412,DB01597,Cilastatin
,3464783,peak,"The peak of the susceptibility distribution of K. pneumoniae was 0.2 microgram/ml, and those of S. marcescens and Salmonella ranged from 0.2 to 1.56 micrograms/ml and from 0.1 to 0.39 microgram/ml, respectively.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],0.2 to 1.56,17413,DB01597,Cilastatin
,3464783,susceptibility distribution,"The peak of the susceptibility distribution of K. pneumoniae was 0.2 microgram/ml, and those of S. marcescens and Salmonella ranged from 0.2 to 1.56 micrograms/ml and from 0.1 to 0.39 microgram/ml, respectively.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],0.2,17414,DB01597,Cilastatin
,3464783,susceptibility distribution,"The peak of the susceptibility distribution of K. pneumoniae was 0.2 microgram/ml, and those of S. marcescens and Salmonella ranged from 0.2 to 1.56 micrograms/ml and from 0.1 to 0.39 microgram/ml, respectively.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],0.2 to 1.56,17415,DB01597,Cilastatin
,3464783,susceptibility distribution,"The peak of the susceptibility distribution of K. pneumoniae was 0.2 microgram/ml, and those of S. marcescens and Salmonella ranged from 0.2 to 1.56 micrograms/ml and from 0.1 to 0.39 microgram/ml, respectively.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],0.1 to 0.39,17416,DB01597,Cilastatin
,3464783,peak plasma levels,"With drip infusion of imipenem/cilastatin sodium, the peak plasma levels obtained with the two doses (10 and 20 mg/kg) were 20.6/26.4 micrograms/ml and 19.4/36.5 micrograms/ml, respectively on completion of the infusion.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],20.6,17417,DB01597,Cilastatin
,3464783,peak plasma levels,"With drip infusion of imipenem/cilastatin sodium, the peak plasma levels obtained with the two doses (10 and 20 mg/kg) were 20.6/26.4 micrograms/ml and 19.4/36.5 micrograms/ml, respectively on completion of the infusion.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],26.4,17418,DB01597,Cilastatin
,3464783,peak plasma levels,"With drip infusion of imipenem/cilastatin sodium, the peak plasma levels obtained with the two doses (10 and 20 mg/kg) were 20.6/26.4 micrograms/ml and 19.4/36.5 micrograms/ml, respectively on completion of the infusion.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),[μg] / [ml],19.4,17419,DB01597,Cilastatin
,3464783,clinical effectiveness ratio,"Clinical responses to imipenem/cilastatin sodium were excellent in 6 patients and fairly good in 1 patient, and the clinical effectiveness ratio was 85.7%.",[Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464783/),%,85.7,17420,DB01597,Cilastatin
not exceed,2599653,MICs,"Selection of mutants with decreased sensitivity to ciprofloxacin occurred during therapy, however, post-therapy MICs of ciprofloxacin did not exceed a level of 1 mg/l and rises of MICs did not detrimentally influence treatment outcome.","Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2599653/),[mg] / [l],1,17488,DB01597,Cilastatin
,8851616,areas under the concentration-time curve,"L-695,256 had larger areas under the concentration-time curve than imipenem-cilastatin (30 +/- 5 versus 24 +/- 1 micrograms.h/ml in the rhesus monkeys and 77 versus 60 micrograms.h/ml in the chimpanzee) and a longer half-life at beta phase (1.2 +/- 0.1 versus 0.6 +/- 0.1 h in the rhesus monkeys and 1.0 versus 0.8 h in the chimpanzee).",Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851616/),[h·μg] / [ml],30,18249,DB01597,Cilastatin
,8851616,areas under the concentration-time curve,"L-695,256 had larger areas under the concentration-time curve than imipenem-cilastatin (30 +/- 5 versus 24 +/- 1 micrograms.h/ml in the rhesus monkeys and 77 versus 60 micrograms.h/ml in the chimpanzee) and a longer half-life at beta phase (1.2 +/- 0.1 versus 0.6 +/- 0.1 h in the rhesus monkeys and 1.0 versus 0.8 h in the chimpanzee).",Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851616/),[h·μg] / [ml],24,18250,DB01597,Cilastatin
,8851616,areas under the concentration-time curve,"L-695,256 had larger areas under the concentration-time curve than imipenem-cilastatin (30 +/- 5 versus 24 +/- 1 micrograms.h/ml in the rhesus monkeys and 77 versus 60 micrograms.h/ml in the chimpanzee) and a longer half-life at beta phase (1.2 +/- 0.1 versus 0.6 +/- 0.1 h in the rhesus monkeys and 1.0 versus 0.8 h in the chimpanzee).",Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851616/),[h·μg] / [ml],77,18251,DB01597,Cilastatin
,8851616,areas under the concentration-time curve,"L-695,256 had larger areas under the concentration-time curve than imipenem-cilastatin (30 +/- 5 versus 24 +/- 1 micrograms.h/ml in the rhesus monkeys and 77 versus 60 micrograms.h/ml in the chimpanzee) and a longer half-life at beta phase (1.2 +/- 0.1 versus 0.6 +/- 0.1 h in the rhesus monkeys and 1.0 versus 0.8 h in the chimpanzee).",Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851616/),[h·μg] / [ml],60,18252,DB01597,Cilastatin
,8851616,half-life at beta phase,"L-695,256 had larger areas under the concentration-time curve than imipenem-cilastatin (30 +/- 5 versus 24 +/- 1 micrograms.h/ml in the rhesus monkeys and 77 versus 60 micrograms.h/ml in the chimpanzee) and a longer half-life at beta phase (1.2 +/- 0.1 versus 0.6 +/- 0.1 h in the rhesus monkeys and 1.0 versus 0.8 h in the chimpanzee).",Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851616/),h,1.2,18253,DB01597,Cilastatin
,8851616,half-life at beta phase,"L-695,256 had larger areas under the concentration-time curve than imipenem-cilastatin (30 +/- 5 versus 24 +/- 1 micrograms.h/ml in the rhesus monkeys and 77 versus 60 micrograms.h/ml in the chimpanzee) and a longer half-life at beta phase (1.2 +/- 0.1 versus 0.6 +/- 0.1 h in the rhesus monkeys and 1.0 versus 0.8 h in the chimpanzee).",Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851616/),h,0.6,18254,DB01597,Cilastatin
,8851616,half-life at beta phase,"L-695,256 had larger areas under the concentration-time curve than imipenem-cilastatin (30 +/- 5 versus 24 +/- 1 micrograms.h/ml in the rhesus monkeys and 77 versus 60 micrograms.h/ml in the chimpanzee) and a longer half-life at beta phase (1.2 +/- 0.1 versus 0.6 +/- 0.1 h in the rhesus monkeys and 1.0 versus 0.8 h in the chimpanzee).",Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851616/),h,1.0,18255,DB01597,Cilastatin
,8851616,half-life at beta phase,"L-695,256 had larger areas under the concentration-time curve than imipenem-cilastatin (30 +/- 5 versus 24 +/- 1 micrograms.h/ml in the rhesus monkeys and 77 versus 60 micrograms.h/ml in the chimpanzee) and a longer half-life at beta phase (1.2 +/- 0.1 versus 0.6 +/- 0.1 h in the rhesus monkeys and 1.0 versus 0.8 h in the chimpanzee).",Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851616/),h,0.8,18256,DB01597,Cilastatin
,25403667,volumes of distribution (V),"The PK profiles of IMP/C and MK7655 were linear over the dosing range studied and comparable with volumes of distribution (V) of 0.434 and 0.544 liter/kg and half-lives (t1/2) of 0.24 and 0.25 h, respectively.",Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403667/),[l] / [kg],0.434,19930,DB01597,Cilastatin
,25403667,volumes of distribution (V),"The PK profiles of IMP/C and MK7655 were linear over the dosing range studied and comparable with volumes of distribution (V) of 0.434 and 0.544 liter/kg and half-lives (t1/2) of 0.24 and 0.25 h, respectively.",Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403667/),[l] / [kg],0.544,19931,DB01597,Cilastatin
,25403667,half-lives (t1/2),"The PK profiles of IMP/C and MK7655 were linear over the dosing range studied and comparable with volumes of distribution (V) of 0.434 and 0.544 liter/kg and half-lives (t1/2) of 0.24 and 0.25 h, respectively.",Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403667/),h,0.24,19932,DB01597,Cilastatin
,25403667,half-lives (t1/2),"The PK profiles of IMP/C and MK7655 were linear over the dosing range studied and comparable with volumes of distribution (V) of 0.434 and 0.544 liter/kg and half-lives (t1/2) of 0.24 and 0.25 h, respectively.",Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403667/),h,0.25,19933,DB01597,Cilastatin
,25403667,Protein binding,Protein binding of MK7655 was 20%.,Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403667/),%,20,19934,DB01597,Cilastatin
,25403667,"area under the concentration-time curve for the free, unbound fraction of the drug (fAUC)","Escalating doses of MK7655 and IMP/C showed that the AUC of MK7655 required for a static effect was dependent on the dose of IMP/C and the MIC of the strain, with a mean area under the concentration-time curve for the free, unbound fraction of the drug (fAUC) of 26.0 mg · h/liter.",Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403667/),[h·mg] / [l],26.0,19935,DB01597,Cilastatin
,3465739,limits of reliable detection,"The limits of reliable detection were 0.75 and 2.5 micrograms/ml in plasma and urine, respectively.",High-performance liquid chromatographic determination of cilastatin in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465739/),[μg] / [ml],0.75,28164,DB01597,Cilastatin
,3465739,limits of reliable detection,"The limits of reliable detection were 0.75 and 2.5 micrograms/ml in plasma and urine, respectively.",High-performance liquid chromatographic determination of cilastatin in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465739/),[μg] / [ml],2.5,28165,DB01597,Cilastatin
,3464785,Peak plasma concentrations,Pharmacokinetic studies Peak plasma concentrations of MK-0787/MK-0791 were 27.7-190.0/28.3-216.4 micrograms/ml at doses of 10/10-50/50 mg/kg administered by a 30 or 60-minute drip infusion.,[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),[μg] / [ml],27.7-190.0,28168,DB01597,Cilastatin
,3464785,Peak plasma concentrations,Pharmacokinetic studies Peak plasma concentrations of MK-0787/MK-0791 were 27.7-190.0/28.3-216.4 micrograms/ml at doses of 10/10-50/50 mg/kg administered by a 30 or 60-minute drip infusion.,[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),[μg] / [ml],28.3-216.4,28169,DB01597,Cilastatin
,3464785,urinary excretion,"Over a period of 6 or 7 hours, the urinary excretion of MK-0787 and MK-0791 totaled 54.2-88.0% and 53.6-89.0% of the dose administered, respectively.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),%,54.2-88.0,28170,DB01597,Cilastatin
,3464785,urinary excretion,"Over a period of 6 or 7 hours, the urinary excretion of MK-0787 and MK-0791 totaled 54.2-88.0% and 53.6-89.0% of the dose administered, respectively.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),%,53.6-89.0,28171,DB01597,Cilastatin
,3464785,Plasma half-lives,"Plasma half-lives of MK-0787 and MK-0791 in the beta-phase were 0.87-1.05 hours and 0.59-0.95 hour, respectively.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),h,0.87-1.05,28172,DB01597,Cilastatin
,3464785,Plasma half-lives,"Plasma half-lives of MK-0787 and MK-0791 in the beta-phase were 0.87-1.05 hours and 0.59-0.95 hour, respectively.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),h,0.59-0.95,28173,DB01597,Cilastatin
,3464785,clinical efficacy rate,The clinical efficacy rate was 92.5% among 187 patients with identified etiologic pathogens.,[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),%,92.,28174,DB01597,Cilastatin
,3464785,clinical efficacy rate,"The clinical efficacy rate was 96.7% in 90 patients with respiratory tract infection (pneumonia, lung abscess, etc.), 96.5% in 57 patients with urinary tract infection, 90.9% in 11 patients with SSTI.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),%,96,28175,DB01597,Cilastatin
,3464785,eradication rate,"Bacteriologically, the eradication rate for S. aureus was 87.9% of 33 isolates.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),%,87.9,28176,DB01597,Cilastatin
,3464785,eradication rate,"Comprehensively, the eradication rate for Gram-positive bacteria was 94.7% of 75 isolates.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),%,94.7,28177,DB01597,Cilastatin
,3464785,eradication rate,The eradication rate for P. aeruginosa was 87.5% of 8 isolates.,[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),%,87.5,28178,DB01597,Cilastatin
,3464785,era,"Including these strains, the eradication rate for Gram-negative bacteria was 90.3% of 134 isolates.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),%,90,28179,DB01597,Cilastatin
,3464785,eradication rate,The MK-0787/MK-0791 exhibited an eradication rate of 91.9% among a total of 211 Gram-positive and Gram-negative bacteria including anaerobes.,[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464785/),%,91.9,28180,DB01597,Cilastatin
,3464773,overall efficacy rate,The overall efficacy rate was 75%.,[Clinical evaluation of imipenem/cilastatin sodium in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464773/),%,75,29212,DB01597,Cilastatin
,3464773,half-life (T1/2),"The mean half-life (T1/2) of MK-0787 was 1.03 hours and MK-0791, 0.69 hour.",[Clinical evaluation of imipenem/cilastatin sodium in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464773/),h,1.03,29213,DB01597,Cilastatin
,3464773,half-life (T1/2),"The mean half-life (T1/2) of MK-0787 was 1.03 hours and MK-0791, 0.69 hour.",[Clinical evaluation of imipenem/cilastatin sodium in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464773/),h,0.69,29214,DB01597,Cilastatin
,3464773,urinary recovery rate,"The mean urinary recovery rate of MK-0787 within 6.5-7 hours after administration was 62.5% and MK-0791, 76.7%.",[Clinical evaluation of imipenem/cilastatin sodium in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464773/),%,62.5,29215,DB01597,Cilastatin
,3464773,urinary recovery rate,"The mean urinary recovery rate of MK-0787 within 6.5-7 hours after administration was 62.5% and MK-0791, 76.7%.",[Clinical evaluation of imipenem/cilastatin sodium in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464773/),%,76.7,29216,DB01597,Cilastatin
,17620371,MICs,The probability of target attainment by MIC for intermittent infusion was robust (>90%) up to MICs of 1 to 2 mg/liter.,"Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620371/),[mg] / [l],1 to 2,31500,DB01597,Cilastatin
,17620371,fT(>MIC),"Although all 20 patients had an fT(>MIC) of 100%, 3 patients died.","Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620371/),%,100,31501,DB01597,Cilastatin
,3859216,half-life,"Consequently, as the glomerular filtration rate declined, the half-life of imipenem increased from 1.02 hours in normal subjects to 3.69 hours in those undergoing dialysis.",Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859216/),h,1.02,32744,DB01597,Cilastatin
,3859216,half-life,"Consequently, as the glomerular filtration rate declined, the half-life of imipenem increased from 1.02 hours in normal subjects to 3.69 hours in those undergoing dialysis.",Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859216/),h,3.69,32745,DB01597,Cilastatin
,3859216,half-life,Dialysis reduced the half-life of imipenem from 4.80 to 2.45 hours and that of cilastatin from 16.63 to 3.86 hours.,Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859216/),h,4.80 to 2.45,32746,DB01597,Cilastatin
,3859216,half-life,Dialysis reduced the half-life of imipenem from 4.80 to 2.45 hours and that of cilastatin from 16.63 to 3.86 hours.,Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859216/),h,16.63 to 3.86,32747,DB01597,Cilastatin
,8721283,Analytical recovery,Analytical recovery ranged from 85 to 95%.,Evaluation of a fluorescence polarographic immunoassay with increased sensitivity for measurement of low concentrations of tobramycin in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721283/),%,85 to 95,38115,DB01597,Cilastatin
,2379384,VC,"Combined mean (+/- SD) parameter estimates for the two dosing periods were as follows: VC, 0.11 +/- 0.06 L/kg; Vss, 0.22 +/- 0.06 L/kg; CL, 12.5 +/- 3.6 L/hr/1.73 m2; t1/2 alpha, 0.18 +/- 0.13 hr; t1/2 beta, 1.12 +/- 0.44 hr.",Imipenem pharmacokinetics in patients with burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379384/),[l] / [kg],0.11,38617,DB01597,Cilastatin
,2379384,Vss,"Combined mean (+/- SD) parameter estimates for the two dosing periods were as follows: VC, 0.11 +/- 0.06 L/kg; Vss, 0.22 +/- 0.06 L/kg; CL, 12.5 +/- 3.6 L/hr/1.73 m2; t1/2 alpha, 0.18 +/- 0.13 hr; t1/2 beta, 1.12 +/- 0.44 hr.",Imipenem pharmacokinetics in patients with burns. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379384/),[l] / [kg],0.22,38618,DB01597,Cilastatin
,2379384,CL,"Combined mean (+/- SD) parameter estimates for the two dosing periods were as follows: VC, 0.11 +/- 0.06 L/kg; Vss, 0.22 +/- 0.06 L/kg; CL, 12.5 +/- 3.6 L/hr/1.73 m2; t1/2 alpha, 0.18 +/- 0.13 hr; t1/2 beta, 1.12 +/- 0.44 hr.",Imipenem pharmacokinetics in patients with burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379384/),[l] / [1.73·h·m2],12.5,38619,DB01597,Cilastatin
,2379384,t1/2 alpha,"Combined mean (+/- SD) parameter estimates for the two dosing periods were as follows: VC, 0.11 +/- 0.06 L/kg; Vss, 0.22 +/- 0.06 L/kg; CL, 12.5 +/- 3.6 L/hr/1.73 m2; t1/2 alpha, 0.18 +/- 0.13 hr; t1/2 beta, 1.12 +/- 0.44 hr.",Imipenem pharmacokinetics in patients with burns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379384/),h,0.18,38620,DB01597,Cilastatin
,2379384,t1/2 beta,"Combined mean (+/- SD) parameter estimates for the two dosing periods were as follows: VC, 0.11 +/- 0.06 L/kg; Vss, 0.22 +/- 0.06 L/kg; CL, 12.5 +/- 3.6 L/hr/1.73 m2; t1/2 alpha, 0.18 +/- 0.13 hr; t1/2 beta, 1.12 +/- 0.44 hr.",Imipenem pharmacokinetics in patients with burns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379384/),h,1.12,38621,DB01597,Cilastatin
,2379384,clearance,Mean clearance in two patients with creatinine clearance values greater than 150 ml/min/1.73 m2 was 17.7 L/hr/1.73 m2.,Imipenem pharmacokinetics in patients with burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379384/),[l] / [1.73·h·m2],17.7,38622,DB01597,Cilastatin
,2379384,clearance,Mean clearance in two patients with creatinine clearance values less than 50 ml/min/1.73 m2 was 8.5 L/hr/1.73 m2.,Imipenem pharmacokinetics in patients with burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379384/),[l] / [1.73·h·m2],8.5,38623,DB01597,Cilastatin
,31479762,fAUC/MIC,"Simulations demonstrated that the ratio of the area under the concentration-time curve for free drug to the minimum inhibitory concentration (fAUC/MIC) was the pharmacokinetic driver for relebactam, with a target fAUC/MIC=7.5 associated with 2-log kill.",A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479762/),,7.5,50887,DB01597,Cilastatin
≤,31479762,MIC,"At a clinical dose of 250mg relebactam, greater than 2-log reductions in bacterial load are projected for imipenem-resistant strains with an imipenem/relebactam MIC≤4μg/mL.",A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479762/),[μg] / [ml],4,50888,DB01597,Cilastatin
,31479762,fAUC/MIC ratio,"The study confirms that the pharmacokinetic/pharmacodynamic driver for relebactam is fAUC/MIC, that an fAUC/MIC ratio of 7.5 is associated with 2-log kill in vitro, and that a 250mg clinical dose of relebactam achieves this target value when delivered in combination with imipenem/cilastatin.",A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479762/),,7.5,50889,DB01597,Cilastatin
,1438026,u,The urinary recovery of imipenem and cilastatin averaged 50-70% of the administered dose.,Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438026/),,50,55419,DB01597,Cilastatin
,1438026,plasma t1/2,The plasma t1/2 for imipenem averaged 55 min.,Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438026/),min,55,55420,DB01597,Cilastatin
,3464780,Concentrations,"Concentrations of the drug decreased as the time after the administration increased, and they reached 0.14 microgram/ml and 0.12 microgram/ml, respectively in the older and the younger children at 6 hours after the administration.",[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),[μg] / [ml],0.14,59312,DB01597,Cilastatin
,3464780,Concentrations,"Concentrations of the drug decreased as the time after the administration increased, and they reached 0.14 microgram/ml and 0.12 microgram/ml, respectively in the older and the younger children at 6 hours after the administration.",[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),[μg] / [ml],0.12,59313,DB01597,Cilastatin
,3464780,Half-lives (T 1/2),"Half-lives (T 1/2) of the drug in serum were calculated to be 1.21 hours and 1.04 hours, respectively.",[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),h,1.21,59314,DB01597,Cilastatin
,3464780,Half-lives (T 1/2),"Half-lives (T 1/2) of the drug in serum were calculated to be 1.21 hours and 1.04 hours, respectively.",[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),h,1.04,59315,DB01597,Cilastatin
,3464780,Peak serum concentrations,"Peak serum concentrations of MK-0791 in the 2 children were 53.73 micrograms/ml and 22.99 micrograms/ml, respectively, at the end of drip infusion.",[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),[μg] / [ml],53.73,59316,DB01597,Cilastatin
,3464780,Peak serum concentrations,"Peak serum concentrations of MK-0791 in the 2 children were 53.73 micrograms/ml and 22.99 micrograms/ml, respectively, at the end of drip infusion.",[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),[μg] / [ml],22.99,59317,DB01597,Cilastatin
,3464780,Urinary recovery rates,Urinary recovery rates of MK-0787 in 6 hours after the drip infusion was 82.9% and 63.6% in the 2 children and those of MK-0791 were 57.9% and 74.6%.,[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),%,82.9,59318,DB01597,Cilastatin
,3464780,Urinary recovery rates,Urinary recovery rates of MK-0787 in 6 hours after the drip infusion was 82.9% and 63.6% in the 2 children and those of MK-0791 were 57.9% and 74.6%.,[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),%,63.6,59319,DB01597,Cilastatin
,3464780,Urinary recovery rates,Urinary recovery rates of MK-0787 in 6 hours after the drip infusion was 82.9% and 63.6% in the 2 children and those of MK-0791 were 57.9% and 74.6%.,[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),%,57.9,59320,DB01597,Cilastatin
,3464780,Urinary recovery rates,Urinary recovery rates of MK-0787 in 6 hours after the drip infusion was 82.9% and 63.6% in the 2 children and those of MK-0791 were 57.9% and 74.6%.,[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),%,74.6,59321,DB01597,Cilastatin
,3464780,Lengths of treatment,Lengths of treatment were 2 2/3-4 days for 5 cases and 6 days for 1 case.,[Clinical study on imipenem/cilastatin sodium in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464780/),d,2,59322,DB01597,Cilastatin
,10508037,nonrenal clearance (CL(NR)),"After intravenous infusion, the nonrenal clearance (CL(NR)) of DA-1131 was significantly slower in rats (3.00 versus 8.01 ml/min/kg) and rabbits (2.41 versus 6.77 ml/min/kg) when the drug was coadministered with cilastatin; this could be due to the slower metabolism of DA-1131 by rat and rabbit kidney DHP-I.","Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508037/),[ml] / [kg·min],3.00,60633,DB01597,Cilastatin
,10508037,nonrenal clearance (CL(NR)),"After intravenous infusion, the nonrenal clearance (CL(NR)) of DA-1131 was significantly slower in rats (3.00 versus 8.01 ml/min/kg) and rabbits (2.41 versus 6.77 ml/min/kg) when the drug was coadministered with cilastatin; this could be due to the slower metabolism of DA-1131 by rat and rabbit kidney DHP-I.","Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508037/),[ml] / [kg·min],8.01,60634,DB01597,Cilastatin
,10508037,nonrenal clearance (CL(NR)),"After intravenous infusion, the nonrenal clearance (CL(NR)) of DA-1131 was significantly slower in rats (3.00 versus 8.01 ml/min/kg) and rabbits (2.41 versus 6.77 ml/min/kg) when the drug was coadministered with cilastatin; this could be due to the slower metabolism of DA-1131 by rat and rabbit kidney DHP-I.","Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508037/),[ml] / [kg·min],2.41,60635,DB01597,Cilastatin
,10508037,nonrenal clearance (CL(NR)),"After intravenous infusion, the nonrenal clearance (CL(NR)) of DA-1131 was significantly slower in rats (3.00 versus 8.01 ml/min/kg) and rabbits (2.41 versus 6.77 ml/min/kg) when the drug was coadministered with cilastatin; this could be due to the slower metabolism of DA-1131 by rat and rabbit kidney DHP-I.","Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508037/),[ml] / [kg·min],6.77,60636,DB01597,Cilastatin
,9333062,50% effective doses,"In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem.","Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333062/),[mg] / [kg],4.80,66258,DB01597,Cilastatin
,9333062,50% effective doses,"In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem.","Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333062/),[mg] / [kg],6.06,66259,DB01597,Cilastatin
,9333062,50% effective doses,"In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem.","Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333062/),[mg] / [kg],0.46,66260,DB01597,Cilastatin
,9333062,50% effective doses,"In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem.","Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333062/),[mg] / [kg],5.56,66261,DB01597,Cilastatin
,9333062,50% effective doses,"In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem.","Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333062/),[mg] / [kg],2.15,66262,DB01597,Cilastatin
,9333062,50% effective doses,"In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem.","Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333062/),[mg] / [kg],1.79,66263,DB01597,Cilastatin
>,9333062,50% effective doses,"In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem.","Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333062/),[mg] / [kg],200,66264,DB01597,Cilastatin
,9333062,50% effective doses,"In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem.","Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333062/),[mg] / [kg],15.9,66265,DB01597,Cilastatin
,2719464,concentrations,The mean concentrations in serum at 1 h after the first imipenem dose were 15.9 +/- 1.7 micrograms/ml for the 0.5-g dose and 68.2 +/- 8.2 micrograms/ml for the 1.0-g dose.,Imipenem concentrations in colorectal surgery and impact on the colonic microflora. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719464/),[μg] / [ml],15.9,67029,DB01597,Cilastatin
,2719464,concentrations,The mean concentrations in serum at 1 h after the first imipenem dose were 15.9 +/- 1.7 micrograms/ml for the 0.5-g dose and 68.2 +/- 8.2 micrograms/ml for the 1.0-g dose.,Imipenem concentrations in colorectal surgery and impact on the colonic microflora. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719464/),[μg] / [ml],68.2,67030,DB01597,Cilastatin
,2719464,half-lives,"The mean half-lives were 1.5 and 1.4 h, respectively, and the mean areas under the serum concentration-time curve were 41.2 +/- 6.0 and 128.3 +/- 13.5 mg.h/liter, respectively.",Imipenem concentrations in colorectal surgery and impact on the colonic microflora. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719464/),h,1.5,67031,DB01597,Cilastatin
,2719464,half-lives,"The mean half-lives were 1.5 and 1.4 h, respectively, and the mean areas under the serum concentration-time curve were 41.2 +/- 6.0 and 128.3 +/- 13.5 mg.h/liter, respectively.",Imipenem concentrations in colorectal surgery and impact on the colonic microflora. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719464/),h,1.4,67032,DB01597,Cilastatin
,2719464,areas under the serum concentration-time curve,"The mean half-lives were 1.5 and 1.4 h, respectively, and the mean areas under the serum concentration-time curve were 41.2 +/- 6.0 and 128.3 +/- 13.5 mg.h/liter, respectively.",Imipenem concentrations in colorectal surgery and impact on the colonic microflora. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719464/),[h·mg] / [l],41.2,67033,DB01597,Cilastatin
,2719464,areas under the serum concentration-time curve,"The mean half-lives were 1.5 and 1.4 h, respectively, and the mean areas under the serum concentration-time curve were 41.2 +/- 6.0 and 128.3 +/- 13.5 mg.h/liter, respectively.",Imipenem concentrations in colorectal surgery and impact on the colonic microflora. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719464/),[h·mg] / [l],128.3,67034,DB01597,Cilastatin
,12604907,minimal inhibitory concentrations (MIC90),"The minimal inhibitory concentrations (MIC90) for organisms usually isolated from infected pancreatic necrosis vary between 0.05 and 8 mg/L, which is between nine and 1,500 times lower than the mean peak concentration found in necrotic pancreatic tissue.",Cefepime tissue penetration in experimental acute pancreatitis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604907/),[mg] / [l],0.05 and 8,69156,DB01597,Cilastatin
,8787889,urinary recoveries,"At the end of infusion, the mean concentrations of imipenem and meropenem measured in serum were 61.2 +/- 9.8 and 51.6 +/- 6.5 mg/liter, respectively; urinary recoveries were 48.6% +/- 8.2% and 60.0% +/- 6.5% of the dose in 12 h, respectively; and the areas under the concentration-time curve from time zero to infinity were 96.1 +/- 14.4 and 70.5 +/- 10.3 mg.h/liter, respectively (P < or = 0.02).",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),%,48.6,69286,DB01597,Cilastatin
,8787889,urinary recoveries,"At the end of infusion, the mean concentrations of imipenem and meropenem measured in serum were 61.2 +/- 9.8 and 51.6 +/- 6.5 mg/liter, respectively; urinary recoveries were 48.6% +/- 8.2% and 60.0% +/- 6.5% of the dose in 12 h, respectively; and the areas under the concentration-time curve from time zero to infinity were 96.1 +/- 14.4 and 70.5 +/- 10.3 mg.h/liter, respectively (P < or = 0.02).",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),%,60.0,69287,DB01597,Cilastatin
,8787889,areas under the concentration-time curve from time zero to infinity,"At the end of infusion, the mean concentrations of imipenem and meropenem measured in serum were 61.2 +/- 9.8 and 51.6 +/- 6.5 mg/liter, respectively; urinary recoveries were 48.6% +/- 8.2% and 60.0% +/- 6.5% of the dose in 12 h, respectively; and the areas under the concentration-time curve from time zero to infinity were 96.1 +/- 14.4 and 70.5 +/- 10.3 mg.h/liter, respectively (P < or = 0.02).",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),[h·mg] / [l],96.1,69288,DB01597,Cilastatin
,8787889,areas under the concentration-time curve from time zero to infinity,"At the end of infusion, the mean concentrations of imipenem and meropenem measured in serum were 61.2 +/- 9.8 and 51.6 +/- 6.5 mg/liter, respectively; urinary recoveries were 48.6% +/- 8.2% and 60.0% +/- 6.5% of the dose in 12 h, respectively; and the areas under the concentration-time curve from time zero to infinity were 96.1 +/- 14.4 and 70.5 +/- 10.3 mg.h/liter, respectively (P < or = 0.02).",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),[h·mg] / [l],70.5,69289,DB01597,Cilastatin
,8787889,half-life,Imipenem had a mean half-life of 66.7 +/- 10.4 min; that of meropenem was 64.4 +/- 6.9 min.,Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),min,66.7,69290,DB01597,Cilastatin
,8787889,half-life,Imipenem had a mean half-life of 66.7 +/- 10.4 min; that of meropenem was 64.4 +/- 6.9 min.,Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),min,64.4,69291,DB01597,Cilastatin
,8787889,volumes of distribution at steady state,"The volumes of distribution at steady state of imipenem and meropenem were 15.3 +/- 3.3 and 18.6 +/- 3.0 liters/70 kg, respectively, and the mean renal clearances per 1.73 m2 were 85.6 +/- 17.6 and 144.6 +/- 26.0 ml/min, respectively.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),[l] / [70·kg],15.3,69292,DB01597,Cilastatin
,8787889,volumes of distribution at steady state,"The volumes of distribution at steady state of imipenem and meropenem were 15.3 +/- 3.3 and 18.6 +/- 3.0 liters/70 kg, respectively, and the mean renal clearances per 1.73 m2 were 85.6 +/- 17.6 and 144.6 +/- 26.0 ml/min, respectively.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),[l] / [70·kg],18.6,69293,DB01597,Cilastatin
,8787889,renal clearances per,"The volumes of distribution at steady state of imipenem and meropenem were 15.3 +/- 3.3 and 18.6 +/- 3.0 liters/70 kg, respectively, and the mean renal clearances per 1.73 m2 were 85.6 +/- 17.6 and 144.6 +/- 26.0 ml/min, respectively.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),[ml] / [min],85.6,69294,DB01597,Cilastatin
,8787889,renal clearances per,"The volumes of distribution at steady state of imipenem and meropenem were 15.3 +/- 3.3 and 18.6 +/- 3.0 liters/70 kg, respectively, and the mean renal clearances per 1.73 m2 were 85.6 +/- 17.6 and 144.6 +/- 26.0 ml/min, respectively.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),[ml] / [min],144.6,69295,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,409,69296,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,34.9,69297,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,97.9,69298,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,5.8,69299,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,19.9,69300,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,4.4,69301,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,19.4,69302,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,4.8,69303,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,34.3,69304,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,2.2,69305,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,232,69306,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,15.5,69307,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,13.4,69308,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,2.25,69309,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,90.7,69310,DB01597,Cilastatin
,8787889,SBAs,"After 1 and 6 h the median SBAs for imipenem and meropenem, were 409 and 34.9 and 97.9 and 5.8, respectively, against Staphylococcus aureus, 19.9 and 4.4 and 19.4 and 4.8, respectively, against Pseudomonas aeruginosa, 34.3 and 2.2 and 232 and 15.5, respectively, against Enterobacter cloacae, and 13.4 and 2.25 and 90.7 and 7.9, respectively, against Proteus mirabilis.",Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787889/),,7.9,69311,DB01597,Cilastatin
,3377464,elimination half-life,The elimination half-life of imipenem (3.28 h) or cilastatin (8.84 h) in our patients was in the same range as observed in patients with minimal renal function undergoing hemodialysis.,Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377464/),h,3.28,69382,DB01597,Cilastatin
,3377464,elimination half-life,The elimination half-life of imipenem (3.28 h) or cilastatin (8.84 h) in our patients was in the same range as observed in patients with minimal renal function undergoing hemodialysis.,Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377464/),h,8.84,69383,DB01597,Cilastatin
,1527259,clearance rate,"If a patient develops anuria, the clearance rate of imipenem decreases from the normal value of 245 ml/min to 116 ml/min.",Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527259/),[ml] / [min],245,72007,DB01597,Cilastatin
,1527259,clearance rate,"If a patient develops anuria, the clearance rate of imipenem decreases from the normal value of 245 ml/min to 116 ml/min.",Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527259/),[ml] / [min],116,72008,DB01597,Cilastatin
,1527259,Clearance rate,"Clearance rate of cilastatin, however, decreases from 230 ml/min to 3 ml/min.",Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527259/),[ml] / [min],230,72009,DB01597,Cilastatin
,1527259,Clearance rate,"Clearance rate of cilastatin, however, decreases from 230 ml/min to 3 ml/min.",Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1527259/),[ml] / [min],3,72010,DB01597,Cilastatin
,31956969,Ke,The parametric population parameter estimates were Ke 0.637 h-1 (between-subject variability [BSV]: 19.0% coefficient of variation [CV]) and central distribution volume (Vc) 29.6 L (without BSV).,Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956969/),1/[h],0.637,72762,DB01597,Cilastatin
,31956969,central distribution volume (Vc),The parametric population parameter estimates were Ke 0.637 h-1 (between-subject variability [BSV]: 19.0% coefficient of variation [CV]) and central distribution volume (Vc) 29.6 L (without BSV).,Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956969/),l,29.6,72763,DB01597,Cilastatin
,31956969,Ke,The nonparametric values were Ke 0.681 h-1 (34.0% CV) and Vc 31.1 L (42.6% CV).,Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956969/),1/[h],0.681,72764,DB01597,Cilastatin
,31956969,Vc,The nonparametric values were Ke 0.681 h-1 (34.0% CV) and Vc 31.1 L (42.6% CV).,Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956969/),l,31.1,72765,DB01597,Cilastatin
,6591852,Recovery,"Recovery from serum was 99% for both imipenem and cilastatin, and the limits of detectability for the two compounds were 0.3 and 0.5 microgram/ml, respectively.",Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6591852/),%,99,73100,DB01597,Cilastatin
,2746858,half-lives,"Concentrations decreased with half-lives of 1.87 +/- 0.71 hours and 1.97 +/- 0.21 hours for the low and the high dosages, and plasma levels at 8 hours after administration were 0.3 +/- 0.1 microgram/ml and 0.8 +/- 0.3 microgram/ml, respectively.","[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746858/),h,1.87,73706,DB01597,Cilastatin
,2746858,half-lives,"Concentrations decreased with half-lives of 1.87 +/- 0.71 hours and 1.97 +/- 0.21 hours for the low and the high dosages, and plasma levels at 8 hours after administration were 0.3 +/- 0.1 microgram/ml and 0.8 +/- 0.3 microgram/ml, respectively.","[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746858/),h,1.97,73707,DB01597,Cilastatin
,2746858,plasma levels,"Concentrations decreased with half-lives of 1.87 +/- 0.71 hours and 1.97 +/- 0.21 hours for the low and the high dosages, and plasma levels at 8 hours after administration were 0.3 +/- 0.1 microgram/ml and 0.8 +/- 0.3 microgram/ml, respectively.","[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746858/),[μg] / [ml],0.3,73708,DB01597,Cilastatin
,2746858,plasma levels,"Concentrations decreased with half-lives of 1.87 +/- 0.71 hours and 1.97 +/- 0.21 hours for the low and the high dosages, and plasma levels at 8 hours after administration were 0.3 +/- 0.1 microgram/ml and 0.8 +/- 0.3 microgram/ml, respectively.","[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746858/),[μg] / [ml],0.8,73709,DB01597,Cilastatin
,2746858,urinary recovery rates,Mean urinary recovery rates in 8 hours after administration were 37.6 +/- 11.8% and 26.8 +/- 17.2% for the low and the high dosages.,"[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746858/),%,37.6,73710,DB01597,Cilastatin
,2746858,urinary recovery rates,Mean urinary recovery rates in 8 hours after administration were 37.6 +/- 11.8% and 26.8 +/- 17.2% for the low and the high dosages.,"[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746858/),%,26.8,73711,DB01597,Cilastatin
,3210305,biological half-life,The mean biological half-life of IPM in maternal serum was 30 minutes.,[Study of imipenem/cilastatin sodium in the perinatal period]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210305/),min,30,74189,DB01597,Cilastatin
,1879184,peak imipenem concentration,The mean peak imipenem concentration in 15 patients was 10.7 micrograms/ml (range 3.3-17.8); the mean trough concentration was 2.1 micrograms/ml (range 0.8-4.9).,Twice daily intramuscular imipenem/cilastatin in the treatment of skin and soft tissue infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879184/),[μg] / [ml],10.7,74510,DB01597,Cilastatin
,1879184,trough concentration,The mean peak imipenem concentration in 15 patients was 10.7 micrograms/ml (range 3.3-17.8); the mean trough concentration was 2.1 micrograms/ml (range 0.8-4.9).,Twice daily intramuscular imipenem/cilastatin in the treatment of skin and soft tissue infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879184/),[μg] / [ml],2.1,74511,DB01597,Cilastatin
≤,31508899,MIC,These dosing regimens provide sufficient antibacterial coverage (MIC ≤ 4 μg/mL) for all renal groups.,Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31508899/),[μg] / [ml],4,75101,DB01597,Cilastatin
,3464782,half-lives,"Concentrations decreased with half-lives of 0.82 +/- 0.10 hour and 0.74 +/- 0.04 hour for the low and high doses, respectively, and serum levels at 6 hours after administration were 0.3 +/- 0.1 microgram/ml and 0.4 +/- 0.1 microgram/ml, respectively.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),h,0.82,75458,DB01597,Cilastatin
,3464782,half-lives,"Concentrations decreased with half-lives of 0.82 +/- 0.10 hour and 0.74 +/- 0.04 hour for the low and high doses, respectively, and serum levels at 6 hours after administration were 0.3 +/- 0.1 microgram/ml and 0.4 +/- 0.1 microgram/ml, respectively.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),h,0.74,75459,DB01597,Cilastatin
,3464782,serum levels,"Concentrations decreased with half-lives of 0.82 +/- 0.10 hour and 0.74 +/- 0.04 hour for the low and high doses, respectively, and serum levels at 6 hours after administration were 0.3 +/- 0.1 microgram/ml and 0.4 +/- 0.1 microgram/ml, respectively.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),[μg] / [ml],0.3,75460,DB01597,Cilastatin
,3464782,serum levels,"Concentrations decreased with half-lives of 0.82 +/- 0.10 hour and 0.74 +/- 0.04 hour for the low and high doses, respectively, and serum levels at 6 hours after administration were 0.3 +/- 0.1 microgram/ml and 0.4 +/- 0.1 microgram/ml, respectively.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),[μg] / [ml],0.4,75461,DB01597,Cilastatin
,3464782,Peak concentrations,Peak concentrations of MK-0791 were 22.6 +/- 4.8 micrograms/ml in the 10 mg/10 mg/kg group and 52.9 +/- 4.7 micrograms/ml in the 20 mg/20 mg/kg group at the end of the drip infusion.,[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),[μg] / [ml],22.6,75462,DB01597,Cilastatin
,3464782,Peak concentrations,Peak concentrations of MK-0791 were 22.6 +/- 4.8 micrograms/ml in the 10 mg/10 mg/kg group and 52.9 +/- 4.7 micrograms/ml in the 20 mg/20 mg/kg group at the end of the drip infusion.,[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),[μg] / [ml],52.9,75463,DB01597,Cilastatin
,3464782,Half-lives,"Half-lives were 0.56 +/- 0.17 hour and 0.46 +/- 0.11 hour for the 2 doses, respectively while MK-0791 levels were below detection limit at 6 hours after administration.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),h,0.56,75464,DB01597,Cilastatin
,3464782,Half-lives,"Half-lives were 0.56 +/- 0.17 hour and 0.46 +/- 0.11 hour for the 2 doses, respectively while MK-0791 levels were below detection limit at 6 hours after administration.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),h,0.46,75465,DB01597,Cilastatin
,3464782,urinary recovery rates,"Mean urinary recovery rates in 6 hours after administration were 54.0 +/- 15.3% and 49.3 +/- 7.8% for MK-0787 and MK-0791, respectively, in the group of 10 mg/10 mg/kg, and 62.0 +/- 7.4% and 65.3 +/- 9.2%, respectively, in the group of 20 mg/20 mg/kg.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),%,54.0,75466,DB01597,Cilastatin
,3464782,urinary recovery rates,"Mean urinary recovery rates in 6 hours after administration were 54.0 +/- 15.3% and 49.3 +/- 7.8% for MK-0787 and MK-0791, respectively, in the group of 10 mg/10 mg/kg, and 62.0 +/- 7.4% and 65.3 +/- 9.2%, respectively, in the group of 20 mg/20 mg/kg.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),%,49.3,75467,DB01597,Cilastatin
,3464782,urinary recovery rates,"Mean urinary recovery rates in 6 hours after administration were 54.0 +/- 15.3% and 49.3 +/- 7.8% for MK-0787 and MK-0791, respectively, in the group of 10 mg/10 mg/kg, and 62.0 +/- 7.4% and 65.3 +/- 9.2%, respectively, in the group of 20 mg/20 mg/kg.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),%,62.0,75468,DB01597,Cilastatin
,3464782,urinary recovery rates,"Mean urinary recovery rates in 6 hours after administration were 54.0 +/- 15.3% and 49.3 +/- 7.8% for MK-0787 and MK-0791, respectively, in the group of 10 mg/10 mg/kg, and 62.0 +/- 7.4% and 65.3 +/- 9.2%, respectively, in the group of 20 mg/20 mg/kg.",[Studies on imipenem/cilastatin sodium in the field of pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464782/),%,65.3,75469,DB01597,Cilastatin
,1482132,peak concentrations,"The mean peak concentrations in plasma were 14.7 +/- 4.9, 14.9 +/- 5.2, and 43 +/- 28.3 micrograms/ml in early pregnancy, late pregnancy, and the nonpregnant state, respectively.",Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[μg] / [ml],14.7,76995,DB01597,Cilastatin
,1482132,peak concentrations,"The mean peak concentrations in plasma were 14.7 +/- 4.9, 14.9 +/- 5.2, and 43 +/- 28.3 micrograms/ml in early pregnancy, late pregnancy, and the nonpregnant state, respectively.",Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[μg] / [ml],14.9,76996,DB01597,Cilastatin
,1482132,peak concentrations,"The mean peak concentrations in plasma were 14.7 +/- 4.9, 14.9 +/- 5.2, and 43 +/- 28.3 micrograms/ml in early pregnancy, late pregnancy, and the nonpregnant state, respectively.",Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[μg] / [ml],43,76997,DB01597,Cilastatin
,1482132,volumes of distribution,"The volumes of distribution were significantly larger during early pregnancy (0.98 +/- 0.45 liter/kg of body weight, P < 0.005) and late pregnancy (0.59 +/- 0.19 liter/kg, P < 0.05) than in the nonpregnant state (0.33 +/- 0.10 liter/kg), and total clearances from plasma were faster in early pregnancy (12.7 +/- 7.8 ml min-1 kg-1, P < 0.05) and late pregnancy (10.7 +/- 4.6 ml min-1 kg-1, P < 0.05) than in the nonpregnant state (5.77 +/- 1.19 ml min-1 kg-1).",Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[l] / [kg],0.98,76998,DB01597,Cilastatin
,1482132,volumes of distribution,"The volumes of distribution were significantly larger during early pregnancy (0.98 +/- 0.45 liter/kg of body weight, P < 0.005) and late pregnancy (0.59 +/- 0.19 liter/kg, P < 0.05) than in the nonpregnant state (0.33 +/- 0.10 liter/kg), and total clearances from plasma were faster in early pregnancy (12.7 +/- 7.8 ml min-1 kg-1, P < 0.05) and late pregnancy (10.7 +/- 4.6 ml min-1 kg-1, P < 0.05) than in the nonpregnant state (5.77 +/- 1.19 ml min-1 kg-1).",Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[l] / [kg],0.59,76999,DB01597,Cilastatin
,1482132,volumes of distribution,"The volumes of distribution were significantly larger during early pregnancy (0.98 +/- 0.45 liter/kg of body weight, P < 0.005) and late pregnancy (0.59 +/- 0.19 liter/kg, P < 0.05) than in the nonpregnant state (0.33 +/- 0.10 liter/kg), and total clearances from plasma were faster in early pregnancy (12.7 +/- 7.8 ml min-1 kg-1, P < 0.05) and late pregnancy (10.7 +/- 4.6 ml min-1 kg-1, P < 0.05) than in the nonpregnant state (5.77 +/- 1.19 ml min-1 kg-1).",Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[l] / [kg],0.33,77000,DB01597,Cilastatin
,1482132,total clearances,"The volumes of distribution were significantly larger during early pregnancy (0.98 +/- 0.45 liter/kg of body weight, P < 0.005) and late pregnancy (0.59 +/- 0.19 liter/kg, P < 0.05) than in the nonpregnant state (0.33 +/- 0.10 liter/kg), and total clearances from plasma were faster in early pregnancy (12.7 +/- 7.8 ml min-1 kg-1, P < 0.05) and late pregnancy (10.7 +/- 4.6 ml min-1 kg-1, P < 0.05) than in the nonpregnant state (5.77 +/- 1.19 ml min-1 kg-1).",Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[ml] / [kg·min],12.7,77001,DB01597,Cilastatin
,1482132,total clearances,"The volumes of distribution were significantly larger during early pregnancy (0.98 +/- 0.45 liter/kg of body weight, P < 0.005) and late pregnancy (0.59 +/- 0.19 liter/kg, P < 0.05) than in the nonpregnant state (0.33 +/- 0.10 liter/kg), and total clearances from plasma were faster in early pregnancy (12.7 +/- 7.8 ml min-1 kg-1, P < 0.05) and late pregnancy (10.7 +/- 4.6 ml min-1 kg-1, P < 0.05) than in the nonpregnant state (5.77 +/- 1.19 ml min-1 kg-1).",Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[ml] / [kg·min],10.7,77002,DB01597,Cilastatin
,1482132,total clearances,"The volumes of distribution were significantly larger during early pregnancy (0.98 +/- 0.45 liter/kg of body weight, P < 0.005) and late pregnancy (0.59 +/- 0.19 liter/kg, P < 0.05) than in the nonpregnant state (0.33 +/- 0.10 liter/kg), and total clearances from plasma were faster in early pregnancy (12.7 +/- 7.8 ml min-1 kg-1, P < 0.05) and late pregnancy (10.7 +/- 4.6 ml min-1 kg-1, P < 0.05) than in the nonpregnant state (5.77 +/- 1.19 ml min-1 kg-1).",Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[ml] / [kg·min],5.77,77003,DB01597,Cilastatin
,1482132,concentrations,The mean concentrations in amniotic fluid were 0.07 +/- 0.01 and 0.72 +/- 0.85 micrograms/ml in early and late pregnancy.,Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),μ,0.07,77004,DB01597,Cilastatin
,1482132,concentrations,The mean concentrations in amniotic fluid were 0.07 +/- 0.01 and 0.72 +/- 0.85 micrograms/ml in early and late pregnancy.,Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),μ,0.72,77005,DB01597,Cilastatin
,1482132,um,The mean umbilical venous and arterial drug concentrations were 1.72 +/- 1.22 and 1.64 +/- 1.22 micrograms/ml.,Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[μg] / [ml],1.72,77006,DB01597,Cilastatin
,1482132,venous,The mean umbilical venous and arterial drug concentrations were 1.72 +/- 1.22 and 1.64 +/- 1.22 micrograms/ml.,Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[μg] / [ml],1.72,77007,DB01597,Cilastatin
,1482132,arterial drug concentrations,The mean umbilical venous and arterial drug concentrations were 1.72 +/- 1.22 and 1.64 +/- 1.22 micrograms/ml.,Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),[μg] / [ml],1.64,77008,DB01597,Cilastatin
,1482132,feto-maternal ratio,The feto-maternal ratio at the time of cesarean section was 0.33 +/- 0.12.,Pharmacokinetics and transplacental passage of imipenem during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482132/),,0.33,77009,DB01597,Cilastatin
,6583194,half life in the beta-phase,The half life in the beta-phase was about 1 h in 48 subjects with normal renal function and about 80 min in one subject with a glomerular filtration rate (GFR) of about 50 ml/min/1 X 73 m2.,Pharmacokinetics of imipenem in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6583194/),h,1,77225,DB01597,Cilastatin
,6583194,half life in the beta-phase,The half life in the beta-phase was about 1 h in 48 subjects with normal renal function and about 80 min in one subject with a glomerular filtration rate (GFR) of about 50 ml/min/1 X 73 m2.,Pharmacokinetics of imipenem in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6583194/),min,80,77226,DB01597,Cilastatin
,6583194,volume of distribution in the central compartment,The volume of distribution in the central compartment was about 101.,Pharmacokinetics of imipenem in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6583194/),,101,77227,DB01597,Cilastatin
,3459390,trough (5.5,"The trough (5.5-h) moxalactam serum levels were 10 times greater than those of imipenem (18.5 and 1.7 micrograms/ml, respectively).",Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459390/),[μg] / [ml],18.5,78189,DB01597,Cilastatin
,3459390,trough (5.5,"The trough (5.5-h) moxalactam serum levels were 10 times greater than those of imipenem (18.5 and 1.7 micrograms/ml, respectively).",Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459390/),[μg] / [ml],1.7,78190,DB01597,Cilastatin
,3459390,serum levels,"The trough (5.5-h) moxalactam serum levels were 10 times greater than those of imipenem (18.5 and 1.7 micrograms/ml, respectively).",Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459390/),[μg] / [ml],18.5,78191,DB01597,Cilastatin
,3459390,serum levels,"The trough (5.5-h) moxalactam serum levels were 10 times greater than those of imipenem (18.5 and 1.7 micrograms/ml, respectively).",Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459390/),[μg] / [ml],1.7,78192,DB01597,Cilastatin
more,3459390,peak bactericidal titers,The geometric mean peak bactericidal titers from volunteers receiving imipenem were more than 1:8 against all bacteria and were significantly higher than the titers from volunteers receiving moxalactam against S. aureus (1:7.3) and Pseudomonas aeruginosa (1:4.5).,Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459390/),,1:8,78193,DB01597,Cilastatin
,3859243,peak plasma levels,"The mean peak plasma levels of imipenem 30 min postinfusion were 55.4 and 27.2 micrograms/ml, and the mean t1/2 beta values were 2.1 and 1.8 h at doses of 25 and 15 mg/kg, respectively.",Single-dose pharmacokinetics of imipenem-cilastatin in neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859243/),[μg] / [ml],55.4,83873,DB01597,Cilastatin
,3859243,peak plasma levels,"The mean peak plasma levels of imipenem 30 min postinfusion were 55.4 and 27.2 micrograms/ml, and the mean t1/2 beta values were 2.1 and 1.8 h at doses of 25 and 15 mg/kg, respectively.",Single-dose pharmacokinetics of imipenem-cilastatin in neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859243/),[μg] / [ml],27.2,83874,DB01597,Cilastatin
,3859243,t1/2 beta,"The mean peak plasma levels of imipenem 30 min postinfusion were 55.4 and 27.2 micrograms/ml, and the mean t1/2 beta values were 2.1 and 1.8 h at doses of 25 and 15 mg/kg, respectively.",Single-dose pharmacokinetics of imipenem-cilastatin in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859243/),h,2.1,83875,DB01597,Cilastatin
,3859243,t1/2 beta,"The mean peak plasma levels of imipenem 30 min postinfusion were 55.4 and 27.2 micrograms/ml, and the mean t1/2 beta values were 2.1 and 1.8 h at doses of 25 and 15 mg/kg, respectively.",Single-dose pharmacokinetics of imipenem-cilastatin in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859243/),h,1.8,83876,DB01597,Cilastatin
,3859243,volume of distribution,The calculated volume of distribution was 0.41 liters/kg.,Single-dose pharmacokinetics of imipenem-cilastatin in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3859243/),[l] / [kg],0.41,83877,DB01597,Cilastatin
,29311084,apparent terminal half-lives,"Both drugs penetrated the epithelial lining fluid (ELF) to a similar degree, with the profiles being similar in shape to the corresponding plasma profiles and with the apparent terminal half-lives in plasma and ELF being 1.2 and 1.3 h, respectively, for relebactam and 1.0 h in both compartments for imipenem.","Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29311084/),h,1.2,83986,DB01597,Cilastatin
,29311084,apparent terminal half-lives,"Both drugs penetrated the epithelial lining fluid (ELF) to a similar degree, with the profiles being similar in shape to the corresponding plasma profiles and with the apparent terminal half-lives in plasma and ELF being 1.2 and 1.3 h, respectively, for relebactam and 1.0 h in both compartments for imipenem.","Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29311084/),h,1.3,83987,DB01597,Cilastatin
,29311084,apparent terminal half-lives,"Both drugs penetrated the epithelial lining fluid (ELF) to a similar degree, with the profiles being similar in shape to the corresponding plasma profiles and with the apparent terminal half-lives in plasma and ELF being 1.2 and 1.3 h, respectively, for relebactam and 1.0 h in both compartments for imipenem.","Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29311084/),h,1.0,83988,DB01597,Cilastatin
,29311084,time-invariant partition coefficient,"In this model, the time-invariant partition coefficient for relebactam was found to be 55%, based on free drug levels.","Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29311084/),%,55,83989,DB01597,Cilastatin
,3464784,peak plasma concentrations,"In 6 children, 3 each who were given doses of 10 or 20 mg/kg, the mean peak plasma concentrations of the drugs were found at the end of the 30 minutes-infusion with values of 35.20 and 74.90 micrograms/ml for MK-0787 and 44.85 and 93.32 micrograms/ml for MK-0791 after the dose of 10 and 20 mg/kg, respectively.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464784/),[μg] / [ml],35.20,90678,DB01597,Cilastatin
,3464784,peak plasma concentrations,"In 6 children, 3 each who were given doses of 10 or 20 mg/kg, the mean peak plasma concentrations of the drugs were found at the end of the 30 minutes-infusion with values of 35.20 and 74.90 micrograms/ml for MK-0787 and 44.85 and 93.32 micrograms/ml for MK-0791 after the dose of 10 and 20 mg/kg, respectively.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464784/),[μg] / [ml],74.90,90679,DB01597,Cilastatin
,3464784,peak plasma concentrations,"In 6 children, 3 each who were given doses of 10 or 20 mg/kg, the mean peak plasma concentrations of the drugs were found at the end of the 30 minutes-infusion with values of 35.20 and 74.90 micrograms/ml for MK-0787 and 44.85 and 93.32 micrograms/ml for MK-0791 after the dose of 10 and 20 mg/kg, respectively.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464784/),[μg] / [ml],44.85,90680,DB01597,Cilastatin
,3464784,peak plasma concentrations,"In 6 children, 3 each who were given doses of 10 or 20 mg/kg, the mean peak plasma concentrations of the drugs were found at the end of the 30 minutes-infusion with values of 35.20 and 74.90 micrograms/ml for MK-0787 and 44.85 and 93.32 micrograms/ml for MK-0791 after the dose of 10 and 20 mg/kg, respectively.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464784/),[μg] / [ml],93.32,90681,DB01597,Cilastatin
,3464784,half-lives,"In the 10 mg/kg group, the mean half-lives of MK-0787 and MK-0791 were 0.97 and 0.71 hour, respectively and those values were 0.89 and 0.63 hour, respectively in the 20 mg/kg group.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464784/),h,0.97,90682,DB01597,Cilastatin
,3464784,half-lives,"In the 10 mg/kg group, the mean half-lives of MK-0787 and MK-0791 were 0.97 and 0.71 hour, respectively and those values were 0.89 and 0.63 hour, respectively in the 20 mg/kg group.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464784/),h,0.71,90683,DB01597,Cilastatin
,3464784,half-lives,"In the 10 mg/kg group, the mean half-lives of MK-0787 and MK-0791 were 0.97 and 0.71 hour, respectively and those values were 0.89 and 0.63 hour, respectively in the 20 mg/kg group.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464784/),h,0.89,90684,DB01597,Cilastatin
,3464784,half-lives,"In the 10 mg/kg group, the mean half-lives of MK-0787 and MK-0791 were 0.97 and 0.71 hour, respectively and those values were 0.89 and 0.63 hour, respectively in the 20 mg/kg group.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464784/),h,0.63,90685,DB01597,Cilastatin
,7994939,elimination phase half-life,The elimination phase half-life of imipenem was 3.1 +/- 0.3 h and that of cilastatin was 9.7 +/- 1.2 h.,Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7994939/),h,3.1,91521,DB01597,Cilastatin
,7994939,elimination phase half-life,The elimination phase half-life of imipenem was 3.1 +/- 0.3 h and that of cilastatin was 9.7 +/- 1.2 h.,Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7994939/),h,9.7,91522,DB01597,Cilastatin
,7994939,total body clearance,"The total body clearance of imipenem and cilastatin was 84.0 +/- 7.2 and 32.2 +/- 2.4 ml/min, respectively.",Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7994939/),[ml] / [min],84.0,91523,DB01597,Cilastatin
,7994939,total body clearance,"The total body clearance of imipenem and cilastatin was 84.0 +/- 7.2 and 32.2 +/- 2.4 ml/min, respectively.",Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7994939/),[ml] / [min],32.2,91524,DB01597,Cilastatin
,7994939,Clearance,"Clearance of imipenem and cilastatin during slow HD was 24.3 +/- 2.4 and 54.3 +/- 3.1%, respectively, of total body clearance.",Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7994939/),%,24.3,91525,DB01597,Cilastatin
,7994939,Clearance,"Clearance of imipenem and cilastatin during slow HD was 24.3 +/- 2.4 and 54.3 +/- 3.1%, respectively, of total body clearance.",Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7994939/),%,54.3,91526,DB01597,Cilastatin
,16493791,AUC0-360,"Among the drug solutions containing CS, MEPM/CS had the highest pleural fluid AUC0-360 (1594.8+/-510.3 microg min/ml), and the highest pleural fluid AUC0-360/plasma AUC0-360 ratio (0.79+/-0.04).",Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16493791/),[min·μg] / [ml],1594.8,92720,DB01597,Cilastatin
,16493791,AUC0-360/plasma AUC0-360 ratio,"Among the drug solutions containing CS, MEPM/CS had the highest pleural fluid AUC0-360 (1594.8+/-510.3 microg min/ml), and the highest pleural fluid AUC0-360/plasma AUC0-360 ratio (0.79+/-0.04).",Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16493791/),,0.79,92721,DB01597,Cilastatin
,16493791,plasma AUC0-360,BIPM/CS had the highest plasma AUC0-360 (3040.1+/-1525.9 microg min/ml).,Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16493791/),[min·μg] / [ml],3040.1,92722,DB01597,Cilastatin
,7652497,terminal half-life,The terminal half-life is approximately 1 hour and the plasma clearance is approximately 15.5 L/h/70 kg.,The pharmacokinetics of meropenem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652497/),h,1,98629,DB01597,Cilastatin
,7652497,plasma clearance,The terminal half-life is approximately 1 hour and the plasma clearance is approximately 15.5 L/h/70 kg.,The pharmacokinetics of meropenem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652497/),[l] / [70·h·kg],15.5,98630,DB01597,Cilastatin
greater,7652497,trough concentration,The plasma concentrations after a 1 g dose show a trough concentration (8 hours) of slightly greater than 0.25 mg/L.,The pharmacokinetics of meropenem. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652497/),[mg] / [l],0.25,98631,DB01597,Cilastatin
,3461422,peak,"After a 25 mg/kg dose, the mean peak and trough (6 hr) plasma concentrations of imipenem were 78.8 and 0.68 micrograms/ml, respectively, and the half-lives of imipenem and cilastatin were 1.12 and 0.97 hr, respectively.",Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3461422/),[μg] / [ml],78.8,99485,DB01597,Cilastatin
,3461422,trough (6 hr,"After a 25 mg/kg dose, the mean peak and trough (6 hr) plasma concentrations of imipenem were 78.8 and 0.68 micrograms/ml, respectively, and the half-lives of imipenem and cilastatin were 1.12 and 0.97 hr, respectively.",Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3461422/),[μg] / [ml],78.8,99486,DB01597,Cilastatin
,3461422,half-lives,"After a 25 mg/kg dose, the mean peak and trough (6 hr) plasma concentrations of imipenem were 78.8 and 0.68 micrograms/ml, respectively, and the half-lives of imipenem and cilastatin were 1.12 and 0.97 hr, respectively.",Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3461422/),h,1.12,99487,DB01597,Cilastatin
,3461422,half-lives,"After a 25 mg/kg dose, the mean peak and trough (6 hr) plasma concentrations of imipenem were 78.8 and 0.68 micrograms/ml, respectively, and the half-lives of imipenem and cilastatin were 1.12 and 0.97 hr, respectively.",Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3461422/),h,0.97,99488,DB01597,Cilastatin
,3461422,Urinary excretion,Urinary excretion of imipenem was 43-47% during the 6 hr following administration of either dosage.,Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3461422/),%,43-47,99489,DB01597,Cilastatin
,8430678,total clearance,"The total clearance of imipenem, a carbapenem antibiotic, is reduced from approximately 230 mL/min in patients with normal renal function to approximately 50 mL/min in patients with chronic renal failure.",Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430678/),[ml] / [min],230,100228,DB01597,Cilastatin
,8430678,total clearance,"The total clearance of imipenem, a carbapenem antibiotic, is reduced from approximately 230 mL/min in patients with normal renal function to approximately 50 mL/min in patients with chronic renal failure.",Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430678/),[ml] / [min],50,100229,DB01597,Cilastatin
,8430678,nonrenal clearance,"This decline in clearance results not only from the loss of renal clearance, but also from a reduction in the nonrenal clearance from 130 to 50 mL/min.",Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430678/),[ml] / [min],130,100230,DB01597,Cilastatin
,8430678,nonrenal clearance,"This decline in clearance results not only from the loss of renal clearance, but also from a reduction in the nonrenal clearance from 130 to 50 mL/min.",Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430678/),[ml] / [min],50,100231,DB01597,Cilastatin
,8430678,total clearance,The total clearance of imipenem in patients with acute renal failure (108.3 +/- 13.8 mL/min; mean +/- SD) was significantly greater than the total clearance measured in patients with chronic renal failure (64.4 +/- 10.5 mL/min; P < 0.02).,Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430678/),[ml] / [min],108.3,100232,DB01597,Cilastatin
,8430678,total clearance,The total clearance of imipenem in patients with acute renal failure (108.3 +/- 13.8 mL/min; mean +/- SD) was significantly greater than the total clearance measured in patients with chronic renal failure (64.4 +/- 10.5 mL/min; P < 0.02).,Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430678/),[ml] / [min],64.4,100233,DB01597,Cilastatin
,8430678,nonrenal clearance,This increased clearance resulted from a greater nonrenal clearance of the drug in patients with acute renal failure (95.0 +/- 13.8 v 51.1 +/- 10.5 mL/min; P < 0.02).,Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430678/),[ml] / [min],95.0,100234,DB01597,Cilastatin
,8430678,nonrenal clearance,This increased clearance resulted from a greater nonrenal clearance of the drug in patients with acute renal failure (95.0 +/- 13.8 v 51.1 +/- 10.5 mL/min; P < 0.02).,Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430678/),[ml] / [min],51.1,100235,DB01597,Cilastatin
,2674874,elimination half-life,The mean elimination half-life of imipenem was 0.87 h in children and 2.1 h in neonates.,[Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674874/),h,0.87,105397,DB01597,Cilastatin
,2674874,elimination half-life,The mean elimination half-life of imipenem was 0.87 h in children and 2.1 h in neonates.,[Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674874/),h,2.1,105398,DB01597,Cilastatin
,2674874,elimination half-life,The mean cilastatin elimination half-life was 0.73 h in children and 5.1 h in neonates.,[Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674874/),h,0.73,105399,DB01597,Cilastatin
,2674874,elimination half-life,The mean cilastatin elimination half-life was 0.73 h in children and 5.1 h in neonates.,[Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674874/),h,5.1,105400,DB01597,Cilastatin
,29914955,terminal half-life (t1/2),"Following single- or multiple-dose intravenous administration over 30 min, plasma relebactam concentrations declined biexponentially, with a terminal half-life (t1/2) ranging from 1.35 to 1.85 h independently of the dose.","Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29914955/),h,1.35 to 1.85,107045,DB01597,Cilastatin
,3469182,half life,"The mean half life was 1.6 h for imipenem and 2.1 h for cilastatin, values similar to those reported for patients with moderate renal impairment.",Pharmacokinetic studies of imipenem/cilastatin in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3469182/),h,1.6,111910,DB01597,Cilastatin
,3469182,half life,"The mean half life was 1.6 h for imipenem and 2.1 h for cilastatin, values similar to those reported for patients with moderate renal impairment.",Pharmacokinetic studies of imipenem/cilastatin in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3469182/),h,2.1,111911,DB01597,Cilastatin
,27862103,CLHF,"The imipenem CLHF was 3.27 ± 0.48 L/hour, which accounted for 23 ± 4% of the CLTotal (14.74 ± 4.75 L/hr).",Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862103/),[l] / [h],3.27,114096,DB01597,Cilastatin
,27862103,CLTotal,"The imipenem CLHF was 3.27 ± 0.48 L/hour, which accounted for 23 ± 4% of the CLTotal (14.74 ± 4.75 L/hr).",Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862103/),[l] / [h],14.74,114097,DB01597,Cilastatin
,27862103,CLHF,"Cilastatin CLHF was 1.98 ± 0.56 L/hour, which accounted for 45 ± 19% of the CLTotal (5.16 + 2.44 L/hr).",Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862103/),[l] / [h],1.98,114098,DB01597,Cilastatin
,27862103,CLTotal,"Cilastatin CLHF was 1.98 ± 0.56 L/hour, which accounted for 45 ± 19% of the CLTotal (5.16 + 2.44 L/hr).",Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862103/),[l] / [h],5.16,114099,DB01597,Cilastatin
,27862103,half-lives,"The imipenem and cilastatin half-lives were 1.77 ± 0.38 hours and 4.21 ± 2.31 hours, respectively.",Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862103/),h,1.77,114100,DB01597,Cilastatin
,27862103,half-lives,"The imipenem and cilastatin half-lives were 1.77 ± 0.38 hours and 4.21 ± 2.31 hours, respectively.",Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862103/),h,4.21,114101,DB01597,Cilastatin
,27862103,Vdss,"Imipenem and cilastatin Vdss were 35.1 ± 10.3 and 32.8 ± 13.8 L, respectively.",Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862103/),l,35.1,114102,DB01597,Cilastatin
,27862103,Vdss,"Imipenem and cilastatin Vdss were 35.1 ± 10.3 and 32.8 ± 13.8 L, respectively.",Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862103/),l,32.8,114103,DB01597,Cilastatin
,3464772,Plasma concentrations,Plasma concentrations of MK-0787 in 2 children were 19.6 and 20.0 micrograms/ml at 15 minutes and 5.6 and 2.1 micrograms/ml at 2 hours after a 10 mg/10 mg/kg intravenous 30-minute drip infusion of MK-0787/MK-0791.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],19.6,115546,DB01597,Cilastatin
,3464772,Plasma concentrations,Plasma concentrations of MK-0787 in 2 children were 19.6 and 20.0 micrograms/ml at 15 minutes and 5.6 and 2.1 micrograms/ml at 2 hours after a 10 mg/10 mg/kg intravenous 30-minute drip infusion of MK-0787/MK-0791.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],20.0,115547,DB01597,Cilastatin
,3464772,Plasma concentrations,Plasma concentrations of MK-0787 in 2 children were 19.6 and 20.0 micrograms/ml at 15 minutes and 5.6 and 2.1 micrograms/ml at 2 hours after a 10 mg/10 mg/kg intravenous 30-minute drip infusion of MK-0787/MK-0791.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],5.6,115548,DB01597,Cilastatin
,3464772,Plasma concentrations,Plasma concentrations of MK-0787 in 2 children were 19.6 and 20.0 micrograms/ml at 15 minutes and 5.6 and 2.1 micrograms/ml at 2 hours after a 10 mg/10 mg/kg intravenous 30-minute drip infusion of MK-0787/MK-0791.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],2.1,115549,DB01597,Cilastatin
,3464772,Plasma half-lives,"Plasma half-lives of MK-0787 were 1.52 and 0.74 hour, and total urinary recoveries were 54.6 and 71.4% during 0-6 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),h,1.52,115550,DB01597,Cilastatin
,3464772,Plasma half-lives,"Plasma half-lives of MK-0787 were 1.52 and 0.74 hour, and total urinary recoveries were 54.6 and 71.4% during 0-6 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),h,0.74,115551,DB01597,Cilastatin
,3464772,total urinary recoveries,"Plasma half-lives of MK-0787 were 1.52 and 0.74 hour, and total urinary recoveries were 54.6 and 71.4% during 0-6 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),%,54.6,115552,DB01597,Cilastatin
,3464772,total urinary recoveries,"Plasma half-lives of MK-0787 were 1.52 and 0.74 hour, and total urinary recoveries were 54.6 and 71.4% during 0-6 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),%,71.4,115553,DB01597,Cilastatin
,3464772,plasma concentrations,"After a 20 mg/20 mg/kg intravenous 30-minute drip infusion into 2 other children, plasma concentrations of MK-0787 were 46.8 and 44.0 micrograms/ml at 15 minutes and 7.8 and 7.4 micrograms/ml at 2 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),μ,46.8,115554,DB01597,Cilastatin
,3464772,plasma concentrations,"After a 20 mg/20 mg/kg intravenous 30-minute drip infusion into 2 other children, plasma concentrations of MK-0787 were 46.8 and 44.0 micrograms/ml at 15 minutes and 7.8 and 7.4 micrograms/ml at 2 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),μ,44.0,115555,DB01597,Cilastatin
,3464772,plasma concentrations,"After a 20 mg/20 mg/kg intravenous 30-minute drip infusion into 2 other children, plasma concentrations of MK-0787 were 46.8 and 44.0 micrograms/ml at 15 minutes and 7.8 and 7.4 micrograms/ml at 2 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],7.8,115556,DB01597,Cilastatin
,3464772,plasma concentrations,"After a 20 mg/20 mg/kg intravenous 30-minute drip infusion into 2 other children, plasma concentrations of MK-0787 were 46.8 and 44.0 micrograms/ml at 15 minutes and 7.8 and 7.4 micrograms/ml at 2 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],7.4,115557,DB01597,Cilastatin
,3464772,Plasma half-lives,"Plasma half-lives were 0.82 and 0.83 hour, and total urinary recoveries were 110.2 and 80.5% during 0-6 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),h,0.82,115558,DB01597,Cilastatin
,3464772,Plasma half-lives,"Plasma half-lives were 0.82 and 0.83 hour, and total urinary recoveries were 110.2 and 80.5% during 0-6 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),h,0.83,115559,DB01597,Cilastatin
,3464772,total urinary recoveries,"Plasma half-lives were 0.82 and 0.83 hour, and total urinary recoveries were 110.2 and 80.5% during 0-6 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),%,110.2,115560,DB01597,Cilastatin
,3464772,total urinary recoveries,"Plasma half-lives were 0.82 and 0.83 hour, and total urinary recoveries were 110.2 and 80.5% during 0-6 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),%,80.5,115561,DB01597,Cilastatin
less,3464772,Plasma concentrations,"Plasma concentrations of MK-0787 were less than 0.2, 0.2 and 1.2 micrograms/ml just before the next doses in 3 patients given 11-20 mg/11-20 mg/kg of MK-0787/MK-0791 every 6-8 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],0.2,115562,DB01597,Cilastatin
,3464772,Plasma concentrations,"Plasma concentrations of MK-0787 were less than 0.2, 0.2 and 1.2 micrograms/ml just before the next doses in 3 patients given 11-20 mg/11-20 mg/kg of MK-0787/MK-0791 every 6-8 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],0.2,115563,DB01597,Cilastatin
,3464772,Plasma concentrations,"Plasma concentrations of MK-0787 were less than 0.2, 0.2 and 1.2 micrograms/ml just before the next doses in 3 patients given 11-20 mg/11-20 mg/kg of MK-0787/MK-0791 every 6-8 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],1.2,115564,DB01597,Cilastatin
,3464772,Plasma concentrations,Plasma concentrations of MK-0787 in a girl were 0.3 micrograms/ml just before the next dose and 8.2 micrograms/ml at 2 hours after multiple doses of 14 mg/14 mg/kg every 6 hours for 3 days and then 28 mg/28 mg/kg every 6 hours for 35 days.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],0.3,115565,DB01597,Cilastatin
,3464772,Plasma concentrations,Plasma concentrations of MK-0787 in a girl were 0.3 micrograms/ml just before the next dose and 8.2 micrograms/ml at 2 hours after multiple doses of 14 mg/14 mg/kg every 6 hours for 3 days and then 28 mg/28 mg/kg every 6 hours for 35 days.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464772/),[μg] / [ml],8.2,115566,DB01597,Cilastatin
,2211452,elimination half-lives,"The elimination half-lives of imipenem and cilastatin during the IHF treatment were almost identical, 1.4 +/- 0.3 and 1.5 +/- 0.3 h, respectively.",Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211452/),h,1.4,117265,DB01597,Cilastatin
,2211452,elimination half-lives,"The elimination half-lives of imipenem and cilastatin during the IHF treatment were almost identical, 1.4 +/- 0.3 and 1.5 +/- 0.3 h, respectively.",Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211452/),h,1.5,117266,DB01597,Cilastatin
,2211452,elimination half-lives,"However, there was a great difference between the elimination half-lives of the two drugs in the post-treatment period, 3.4 +/- 1.0 and 16 +/- 10 h for imipenem and cilastatin, respectively.",Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211452/),h,3.4,117267,DB01597,Cilastatin
,2211452,elimination half-lives,"However, there was a great difference between the elimination half-lives of the two drugs in the post-treatment period, 3.4 +/- 1.0 and 16 +/- 10 h for imipenem and cilastatin, respectively.",Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211452/),h,16,117268,DB01597,Cilastatin
,2211452,ha,The haemofiltration clearance of imipenem was 134 +/- 41 ml/min and that of cilastatin 109 +/- 8 ml/min.,Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211452/),[ml] / [min],134,117269,DB01597,Cilastatin
,2211452,ha,The haemofiltration clearance of imipenem was 134 +/- 41 ml/min and that of cilastatin 109 +/- 8 ml/min.,Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211452/),[ml] / [min],109,117270,DB01597,Cilastatin
,2211452,clearance,The haemofiltration clearance of imipenem was 134 +/- 41 ml/min and that of cilastatin 109 +/- 8 ml/min.,Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211452/),[ml] / [min],134,117271,DB01597,Cilastatin
,2211452,clearance,The haemofiltration clearance of imipenem was 134 +/- 41 ml/min and that of cilastatin 109 +/- 8 ml/min.,Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211452/),[ml] / [min],109,117272,DB01597,Cilastatin
,30831307,CT50,"For the association piperacillin-tazobactam (n=19), 68.7% of CT50 and 93.7% of Cmin reached the pharmacokinetic goals defined (64 mg.L-1 for CT50 and 16 mg.L-1 for Cmin).",PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831307/),[mg] / [l],64,120535,DB01597,Cilastatin
,30831307,Cmin,"For the association piperacillin-tazobactam (n=19), 68.7% of CT50 and 93.7% of Cmin reached the pharmacokinetic goals defined (64 mg.L-1 for CT50 and 16 mg.L-1 for Cmin).",PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831307/),[mg] / [l],16,120536,DB01597,Cilastatin
,30831307,Cmin,"For cefotaxime (n=12), the pharmacokinetic goals (4 mg.L-1 for CT50 and 1 mg.L-1 for Cmin) were achieved in 100% of the cases for CT50 and in 81.8% of the cases for Cmin.",PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831307/),,4,120537,DB01597,Cilastatin
,30831307,Cmin,"For cefotaxime (n=12), the pharmacokinetic goals (4 mg.L-1 for CT50 and 1 mg.L-1 for Cmin) were achieved in 100% of the cases for CT50 and in 81.8% of the cases for Cmin.",PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831307/),,1,120538,DB01597,Cilastatin
,30831307,CT50,"Regarding imipenem (n=10), the pharmacokinetic goals were 16 mg.L-1 for CT50 and 4 mg.L-1 for Cmin.",PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831307/),[mg] / [l],16,120539,DB01597,Cilastatin
,30831307,Cmin,"Regarding imipenem (n=10), the pharmacokinetic goals were 16 mg.L-1 for CT50 and 4 mg.L-1 for Cmin.",PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831307/),[mg] / [l],4,120540,DB01597,Cilastatin
above,30831307,CT50,Only one CT50 was above 16 mg.,PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831307/),mg,16,120541,DB01597,Cilastatin
,2055813,peak serum imipenem concentrations,"Doses of 0.5 and 1.0 g produced mean peak serum imipenem concentrations of 30 and 70 mg/l respectively, about 60% of cilastatin.",Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055813/),[mg] / [l],30,121307,DB01597,Cilastatin
,2055813,peak serum imipenem concentrations,"Doses of 0.5 and 1.0 g produced mean peak serum imipenem concentrations of 30 and 70 mg/l respectively, about 60% of cilastatin.",Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055813/),[mg] / [l],70,121308,DB01597,Cilastatin
,2055813,maximum PDF concentrations,"Peritoneal dialysis fluid (PDF) imipenem concentrations reached 20-30% of the serum peak 4-5 h after iv injection, and the lowest maximum PDF concentrations were 2 mg/l after the 0.5 g dose and 14 mg/l after 1.0 g.",Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055813/),[mg] / [l],2,121309,DB01597,Cilastatin
,2055813,maximum PDF concentrations,"Peritoneal dialysis fluid (PDF) imipenem concentrations reached 20-30% of the serum peak 4-5 h after iv injection, and the lowest maximum PDF concentrations were 2 mg/l after the 0.5 g dose and 14 mg/l after 1.0 g.",Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055813/),[mg] / [l],14,121310,DB01597,Cilastatin
,2055813,half-life,The half-life of imipenem was 6.4 h and the plasma clearance 66 ml/min; serum and PDF imipenem were in equilibration after about 5 h.,Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055813/),h,6.4,121311,DB01597,Cilastatin
,2055813,plasma clearance,The half-life of imipenem was 6.4 h and the plasma clearance 66 ml/min; serum and PDF imipenem were in equilibration after about 5 h.,Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055813/),[ml] / [min],66,121312,DB01597,Cilastatin
,2055813,half-life,"Cilastatin had a prolonged half-life of 19 h and a plasma clearance of 10 ml/min, and accumulated in both serum and PDF.",Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055813/),h,19,121313,DB01597,Cilastatin
,2055813,plasma clearance,"Cilastatin had a prolonged half-life of 19 h and a plasma clearance of 10 ml/min, and accumulated in both serum and PDF.",Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055813/),[ml] / [min],10,121314,DB01597,Cilastatin
,10885853,peak concentrations,A total daily dose of 50 mg/kg birth weight for premature and newborn infants divided into two doses led to imipenem peak concentrations of 17.7 mg/l +/- 9.2 mg/l (range: 1.95-38.05) and trough levels were 2.35 mg/l +/-1.02 (range 2.34-10.88) in premature infants.,Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885853/),[mg] / [l],17.7,124980,DB01597,Cilastatin
,10885853,trough levels,A total daily dose of 50 mg/kg birth weight for premature and newborn infants divided into two doses led to imipenem peak concentrations of 17.7 mg/l +/- 9.2 mg/l (range: 1.95-38.05) and trough levels were 2.35 mg/l +/-1.02 (range 2.34-10.88) in premature infants.,Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885853/),[mg] / [l],2.35,124981,DB01597,Cilastatin
,10885853,peak concentrations,Imipenem peak concentrations of 20.6 +/- 10.8 (range 3.94-32.3) and trough levels of 0.43 +/- 0.17 (range 0.16-0.94) were measured in newborns.,Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885853/),,20.6,124982,DB01597,Cilastatin
,10885853,trough levels,Imipenem peak concentrations of 20.6 +/- 10.8 (range 3.94-32.3) and trough levels of 0.43 +/- 0.17 (range 0.16-0.94) were measured in newborns.,Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885853/),,0.43,124983,DB01597,Cilastatin
,10885853,half-life of elimination,"The half-life of elimination was 3.3 h and 1.86 h, respectively.",Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885853/),h,3.3,124984,DB01597,Cilastatin
,10885853,half-life of elimination,"The half-life of elimination was 3.3 h and 1.86 h, respectively.",Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885853/),h,1.86,124985,DB01597,Cilastatin
,1444289,half-life (t1/2),"Overall, cefpirome exhibited pharmacokinetics similar to those of ceftazidime: half-life (t1/2), 1.95 h; concentration at 1 h (C1h), 47 to 49 micrograms/ml for both antibiotics.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),h,1.95,125770,DB01597,Cilastatin
,1444289,concentration at 1 h (C1h),"Overall, cefpirome exhibited pharmacokinetics similar to those of ceftazidime: half-life (t1/2), 1.95 h; concentration at 1 h (C1h), 47 to 49 micrograms/ml for both antibiotics.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),[μg] / [ml],47 to 49,125771,DB01597,Cilastatin
,1444289,t1/2,"Ceftriaxone displayed the longest t1/2 (7.65 h) and the highest C1h (137.8 micrograms/ml), while we observed the shortest t1/2 (1.05 h) and the lowest C1h (19.85 micrograms/ml) with imipenem.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),h,7.65,125772,DB01597,Cilastatin
,1444289,C1h,"Ceftriaxone displayed the longest t1/2 (7.65 h) and the highest C1h (137.8 micrograms/ml), while we observed the shortest t1/2 (1.05 h) and the lowest C1h (19.85 micrograms/ml) with imipenem.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),[μg] / [ml],137.8,125773,DB01597,Cilastatin
,1444289,t1/2,"Ceftriaxone displayed the longest t1/2 (7.65 h) and the highest C1h (137.8 micrograms/ml), while we observed the shortest t1/2 (1.05 h) and the lowest C1h (19.85 micrograms/ml) with imipenem.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),h,1.05,125774,DB01597,Cilastatin
,1444289,C1h,"Ceftriaxone displayed the longest t1/2 (7.65 h) and the highest C1h (137.8 micrograms/ml), while we observed the shortest t1/2 (1.05 h) and the lowest C1h (19.85 micrograms/ml) with imipenem.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),[μg] / [ml],19.85,125775,DB01597,Cilastatin
,1444289,serum bactericidal activity titers,"Ceftazidime remained the most active agent tested against P. aeruginosa (serum bactericidal activity titers, 1:43 at 1 h) up to 8 h.","Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444289/),,1:43,125776,DB01597,Cilastatin
,2671429,eradication rate,"6. Bacteriologically, the eradication rate was 94.5% in 56 patients; i.e., 52 were eradicated, 2 were decreased, 1 persisted and 1 was unknown.",[Pharmacokinetic and clinical evaluation of imipenem/cilastatin sodium in neonates and premature infants. A study of imipenem/cilastatin sodium by a perinatal co-research group]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2671429/),%,94.5,129774,DB01597,Cilastatin
,3469183,half-life,"The half-life was similar in plasma, muscle and fat (approximately 1 h).",Imipenem pharmacokinetics in elective colorectal surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3469183/),h,1,135711,DB01597,Cilastatin
,3469183,T 1/2,Visceral levels showed a slower fall (T 1/2 83 min).,Imipenem pharmacokinetics in elective colorectal surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3469183/),min,83,135712,DB01597,Cilastatin
,25216543,%fT>MIC,"The objectives of this study were to compare the pharmacokinetic parameters of imipenem administered by standard short infusion (1g imipenem/1g cilastatin over 30min three times daily) and by extended infusion with a reduced total dose (0.5g imipenem/0.5g cilastatin over 3h four times daily) and to compare the target pharmacokinetic/pharmacodynamic indices, namely percentage of the dosing interval for which the free plasma concentration of imipenem exceeds the MIC and 4× MIC (%fT>MIC and %fT>4×MIC) of 0.5, 1, 2 and 4mg/L, for these two regimens in critically ill adult patients with nosocomial pneumonia on Day 2 of empirical antibiotic therapy.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],0.5,135911,DB01597,Cilastatin
,25216543,%fT,"The objectives of this study were to compare the pharmacokinetic parameters of imipenem administered by standard short infusion (1g imipenem/1g cilastatin over 30min three times daily) and by extended infusion with a reduced total dose (0.5g imipenem/0.5g cilastatin over 3h four times daily) and to compare the target pharmacokinetic/pharmacodynamic indices, namely percentage of the dosing interval for which the free plasma concentration of imipenem exceeds the MIC and 4× MIC (%fT>MIC and %fT>4×MIC) of 0.5, 1, 2 and 4mg/L, for these two regimens in critically ill adult patients with nosocomial pneumonia on Day 2 of empirical antibiotic therapy.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],0.5,135912,DB01597,Cilastatin
,25216543,%fT,"The objectives of this study were to compare the pharmacokinetic parameters of imipenem administered by standard short infusion (1g imipenem/1g cilastatin over 30min three times daily) and by extended infusion with a reduced total dose (0.5g imipenem/0.5g cilastatin over 3h four times daily) and to compare the target pharmacokinetic/pharmacodynamic indices, namely percentage of the dosing interval for which the free plasma concentration of imipenem exceeds the MIC and 4× MIC (%fT>MIC and %fT>4×MIC) of 0.5, 1, 2 and 4mg/L, for these two regimens in critically ill adult patients with nosocomial pneumonia on Day 2 of empirical antibiotic therapy.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],1,135913,DB01597,Cilastatin
,25216543,%fT,"The objectives of this study were to compare the pharmacokinetic parameters of imipenem administered by standard short infusion (1g imipenem/1g cilastatin over 30min three times daily) and by extended infusion with a reduced total dose (0.5g imipenem/0.5g cilastatin over 3h four times daily) and to compare the target pharmacokinetic/pharmacodynamic indices, namely percentage of the dosing interval for which the free plasma concentration of imipenem exceeds the MIC and 4× MIC (%fT>MIC and %fT>4×MIC) of 0.5, 1, 2 and 4mg/L, for these two regimens in critically ill adult patients with nosocomial pneumonia on Day 2 of empirical antibiotic therapy.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],2,135914,DB01597,Cilastatin
,25216543,%fT,"The objectives of this study were to compare the pharmacokinetic parameters of imipenem administered by standard short infusion (1g imipenem/1g cilastatin over 30min three times daily) and by extended infusion with a reduced total dose (0.5g imipenem/0.5g cilastatin over 3h four times daily) and to compare the target pharmacokinetic/pharmacodynamic indices, namely percentage of the dosing interval for which the free plasma concentration of imipenem exceeds the MIC and 4× MIC (%fT>MIC and %fT>4×MIC) of 0.5, 1, 2 and 4mg/L, for these two regimens in critically ill adult patients with nosocomial pneumonia on Day 2 of empirical antibiotic therapy.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],4,135915,DB01597,Cilastatin
,25216543,MICs,"Whilst no significant differences were found between both groups for %fT>MIC, %fT>4×MIC was 87.4±12.19%, 68.6±15.08%, 47.31±6.64% and 27.81±9.52% of the 8-h interval in the short infusion group for MICs of 0.5, 1, 2 and 4mg/L, respectively, and 85.15±17.57%, 53.14±27.27%, 13.55±24.47% and 0±0% of the 6-h interval for the extended infusion group.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],0.5,135916,DB01597,Cilastatin
,25216543,MICs,"Whilst no significant differences were found between both groups for %fT>MIC, %fT>4×MIC was 87.4±12.19%, 68.6±15.08%, 47.31±6.64% and 27.81±9.52% of the 8-h interval in the short infusion group for MICs of 0.5, 1, 2 and 4mg/L, respectively, and 85.15±17.57%, 53.14±27.27%, 13.55±24.47% and 0±0% of the 6-h interval for the extended infusion group.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],1,135917,DB01597,Cilastatin
,25216543,MICs,"Whilst no significant differences were found between both groups for %fT>MIC, %fT>4×MIC was 87.4±12.19%, 68.6±15.08%, 47.31±6.64% and 27.81±9.52% of the 8-h interval in the short infusion group for MICs of 0.5, 1, 2 and 4mg/L, respectively, and 85.15±17.57%, 53.14±27.27%, 13.55±24.47% and 0±0% of the 6-h interval for the extended infusion group.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],2,135918,DB01597,Cilastatin
,25216543,MICs,"Whilst no significant differences were found between both groups for %fT>MIC, %fT>4×MIC was 87.4±12.19%, 68.6±15.08%, 47.31±6.64% and 27.81±9.52% of the 8-h interval in the short infusion group for MICs of 0.5, 1, 2 and 4mg/L, respectively, and 85.15±17.57%, 53.14±27.27%, 13.55±24.47% and 0±0% of the 6-h interval for the extended infusion group.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],4,135919,DB01597,Cilastatin
,25216543,MICs,"Whilst no significant differences were found between both groups for %fT>MIC, %fT>4×MIC was 87.4±12.19%, 68.6±15.08%, 47.31±6.64% and 27.81±9.52% of the 8-h interval in the short infusion group for MICs of 0.5, 1, 2 and 4mg/L, respectively, and 85.15±17.57%, 53.14±27.27%, 13.55±24.47% and 0±0% of the 6-h interval for the extended infusion group.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),,0,135920,DB01597,Cilastatin
≥,25216543,MIC,"In conclusion, administration of 0.5g of imipenem by a 3-h infusion every 6h does not provide sufficient drug concentrations to treat infections caused by pathogens with a MIC of ≥2mg/L.",Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25216543/),[mg] / [l],2,135921,DB01597,Cilastatin
,3182087,peak concentration in bile fluid,In group I (500 mg; 12 patients) a mean peak concentration in bile fluid of 10.5 mg/l (range 1.5 to 16.7 mg/l) was reached just after 10 min.,Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182087/),[mg] / [l],10.5,151479,DB01597,Cilastatin
,3182087,half-life,In group I the half-life of imipenem in bile was 0.84 h.,Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182087/),h,0.84,151480,DB01597,Cilastatin
,3182087,peak level in bile fluid,In group II (1000 mg; 12 patients) the mean peak level in bile fluid was 1&.5 mg/l (range 3.5 to 51.3 mg/l).,Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182087/),[mg] / [l],1&.5,151481,DB01597,Cilastatin
,3182087,half-life in bile,The half-life in bile was 1.24 h in this group.,Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3182087/),h,1.24,151482,DB01597,Cilastatin
,7479200,maximum concentration,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),[μg] / [ml],218.7,152226,DB01597,Cilastatin
,7479200,maximum concentration,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),[μg] / [ml],27.8,152227,DB01597,Cilastatin
,7479200,half-life,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),h,1.07,152228,DB01597,Cilastatin
,7479200,half-life,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),h,1.00,152229,DB01597,Cilastatin
,7479200,elimination rate constant,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),1/[h],0.67,152230,DB01597,Cilastatin
,7479200,elimination rate constant,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),1/[h],0.73,152231,DB01597,Cilastatin
,7479200,area under the concentration-time curve from zero hour to infinity,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),[h·mg] / [l],288.5,152232,DB01597,Cilastatin
,7479200,area under the concentration-time curve from zero hour to infinity,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),[h·mg] / [l],36.3,152233,DB01597,Cilastatin
,7479200,total plasma clearance,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),[l] / [h],14.75,152234,DB01597,Cilastatin
,7479200,total plasma clearance,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),[l] / [h],14.78,152235,DB01597,Cilastatin
,7479200,renal clearance,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),[l] / [h],5.69,152236,DB01597,Cilastatin
,7479200,renal clearance,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),[l] / [h],7.85,152237,DB01597,Cilastatin
,7479200,volume of distribution at steady state,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),l,21.00,152238,DB01597,Cilastatin
,7479200,volume of distribution at steady state,"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218.7 +/- 48.9 micrograms/ml and 27.8 +/- 9.1 micrograms/ml; half-life 1.07 +/- 0.22 hours and 1.00 +/- 0.27 hours; elimination rate constant 0.67 +/- 0.13 hr-1 and 0.73 +/- 0.18 hr-1; area under the concentration-time curve from zero hour to infinity 288.5 +/- 71.25 mg.hr/L and 36.3 +/- 9.55 mg.hr/L; total plasma clearance 14.75 +/- 3.93 L/hour and 14.78 +/- 4.39 L/hour; renal clearance 5.69 +/- 1.94 L/hour and 7.85 +/- 3.37 L/hour; volume of distribution at steady state 21.00 +/- 4.18 L and 22.47 +/- 8.27 L; and mean residence time 1.72 +/- 0.29 hours and 1.79 +/- 0.35 hours.",Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479200/),,22.47,152239,DB01597,Cilastatin
,3210299,Serum concentrations,Serum concentrations of IPM were between 18.0 and 96.9 micrograms/ml and those of CS ranged 31.7 and 144.5 micrograms/ml in 6 patients at the end of intravenous drip infusion 20 mg/20 mg/kg during 30 or 60 minutes.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210299/),[μg] / [ml],18.0 and 96.9,153850,DB01597,Cilastatin
,3210299,Serum concentrations,Serum concentrations of IPM were between 18.0 and 96.9 micrograms/ml and those of CS ranged 31.7 and 144.5 micrograms/ml in 6 patients at the end of intravenous drip infusion 20 mg/20 mg/kg during 30 or 60 minutes.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210299/),[μg] / [ml],31.7,153851,DB01597,Cilastatin
,3210299,Serum concentrations,Serum concentrations of IPM were between 18.0 and 96.9 micrograms/ml and those of CS ranged 31.7 and 144.5 micrograms/ml in 6 patients at the end of intravenous drip infusion 20 mg/20 mg/kg during 30 or 60 minutes.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210299/),[μg] / [ml],144,153852,DB01597,Cilastatin
,3210299,Elimination half-lives,"Elimination half-lives of IPM ranged from 1.2 to 2.0 hours, and those of CS ranged from 1.4 to 2.7 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210299/),h,1.2 to 2.0,153853,DB01597,Cilastatin
,3210299,Elimination half-lives,"Elimination half-lives of IPM ranged from 1.2 to 2.0 hours, and those of CS ranged from 1.4 to 2.7 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210299/),h,1.4 to 2.7,153854,DB01597,Cilastatin
,3210299,Serum concentrations,Serum concentrations of IPM was 14.7 micrograms/ml and that of CS was 32.4 micrograms/ml in 1 patient at the end of 30 minute-drip infusion 10 mg/10 mg/kg.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210299/),[μg] / [ml],14.7,153855,DB01597,Cilastatin
,3210299,Serum concentrations,Serum concentrations of IPM was 14.7 micrograms/ml and that of CS was 32.4 micrograms/ml in 1 patient at the end of 30 minute-drip infusion 10 mg/10 mg/kg.,[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210299/),[μg] / [ml],32.4,153856,DB01597,Cilastatin
,3210299,elimination half-lives,"The elimination half-lives of IPM was 1.5 hours, and that of CS was 2.9 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210299/),h,1.5,153857,DB01597,Cilastatin
,3210299,elimination half-lives,"The elimination half-lives of IPM was 1.5 hours, and that of CS was 2.9 hours.",[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210299/),h,2.9,153858,DB01597,Cilastatin
,8222862,total areas under the imipenem serum concentration curves (AUCs) to infinity,The total areas under the imipenem serum concentration curves (AUCs) to infinity were 30.4 +/- 6.8 mg.h/l after the first dose compared with 29.1 +/- 7.1 mg.h/l during steady state (NS).,Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),[h·mg] / [l],30.4,156027,DB01597,Cilastatin
,8222862,total areas under the imipenem serum concentration curves (AUCs) to infinity,The total areas under the imipenem serum concentration curves (AUCs) to infinity were 30.4 +/- 6.8 mg.h/l after the first dose compared with 29.1 +/- 7.1 mg.h/l during steady state (NS).,Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),[h·mg] / [l],29.1,156028,DB01597,Cilastatin
,8222862,AUCs,"The cilastatin AUCs on the 2 days were 40.3 +/- 9.3 and 38.3 +/- 0.4 mg.h/l (NS), respectively.",Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),[h·mg] / [l],40.3,156029,DB01597,Cilastatin
,8222862,AUCs,"The cilastatin AUCs on the 2 days were 40.3 +/- 9.3 and 38.3 +/- 0.4 mg.h/l (NS), respectively.",Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),[h·mg] / [l],38.3,156030,DB01597,Cilastatin
,8222862,urinary recovery,The urinary recovery of imipenem was 47.8 +/- 17.8% after the first dose and 57.8 +/- 24.2% during steady state (NS).,Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),%,47.8,156031,DB01597,Cilastatin
,8222862,urinary recovery,The urinary recovery of imipenem was 47.8 +/- 17.8% after the first dose and 57.8 +/- 24.2% during steady state (NS).,Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),%,57.8,156032,DB01597,Cilastatin
,8222862,half-life,The mean half-life of imipenem in these CF patients was 1.2 +/- 0.4 h on the first day of the examination and within the same range during steady state.,Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),h,1.2,156033,DB01597,Cilastatin
,8222862,distribution volume (Vd beta),"The distribution volume (Vd beta) was in the range of 28 liters, the total body clearance was 16.3 liters/h (285 ml/min) on the first day.",Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),l,28,156034,DB01597,Cilastatin
,8222862,total body clearance,"The distribution volume (Vd beta) was in the range of 28 liters, the total body clearance was 16.3 liters/h (285 ml/min) on the first day.",Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),[l] / [h],16.3,156035,DB01597,Cilastatin
,8222862,t1/2,The t1/2 of cilastatin was 0.59 +/- 0.14 h after the first dose and 0.61 +/- 0.14 h during steady state.,Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),h,0.59,156036,DB01597,Cilastatin
,8222862,t1/2,The t1/2 of cilastatin was 0.59 +/- 0.14 h after the first dose and 0.61 +/- 0.14 h during steady state.,Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222862/),h,0.61,156037,DB01597,Cilastatin
,6595963,plasma concentrations,"The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (+/- 2.1) and 19.1 (+/- 4.6), 20.0 (+/- 3.2) and 17.8 (+/- 4.8), and 23.4 (+/- 2.3) and 19.1 (+/- 3.5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively.",Multiple-dose pharmacokinetics of imipenem-cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[μg] / [ml],18,158790,DB01597,Cilastatin
,6595963,plasma concentrations,"The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (+/- 2.1) and 19.1 (+/- 4.6), 20.0 (+/- 3.2) and 17.8 (+/- 4.8), and 23.4 (+/- 2.3) and 19.1 (+/- 3.5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively.",Multiple-dose pharmacokinetics of imipenem-cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[μg] / [ml],19.1,158791,DB01597,Cilastatin
,6595963,plasma concentrations,"The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (+/- 2.1) and 19.1 (+/- 4.6), 20.0 (+/- 3.2) and 17.8 (+/- 4.8), and 23.4 (+/- 2.3) and 19.1 (+/- 3.5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively.",Multiple-dose pharmacokinetics of imipenem-cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[μg] / [ml],20.0,158792,DB01597,Cilastatin
,6595963,plasma concentrations,"The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (+/- 2.1) and 19.1 (+/- 4.6), 20.0 (+/- 3.2) and 17.8 (+/- 4.8), and 23.4 (+/- 2.3) and 19.1 (+/- 3.5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively.",Multiple-dose pharmacokinetics of imipenem-cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[μg] / [ml],17.8,158793,DB01597,Cilastatin
,6595963,plasma concentrations,"The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (+/- 2.1) and 19.1 (+/- 4.6), 20.0 (+/- 3.2) and 17.8 (+/- 4.8), and 23.4 (+/- 2.3) and 19.1 (+/- 3.5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively.",Multiple-dose pharmacokinetics of imipenem-cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[μg] / [ml],23.4,158794,DB01597,Cilastatin
,6595963,plasma concentrations,"The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (+/- 2.1) and 19.1 (+/- 4.6), 20.0 (+/- 3.2) and 17.8 (+/- 4.8), and 23.4 (+/- 2.3) and 19.1 (+/- 3.5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively.",Multiple-dose pharmacokinetics of imipenem-cilastatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[μg] / [ml],19.1,158795,DB01597,Cilastatin
,6595963,central compartment volumes of distribution,"The central compartment volumes of distribution for imipenem and cilastatin were 0.16 (+/- 0.05) and 0.14 (+/- 0.03) liter/kg, respectively.",Multiple-dose pharmacokinetics of imipenem-cilastatin. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[l] / [kg],0.16,158796,DB01597,Cilastatin
,6595963,central compartment volumes of distribution,"The central compartment volumes of distribution for imipenem and cilastatin were 0.16 (+/- 0.05) and 0.14 (+/- 0.03) liter/kg, respectively.",Multiple-dose pharmacokinetics of imipenem-cilastatin. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[l] / [kg],0.14,158797,DB01597,Cilastatin
,6595963,Elimination half-lives,Elimination half-lives were short: 0.93 (+/- 0.09) h for imipenem and 0.84 (+/- 0.11) h for cilastatin.,Multiple-dose pharmacokinetics of imipenem-cilastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),h,0.93,158798,DB01597,Cilastatin
,6595963,Elimination half-lives,Elimination half-lives were short: 0.93 (+/- 0.09) h for imipenem and 0.84 (+/- 0.11) h for cilastatin.,Multiple-dose pharmacokinetics of imipenem-cilastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),h,0.84,158799,DB01597,Cilastatin
,6595963,Plasma clearances,Plasma clearances were 12.1 (+/- 0.06) liters/h per 1.73 m2 for imipenem and 12.4 (+/- 1.1) liters/h per 1.73 m2 for cilastatin.,Multiple-dose pharmacokinetics of imipenem-cilastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[l] / [1.73·h·m2],12.1,158800,DB01597,Cilastatin
,6595963,Plasma clearances,Plasma clearances were 12.1 (+/- 0.06) liters/h per 1.73 m2 for imipenem and 12.4 (+/- 1.1) liters/h per 1.73 m2 for cilastatin.,Multiple-dose pharmacokinetics of imipenem-cilastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595963/),[l] / [1.73·h·m2],12.4,158801,DB01597,Cilastatin
,6594235,volume of distribution of the central compartment,The volume of distribution of the central compartment was 0.16 +/- 0.04 1/kg; the volume of distribution (area) was 0.28 +/- 0.07 1/kg; the volume of distribution (steady state) was 0.23 +/- 0.03 1/kg.,The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594235/),[1] / [kg],0.16,159317,DB01597,Cilastatin
,6594235,volume of distribution (area),The volume of distribution of the central compartment was 0.16 +/- 0.04 1/kg; the volume of distribution (area) was 0.28 +/- 0.07 1/kg; the volume of distribution (steady state) was 0.23 +/- 0.03 1/kg.,The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594235/),[1] / [kg],0.28,159318,DB01597,Cilastatin
,6594235,volume of distribution (steady state),The volume of distribution of the central compartment was 0.16 +/- 0.04 1/kg; the volume of distribution (area) was 0.28 +/- 0.07 1/kg; the volume of distribution (steady state) was 0.23 +/- 0.03 1/kg.,The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594235/),[1] / [kg],0.23,159319,DB01597,Cilastatin
,6594235,plasma clearance,The mean plasma clearance was 10.1 +/- 1.0 1/h/1.73 m2.,The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594235/),[1] / [1.73·h·m2],10.1,159320,DB01597,Cilastatin
,6594235,terminal excretion half-life,The terminal excretion half-life was short (1.3 +/- 0.4 h).,The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594235/),h,1.3,159321,DB01597,Cilastatin
,3534346,MIC,The MIC of MK-0787 was 0.10 microgram/ml or less against all 14 strains of S. aureus.,[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),[μg] / [ml],0.10,159581,DB01597,Cilastatin
,3534346,MIC,The MIC of MK-0787 was 0.39 microgram/ml or less against all 67 strains of E. coli.,[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),[μg] / [ml],0.39,159582,DB01597,Cilastatin
,3534346,peak serum levels,"The peak serum levels of MK-0787 achieved approximately 1 hour after the administration of 10 mg/10 mg/kg and 20 mg/20 mg/kg doses were 38.6 micrograms/ml and 36.2 micrograms/ml, respectively.",[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),[μg] / [ml],38.6,159583,DB01597,Cilastatin
,3534346,peak serum levels,"The peak serum levels of MK-0787 achieved approximately 1 hour after the administration of 10 mg/10 mg/kg and 20 mg/20 mg/kg doses were 38.6 micrograms/ml and 36.2 micrograms/ml, respectively.",[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),[μg] / [ml],36.2,159584,DB01597,Cilastatin
,3534346,serum half-lives,"The serum half-lives were 0.8 hour and 0.9 hour, respectively.",[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),h,0.8,159585,DB01597,Cilastatin
,3534346,serum half-lives,"The serum half-lives were 0.8 hour and 0.9 hour, respectively.",[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),h,0.9,159586,DB01597,Cilastatin
,3534346,total 6-hour,"The total 6-hour urinary excretions were 82.1% and 66.7%, respectively.",[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),%,82.1,159587,DB01597,Cilastatin
,3534346,total 6-hour,"The total 6-hour urinary excretions were 82.1% and 66.7%, respectively.",[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),%,66.7,159588,DB01597,Cilastatin
,3534346,urinary excretions,"The total 6-hour urinary excretions were 82.1% and 66.7%, respectively.",[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),%,82.1,159589,DB01597,Cilastatin
,3534346,urinary excretions,"The total 6-hour urinary excretions were 82.1% and 66.7%, respectively.",[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),%,66.7,159590,DB01597,Cilastatin
,3534346,overall efficacy rate,The overall efficacy rate was 100%.,[Basic and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3534346/),%,100,159591,DB01597,Cilastatin
,2076910,peak serum concentration,"The mean peak serum concentration was 26 mg/l, the mean half-life 55 min and the AUC 40 mg/l/h-1.",Pharmacokinetics of imipenem in patients undergoing major colon surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076910/),[mg] / [l],26,166855,DB01597,Cilastatin
,2076910,half-life,"The mean peak serum concentration was 26 mg/l, the mean half-life 55 min and the AUC 40 mg/l/h-1.",Pharmacokinetics of imipenem in patients undergoing major colon surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076910/),min,55,166856,DB01597,Cilastatin
,2076910,AUC,"The mean peak serum concentration was 26 mg/l, the mean half-life 55 min and the AUC 40 mg/l/h-1.",Pharmacokinetics of imipenem in patients undergoing major colon surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076910/),[mg] / [h·l],40,166857,DB01597,Cilastatin
,23253883,Maximum plasma concentrations,"Maximum plasma concentrations of imipenem were 13.45 µg/ml (IV), 6.47 µg/ml (IM) and 3.83 µg/ml (SC).","Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),[μg] / [ml],13.45,172139,DB01597,Cilastatin
,23253883,Maximum plasma concentrations,"Maximum plasma concentrations of imipenem were 13.45 µg/ml (IV), 6.47 µg/ml (IM) and 3.83 µg/ml (SC).","Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),[μg] / [ml],6.47,172140,DB01597,Cilastatin
,23253883,Maximum plasma concentrations,"Maximum plasma concentrations of imipenem were 13.45 µg/ml (IV), 6.47 µg/ml (IM) and 3.83 µg/ml (SC).","Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),[μg] / [ml],3.83,172141,DB01597,Cilastatin
,23253883,Bioavailability,Bioavailability was 93.18% (IM) and 107.90% (SC).,"Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),%,93.18,172142,DB01597,Cilastatin
,23253883,Bioavailability,Bioavailability was 93.18% (IM) and 107.90% (SC).,"Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),%,107.90,172143,DB01597,Cilastatin
,23253883,Elimination half-lives,"Elimination half-lives for IV, IM and SC administration were 1.17, 1.44 and 1.55 h, respectively.","Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),h,1.17,172144,DB01597,Cilastatin
,23253883,Elimination half-lives,"Elimination half-lives for IV, IM and SC administration were 1.17, 1.44 and 1.55 h, respectively.","Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),h,1.44,172145,DB01597,Cilastatin
,23253883,Elimination half-lives,"Elimination half-lives for IV, IM and SC administration were 1.17, 1.44 and 1.55 h, respectively.","Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),h,1.55,172146,DB01597,Cilastatin
,23253883,MIC,All tested bacteria were susceptible to imipenem; MIC values were 0.03 µg/ml for Staphylococcus species and <0.25-0.5 µg/ml for E coli.,"Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),[μg] / [ml],0.03,172147,DB01597,Cilastatin
<,23253883,MIC,All tested bacteria were susceptible to imipenem; MIC values were 0.03 µg/ml for Staphylococcus species and <0.25-0.5 µg/ml for E coli.,"Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),[μg] / [ml],0.25-0.5,172148,DB01597,Cilastatin
,23253883,MIC,Mean imipenem concentrations remained above a MIC of 0.5 µg/ml for approximately 4 h (IV and IM) and 9 h (SC).,"Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23253883/),[μg] / [ml],0.5,172149,DB01597,Cilastatin
,3210302,Maximum serum levels,"Maximum serum levels of IPM and CS were 44.2 micrograms/ml and 70.0 micrograms/ml, respectively, in neonates with ages 0-3 days.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),[μg] / [ml],44.2,178478,DB01597,Cilastatin
,3210302,Maximum serum levels,"Maximum serum levels of IPM and CS were 44.2 micrograms/ml and 70.0 micrograms/ml, respectively, in neonates with ages 0-3 days.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),[μg] / [ml],70.0,178479,DB01597,Cilastatin
,3210302,peak levels,"IPM and CS peak levels in premature infants with ages 0-3 days were 47.2 micrograms/ml and 56.1 micrograms/ml, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),[μg] / [ml],47.2,178480,DB01597,Cilastatin
,3210302,peak levels,"IPM and CS peak levels in premature infants with ages 0-3 days were 47.2 micrograms/ml and 56.1 micrograms/ml, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),[μg] / [ml],56.1,178481,DB01597,Cilastatin
,3210302,peak levels,"IPM and CS peak levels in neonates 4 day-old or older were 35.0 micrograms/ml and 41.5 micrograms/ml, respectively, and in premature infants of similar ages were 45.7 micrograms/ml and 65.3 micrograms/ml, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),[μg] / [ml],35.0,178482,DB01597,Cilastatin
,3210302,peak levels,"IPM and CS peak levels in neonates 4 day-old or older were 35.0 micrograms/ml and 41.5 micrograms/ml, respectively, and in premature infants of similar ages were 45.7 micrograms/ml and 65.3 micrograms/ml, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),[μg] / [ml],41.5,178483,DB01597,Cilastatin
,3210302,peak levels,"IPM and CS peak levels in neonates 4 day-old or older were 35.0 micrograms/ml and 41.5 micrograms/ml, respectively, and in premature infants of similar ages were 45.7 micrograms/ml and 65.3 micrograms/ml, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),[μg] / [ml],45.7,178484,DB01597,Cilastatin
,3210302,peak levels,"IPM and CS peak levels in neonates 4 day-old or older were 35.0 micrograms/ml and 41.5 micrograms/ml, respectively, and in premature infants of similar ages were 45.7 micrograms/ml and 65.3 micrograms/ml, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),[μg] / [ml],65.3,178485,DB01597,Cilastatin
,3210302,serum half-lives,"2. Mean serum half-lives of IPM and CS in 0-3 day-old neonates were 1.6 hours and 3.1 hours, respectively, and the mean serum half-lives in premature infants were 2.1 hours and 4.6 hours, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),h,1.6,178486,DB01597,Cilastatin
,3210302,serum half-lives,"2. Mean serum half-lives of IPM and CS in 0-3 day-old neonates were 1.6 hours and 3.1 hours, respectively, and the mean serum half-lives in premature infants were 2.1 hours and 4.6 hours, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),h,3.1,178487,DB01597,Cilastatin
,3210302,serum half-lives,"2. Mean serum half-lives of IPM and CS in 0-3 day-old neonates were 1.6 hours and 3.1 hours, respectively, and the mean serum half-lives in premature infants were 2.1 hours and 4.6 hours, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),h,2.1,178488,DB01597,Cilastatin
,3210302,serum half-lives,"2. Mean serum half-lives of IPM and CS in 0-3 day-old neonates were 1.6 hours and 3.1 hours, respectively, and the mean serum half-lives in premature infants were 2.1 hours and 4.6 hours, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),h,4.6,178489,DB01597,Cilastatin
,3210302,serum half-lives,"In neonates 4 day-old or older, the mean serum half-lives of IPM and CS were 1.6 hours and 2.6 hours, respectively, and in premature infants they were 1.5 hours and 1.9 hours, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),h,1.6,178490,DB01597,Cilastatin
,3210302,serum half-lives,"In neonates 4 day-old or older, the mean serum half-lives of IPM and CS were 1.6 hours and 2.6 hours, respectively, and in premature infants they were 1.5 hours and 1.9 hours, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),h,2.6,178491,DB01597,Cilastatin
,3210302,serum half-lives,"In neonates 4 day-old or older, the mean serum half-lives of IPM and CS were 1.6 hours and 2.6 hours, respectively, and in premature infants they were 1.5 hours and 1.9 hours, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),h,1.5,178492,DB01597,Cilastatin
,3210302,serum half-lives,"In neonates 4 day-old or older, the mean serum half-lives of IPM and CS were 1.6 hours and 2.6 hours, respectively, and in premature infants they were 1.5 hours and 1.9 hours, respectively.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),h,1.9,178493,DB01597,Cilastatin
,3210302,Urinary recovery rates,4. Urinary recovery rates of IPM for the 0- to 6-hour post IPM/CS infusion period ranged between 27.2 and 46.6%.,[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),%,27.2 and 46.6,178494,DB01597,Cilastatin
,3210302,urinary recovery rates,"For CS, urinary recovery rates for the 0- to 6-hour post IPM/CS infusion period ranged between 25.3 and 100.8%.",[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210302/),%,25.3 and 100.8,178495,DB01597,Cilastatin
,17705288,T > MIC,"Simulated bacterial counts correlated only with T > MIC (correlation coefficient: 0.951 for MEPM/CS, 0.982 for IPM/CS) and T > MIC values to achieve a bacteriostatic effect and a 2-log killing effect for both antibiotics were estimated to be approximately 15 and 20%, respectively, which are similar to previously reported results.",Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705288/),%,15,182939,DB01597,Cilastatin
,17705288,T > MIC,"Simulated bacterial counts correlated only with T > MIC (correlation coefficient: 0.951 for MEPM/CS, 0.982 for IPM/CS) and T > MIC values to achieve a bacteriostatic effect and a 2-log killing effect for both antibiotics were estimated to be approximately 15 and 20%, respectively, which are similar to previously reported results.",Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705288/),%,20,182940,DB01597,Cilastatin
,33288637,area under the concentration-time curve (AUC),"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[h·mg] / [l],15.0 to 70.7,189743,DB01597,Cilastatin
,33288637,area under the concentration-time curve (AUC),"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[h·mg] / [l],24.1 to 109.8,189744,DB01597,Cilastatin
,33288637,area under the concentration-time curve (AUC),"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[h·mg] / [l],18.4 to 95.3,189745,DB01597,Cilastatin
,33288637,AUC from 0 to 6 h,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[h·mg] / [l],14.2 to 66.3,189746,DB01597,Cilastatin
,33288637,AUC from 0 to 6 h,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[h·mg] / [l],23.4 to 107.3,189747,DB01597,Cilastatin
,33288637,AUC from 0 to 6 h,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[h·mg] / [l],18.3 to 94.4,189748,DB01597,Cilastatin
,33288637,AUC from 0 to 6 h,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[l] / [h],6.9 to 8.3,189749,DB01597,Cilastatin
,33288637,AUC from 0 to 6 h,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[l] / [h],8.6 to 10.4,189750,DB01597,Cilastatin
,33288637,AUC from 0 to 6 h,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[l] / [h],10.5 to 13.6,189751,DB01597,Cilastatin
,33288637,clearance,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[l] / [h],6.9 to 8.3,189752,DB01597,Cilastatin
,33288637,clearance,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[l] / [h],8.6 to 10.4,189753,DB01597,Cilastatin
,33288637,clearance,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),[l] / [h],10.5 to 13.6,189754,DB01597,Cilastatin
,33288637,half-life,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),h,1.4 to 1.6,189755,DB01597,Cilastatin
,33288637,half-life,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),h,1.0 to 1.2,189756,DB01597,Cilastatin
,33288637,half-life,"After single doses, the area under the concentration-time curve (AUC) extrapolated to infinity (relebactam, 15.0 to 70.7 h · mg/liter; imipenem, 24.1 to 109.8 h · mg/liter; cilastatin, 18.4 to 95.3 h · mg/liter) and the AUC from 0 to 6 h (relebactam, 14.2 to 66.3 h · mg/liter; imipenem, 23.4 to 107.3 h · mg/liter; cilastatin, 18.3 to 94.4 h · mg/liter) increased in a dose-dependent manner; clearance (relebactam, 6.9 to 8.3 liters/h; imipenem, 8.6 to 10.4 liters/h; cilastatin, 10.5 to 13.6 liters/h) and half-life (relebactam, 1.4 to 1.6 h; imipenem, 1.0 to 1.2 h; cilastatin, 0.7 to 1.0 h) were consistent between doses.","A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33288637/),h,0.7 to 1.0,189757,DB01597,Cilastatin
,3210300,Peak concentrations,"Peak concentrations of IPM/CS were 19.0-34.7 micrograms/ml/32.6-73.4 micrograms/ml, respectively, at the end of the drip infusion.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210300/),[μg] / [ml],19.0-34.7,191361,DB01597,Cilastatin
,3210300,Peak concentrations,"Peak concentrations of IPM/CS were 19.0-34.7 micrograms/ml/32.6-73.4 micrograms/ml, respectively, at the end of the drip infusion.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in neonates]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210300/),[μg] / [ml],32.6-73.4,191362,DB01597,Cilastatin
,3210300,Plasma half-lives,"Plasma half-lives of IPM and CS were 1.4-1.6 hours and 1.7-2.1 hours, respectively.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210300/),h,1.4-1.6,191363,DB01597,Cilastatin
,3210300,Plasma half-lives,"Plasma half-lives of IPM and CS were 1.4-1.6 hours and 1.7-2.1 hours, respectively.",[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210300/),h,1.7-2.1,191364,DB01597,Cilastatin
,9116359,blood flow rate,"The objective of this study is to study the pharmacokinetics of imipenem-cilastatin in patients with anuria related to multiorgan failure during continuous venovenous hemodialysis (CVVHD) at a fixed blood flow rate of 60 ml/min, fixed dialysate flow rate of 20 ml/min, and drainage flow rate of 1-3 mil/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[ml] / [min],60,192391,DB01597,Cilastatin
,9116359,dial,"The objective of this study is to study the pharmacokinetics of imipenem-cilastatin in patients with anuria related to multiorgan failure during continuous venovenous hemodialysis (CVVHD) at a fixed blood flow rate of 60 ml/min, fixed dialysate flow rate of 20 ml/min, and drainage flow rate of 1-3 mil/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[ml] / [min],20,192392,DB01597,Cilastatin
,9116359,flow rate,"The objective of this study is to study the pharmacokinetics of imipenem-cilastatin in patients with anuria related to multiorgan failure during continuous venovenous hemodialysis (CVVHD) at a fixed blood flow rate of 60 ml/min, fixed dialysate flow rate of 20 ml/min, and drainage flow rate of 1-3 mil/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[ml] / [min],20,192393,DB01597,Cilastatin
,9116359,drainage flow rate,"The objective of this study is to study the pharmacokinetics of imipenem-cilastatin in patients with anuria related to multiorgan failure during continuous venovenous hemodialysis (CVVHD) at a fixed blood flow rate of 60 ml/min, fixed dialysate flow rate of 20 ml/min, and drainage flow rate of 1-3 mil/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[mil] / [min],1-3,192394,DB01597,Cilastatin
,9116359,peak,"The peak and trough concentrations of imipenem were 32.47 +/- 6.69 micrograms/ml and 1.12 +/- 0.46 micrograms/ml, respectively, whereas those of cilastatin were 50.05 micrograms/ml +/- 14.80 and 9.53 +/- 3.25 micrograms/ml, respectively.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[μg] / [ml],32.47,192395,DB01597,Cilastatin
,9116359,peak,"The peak and trough concentrations of imipenem were 32.47 +/- 6.69 micrograms/ml and 1.12 +/- 0.46 micrograms/ml, respectively, whereas those of cilastatin were 50.05 micrograms/ml +/- 14.80 and 9.53 +/- 3.25 micrograms/ml, respectively.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[μg] / [ml],50.05,192396,DB01597,Cilastatin
,9116359,trough concentrations,"The peak and trough concentrations of imipenem were 32.47 +/- 6.69 micrograms/ml and 1.12 +/- 0.46 micrograms/ml, respectively, whereas those of cilastatin were 50.05 micrograms/ml +/- 14.80 and 9.53 +/- 3.25 micrograms/ml, respectively.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[μg] / [ml],1.12,192397,DB01597,Cilastatin
,9116359,trough concentrations,"The peak and trough concentrations of imipenem were 32.47 +/- 6.69 micrograms/ml and 1.12 +/- 0.46 micrograms/ml, respectively, whereas those of cilastatin were 50.05 micrograms/ml +/- 14.80 and 9.53 +/- 3.25 micrograms/ml, respectively.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[μg] / [ml],9.53,192398,DB01597,Cilastatin
,9116359,half life,"The half life was 2.79 +/- 0.3 hr for imipenem, and 6.67 +/- 0.93 hr for cilastatin.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),h,2.79,192399,DB01597,Cilastatin
,9116359,half life,"The half life was 2.79 +/- 0.3 hr for imipenem, and 6.67 +/- 0.93 hr for cilastatin.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),h,6.67,192400,DB01597,Cilastatin
,9116359,Total body clearance,"Total body clearance of imipenem was 89.4 +/- 17.5 ml/min, including the clearance by CVVHD of 18.7 +/- 1.2 ml/min, and corresponding values for cilastatin were 31.7 +/- 9.0 ml/min and 13.7 +/- 3.4 ml/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[ml] / [min],89.4,192401,DB01597,Cilastatin
,9116359,Total body clearance,"Total body clearance of imipenem was 89.4 +/- 17.5 ml/min, including the clearance by CVVHD of 18.7 +/- 1.2 ml/min, and corresponding values for cilastatin were 31.7 +/- 9.0 ml/min and 13.7 +/- 3.4 ml/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[ml] / [min],31.7,192402,DB01597,Cilastatin
,9116359,Total body clearance,"Total body clearance of imipenem was 89.4 +/- 17.5 ml/min, including the clearance by CVVHD of 18.7 +/- 1.2 ml/min, and corresponding values for cilastatin were 31.7 +/- 9.0 ml/min and 13.7 +/- 3.4 ml/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[ml] / [min],13.7,192403,DB01597,Cilastatin
,9116359,clearance,"Total body clearance of imipenem was 89.4 +/- 17.5 ml/min, including the clearance by CVVHD of 18.7 +/- 1.2 ml/min, and corresponding values for cilastatin were 31.7 +/- 9.0 ml/min and 13.7 +/- 3.4 ml/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[ml] / [min],18.7,192404,DB01597,Cilastatin
,9116359,clearance,"Total body clearance of imipenem was 89.4 +/- 17.5 ml/min, including the clearance by CVVHD of 18.7 +/- 1.2 ml/min, and corresponding values for cilastatin were 31.7 +/- 9.0 ml/min and 13.7 +/- 3.4 ml/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[ml] / [min],31.7,192405,DB01597,Cilastatin
,9116359,clearance,"Total body clearance of imipenem was 89.4 +/- 17.5 ml/min, including the clearance by CVVHD of 18.7 +/- 1.2 ml/min, and corresponding values for cilastatin were 31.7 +/- 9.0 ml/min and 13.7 +/- 3.4 ml/min.",Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9116359/),[ml] / [min],13.7,192406,DB01597,Cilastatin
,15917542,systemic clearance (CL(S)),"Mean systemic clearance (CL(S)) and elimination half-life (t1/2) of imipenem were 145+/-18 ml/min and 2.7+/-1.3 h during CVVH versus 178+/-18 ml/min and 2.6+/-1.6 h during CVVHDF, respectively.",Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917542/),[ml] / [min],145,193547,DB01597,Cilastatin
,15917542,systemic clearance (CL(S)),"Mean systemic clearance (CL(S)) and elimination half-life (t1/2) of imipenem were 145+/-18 ml/min and 2.7+/-1.3 h during CVVH versus 178+/-18 ml/min and 2.6+/-1.6 h during CVVHDF, respectively.",Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917542/),[ml] / [min],178,193548,DB01597,Cilastatin
,15917542,elimination half-life (t1/2),"Mean systemic clearance (CL(S)) and elimination half-life (t1/2) of imipenem were 145+/-18 ml/min and 2.7+/-1.3 h during CVVH versus 178+/-18 ml/min and 2.6+/-1.6 h during CVVHDF, respectively.",Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917542/),h,2.7,193549,DB01597,Cilastatin
,15917542,elimination half-life (t1/2),"Mean systemic clearance (CL(S)) and elimination half-life (t1/2) of imipenem were 145+/-18 ml/min and 2.7+/-1.3 h during CVVH versus 178+/-18 ml/min and 2.6+/-1.6 h during CVVHDF, respectively.",Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917542/),h,2.6,193550,DB01597,Cilastatin
up to,15917542,MIC,"Imipenem doses of 1.0 g/day appear to achieve concentrations adequate to treat most common gram-negative pathogens (MIC up to 2 microg/ml) during CVVH or CVVHDF, but doses of 2.0 g/day or more may be required to adequately treat and prevent resistance in pathogens with higher MICs (MIC=4 to 8 microg/ml).",Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917542/),[μg] / [ml],2,193551,DB01597,Cilastatin
,15917542,MICs (MIC,"Imipenem doses of 1.0 g/day appear to achieve concentrations adequate to treat most common gram-negative pathogens (MIC up to 2 microg/ml) during CVVH or CVVHDF, but doses of 2.0 g/day or more may be required to adequately treat and prevent resistance in pathogens with higher MICs (MIC=4 to 8 microg/ml).",Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917542/),[μg] / [ml],4 to 8,193552,DB01597,Cilastatin
,1929334,elimination-phase half-life,"Hemodialysis accelerated the elimination of both imipenem and cilastatin: the mean elimination-phase half-life of imipenem was shortened from 200 to 78 min, and that of cilastatin was shortened from 445 to 115 min.",Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929334/),min,200 to 78,194382,DB01597,Cilastatin
,1929334,elimination-phase half-life,"Hemodialysis accelerated the elimination of both imipenem and cilastatin: the mean elimination-phase half-life of imipenem was shortened from 200 to 78 min, and that of cilastatin was shortened from 445 to 115 min.",Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929334/),min,445 to 115,194383,DB01597,Cilastatin
,1929334,clearance,"The mean hemodialysis clearance of imipenem was estimated to be 74.08 +/- 13.29 ml/min, and that of cilastatin was estimated to be 65.0 +/- 8.6 ml/min, after consideration of various methodological limitations.",Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929334/),[ml] / [min],74.08,194384,DB01597,Cilastatin
,1929334,clearance,"The mean hemodialysis clearance of imipenem was estimated to be 74.08 +/- 13.29 ml/min, and that of cilastatin was estimated to be 65.0 +/- 8.6 ml/min, after consideration of various methodological limitations.",Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929334/),[ml] / [min],65.0,194385,DB01597,Cilastatin
,2139939,area under the plasma concentration curve,"Following an intravenous infusion of imipenem 500 mg, the main pharmacokinetic values for the antibiotic are: area under the plasma concentration curve 43.2 +/- 4.7 h.mg/l; plasma clearance 195 +/- 25 ml/min; half-life 1.0 +/- 0.1 h; apparent volume of distribution 10.4 +/- 1.7 l.",[Clinical pharmacokinetics of an imipenem-cilastatin combination]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139939/),[h·mg] / [l],43.2,196443,DB01597,Cilastatin
,2139939,plasma clearance,"Following an intravenous infusion of imipenem 500 mg, the main pharmacokinetic values for the antibiotic are: area under the plasma concentration curve 43.2 +/- 4.7 h.mg/l; plasma clearance 195 +/- 25 ml/min; half-life 1.0 +/- 0.1 h; apparent volume of distribution 10.4 +/- 1.7 l.",[Clinical pharmacokinetics of an imipenem-cilastatin combination]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139939/),[ml] / [min],195,196444,DB01597,Cilastatin
,2139939,half-life,"Following an intravenous infusion of imipenem 500 mg, the main pharmacokinetic values for the antibiotic are: area under the plasma concentration curve 43.2 +/- 4.7 h.mg/l; plasma clearance 195 +/- 25 ml/min; half-life 1.0 +/- 0.1 h; apparent volume of distribution 10.4 +/- 1.7 l.",[Clinical pharmacokinetics of an imipenem-cilastatin combination]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139939/),h,1.0,196445,DB01597,Cilastatin
,2139939,apparent volume of distribution,"Following an intravenous infusion of imipenem 500 mg, the main pharmacokinetic values for the antibiotic are: area under the plasma concentration curve 43.2 +/- 4.7 h.mg/l; plasma clearance 195 +/- 25 ml/min; half-life 1.0 +/- 0.1 h; apparent volume of distribution 10.4 +/- 1.7 l.",[Clinical pharmacokinetics of an imipenem-cilastatin combination]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2139939/),l,10.4,196446,DB01597,Cilastatin
,7648757,peak (Cmax),Plasma meropenem concentrations reach a peak (Cmax) of approximately 30 mg/L after administration of a standard dose of 1 g intravenously.,Meropenem clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648757/),[mg] / [l],30,196560,DB01597,Cilastatin
,7648757,elimination half-life (t1/2),"The elimination half-life (t1/2) is approximately 1 hour, and the area under the plasma concentration-time curve increases linearly in a dose-related manner.",Meropenem clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648757/),h,1,196561,DB01597,Cilastatin
,7648757,volume of distribution,"The volume of distribution is 21L, indicating predominantly extracellular distribution.",Meropenem clinical pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648757/),l,21,196562,DB01597,Cilastatin
,30962334,MIC,"As a result, 41.4%, 56.1%, and 67.1% of the children reached the pharmacodynamic target (the percentage of the time during the total dosing interval that the free drug concentration remains above the MIC of 70%) against sensitive pathogens with an MIC of 0.5 mg/liter with imipenem at 15, 20, and 25 mg/kg of body weight every 6 h (q6h), respectively.",Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962334/),[mg] / [l],0.5,197903,DB01597,Cilastatin
,30962334,MIC,"However, only 11.1% of the children achieved the pharmacodynamic target against Pseudomonas aeruginosa isolates with an MIC of 2 mg/liter at a dose of 25 mg/kg q6h.",Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30962334/),[mg] / [l],2,197904,DB01597,Cilastatin
,3463540,serum concentration,The mean serum concentration in 12 patients (mean age 77 years) with normal renal and hepatic function 15 minutes after the beginning of the infusion was 93.1 mg/l imipenem.,[Bone concentrations of imipenem after a dose of imipenem/cilastatin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463540/),[mg] / [l],93.1,198533,DB01597,Cilastatin
,3463540,serum half life t (1/2 beta),"The mean serum half life t (1/2 beta) was 1.32 hours, the total body clearance 108.6 1/h, and the volume of distribution during the beta phase V(beta) 12.4 1.",[Bone concentrations of imipenem after a dose of imipenem/cilastatin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463540/),h,1.32,198534,DB01597,Cilastatin
,3463540,total body clearance,"The mean serum half life t (1/2 beta) was 1.32 hours, the total body clearance 108.6 1/h, and the volume of distribution during the beta phase V(beta) 12.4 1.",[Bone concentrations of imipenem after a dose of imipenem/cilastatin]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463540/),[1] / [h],108.6,198535,DB01597,Cilastatin
,3463540,volume of distribution during the beta phase V(beta),"The mean serum half life t (1/2 beta) was 1.32 hours, the total body clearance 108.6 1/h, and the volume of distribution during the beta phase V(beta) 12.4 1.",[Bone concentrations of imipenem after a dose of imipenem/cilastatin]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463540/),1,12.4,198536,DB01597,Cilastatin
≥,25656151,CL(Cr),"Primary and secondary endpoints were clinical response 28 days after inclusion, and ARC prevalence (CL(Cr)≥130 mL/min) and subthreshold and undetectable concentrations, respectively.","Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656151/),[ml] / [min],130,199118,DB01597,Cilastatin
,25656151,CL(Cr),"From 2010 to 2013, 100 patients were enrolled (mean age, 45 years; median CL(Cr) at inclusion, 144.1 mL/min).","Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656151/),[ml] / [min],144.1,199119,DB01597,Cilastatin
,1864280,terminal half-lives,"The terminal half-lives in plasma were 0.98 h and 1.11 h for meropenem and imipenem, respectively.","Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864280/),h,0.98,201040,DB01597,Cilastatin
,1864280,terminal half-lives,"The terminal half-lives in plasma were 0.98 h and 1.11 h for meropenem and imipenem, respectively.","Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864280/),h,1.11,201041,DB01597,Cilastatin
,1864280,volume of distribution,"The volume of distribution was smaller for meropenem than for imipenem (12.5 l and 14.4 l, respectively).","Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864280/),l,12.5,201042,DB01597,Cilastatin
,1864280,volume of distribution,"The volume of distribution was smaller for meropenem than for imipenem (12.5 l and 14.4 l, respectively).","Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864280/),l,14.4,201043,DB01597,Cilastatin
,1864280,plasma clearance,The plasma clearance for meropenem was 188 (SD 31) ml/min and for imipenem 183 (SD 25) ml/min.,"Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864280/),[ml] / [min],188,201044,DB01597,Cilastatin
,1864280,plasma clearance,The plasma clearance for meropenem was 188 (SD 31) ml/min and for imipenem 183 (SD 25) ml/min.,"Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864280/),[ml] / [min],183,201045,DB01597,Cilastatin
,1864280,Renal clearance,"Renal clearance was on average 139 (SD 24) ml/min and 135 (SD 11) ml/min, respectively.","Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864280/),[ml] / [min],139,201046,DB01597,Cilastatin
,1864280,Renal clearance,"Renal clearance was on average 139 (SD 24) ml/min and 135 (SD 11) ml/min, respectively.","Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864280/),[ml] / [min],135,201047,DB01597,Cilastatin
,3463795,peak levels,"When 500 mg/500 mg of MK-0787/MK-0791 was administered by an intravenous drip infusion, peak levels of MK-0787 in tissues of adnexa uteri and uterus ranged from 14.6 micrograms/g to 25.8 micrograms/g, Tmax ranged from 0.55 hour to 0.98 hour, and the AUC ranged from 25.6 micrograms X hr/g to 45.2 micrograms X hr/g.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463795/),[μg] / [g],14.6,204159,DB01597,Cilastatin
,3463795,peak levels,"When 500 mg/500 mg of MK-0787/MK-0791 was administered by an intravenous drip infusion, peak levels of MK-0787 in tissues of adnexa uteri and uterus ranged from 14.6 micrograms/g to 25.8 micrograms/g, Tmax ranged from 0.55 hour to 0.98 hour, and the AUC ranged from 25.6 micrograms X hr/g to 45.2 micrograms X hr/g.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463795/),[μg] / [g],25.8,204160,DB01597,Cilastatin
,3463795,Tmax,"When 500 mg/500 mg of MK-0787/MK-0791 was administered by an intravenous drip infusion, peak levels of MK-0787 in tissues of adnexa uteri and uterus ranged from 14.6 micrograms/g to 25.8 micrograms/g, Tmax ranged from 0.55 hour to 0.98 hour, and the AUC ranged from 25.6 micrograms X hr/g to 45.2 micrograms X hr/g.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463795/),h,0.55,204161,DB01597,Cilastatin
,3463795,Tmax,"When 500 mg/500 mg of MK-0787/MK-0791 was administered by an intravenous drip infusion, peak levels of MK-0787 in tissues of adnexa uteri and uterus ranged from 14.6 micrograms/g to 25.8 micrograms/g, Tmax ranged from 0.55 hour to 0.98 hour, and the AUC ranged from 25.6 micrograms X hr/g to 45.2 micrograms X hr/g.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463795/),h,0.98,204162,DB01597,Cilastatin
,3463795,AUC,"When 500 mg/500 mg of MK-0787/MK-0791 was administered by an intravenous drip infusion, peak levels of MK-0787 in tissues of adnexa uteri and uterus ranged from 14.6 micrograms/g to 25.8 micrograms/g, Tmax ranged from 0.55 hour to 0.98 hour, and the AUC ranged from 25.6 micrograms X hr/g to 45.2 micrograms X hr/g.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463795/),[h·μg] / [g],25.6,204163,DB01597,Cilastatin
,3463795,AUC,"When 500 mg/500 mg of MK-0787/MK-0791 was administered by an intravenous drip infusion, peak levels of MK-0787 in tissues of adnexa uteri and uterus ranged from 14.6 micrograms/g to 25.8 micrograms/g, Tmax ranged from 0.55 hour to 0.98 hour, and the AUC ranged from 25.6 micrograms X hr/g to 45.2 micrograms X hr/g.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463795/),[h·μg] / [g],45.2,204164,DB01597,Cilastatin
,3463795,MIC80,"Mean MIC80 values of MK-0787 were 0.39-0.78 micrograms/ml against all Gram-positive bacteria, 0.20-0.39 micrograms/ml against all Gram-negative bacteria, and less than or equal to 0.10-0.20 micrograms/ml against all anaerobic bacteria.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463795/),[μg] / [ml],0.39-0.78,204165,DB01597,Cilastatin
,3463795,MIC80,"Mean MIC80 values of MK-0787 were 0.39-0.78 micrograms/ml against all Gram-positive bacteria, 0.20-0.39 micrograms/ml against all Gram-negative bacteria, and less than or equal to 0.10-0.20 micrograms/ml against all anaerobic bacteria.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463795/),[μg] / [ml],0.20-0.39,204166,DB01597,Cilastatin
equal,3463795,MIC80,"Mean MIC80 values of MK-0787 were 0.39-0.78 micrograms/ml against all Gram-positive bacteria, 0.20-0.39 micrograms/ml against all Gram-negative bacteria, and less than or equal to 0.10-0.20 micrograms/ml against all anaerobic bacteria.",[Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463795/),[μg] / [ml],0.10-0.20,204167,DB01597,Cilastatin
,3102453,inflammatory fluid level,The mean inflammatory fluid level of imipenem at 30 min was 6.2 mg/l (or 35% of the plasma level).,The pharmacokinetics and tissue penetration of imipenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102453/),[mg] / [l],6.2,204175,DB01597,Cilastatin
,3102453,overall penetration,The overall penetration of imipenem/cilastatin into inflammatory fluid was 67.8% (+/- 13.8) and imipenem alone 73.2% (+/- 13.9).,The pharmacokinetics and tissue penetration of imipenem. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102453/),%,67.8,204176,DB01597,Cilastatin
,3102453,overall penetration,The overall penetration of imipenem/cilastatin into inflammatory fluid was 67.8% (+/- 13.8) and imipenem alone 73.2% (+/- 13.9).,The pharmacokinetics and tissue penetration of imipenem. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102453/),%,73.2,204177,DB01597,Cilastatin
,3102453,elimination half-life,The mean elimination half-life of imipenem from plasma was 1.1 h and from inflammatory fluid 1.4 h (with or without cilastatin).,The pharmacokinetics and tissue penetration of imipenem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102453/),h,1.1,204178,DB01597,Cilastatin
,3102453,elimination half-life,The mean elimination half-life of imipenem from plasma was 1.1 h and from inflammatory fluid 1.4 h (with or without cilastatin).,The pharmacokinetics and tissue penetration of imipenem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102453/),h,1.4,204179,DB01597,Cilastatin
,3102453,percentage penetration,The mean percentage penetration was 73.4% (+/- 22.1).,The pharmacokinetics and tissue penetration of imipenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102453/),%,73.4,204180,DB01597,Cilastatin
,2746857,peak serum levels,"In mature infants, peak serum levels of IPM and CS were 31.8 micrograms/ml (17.1 approximately 59.0 micrograms/ml) and 59.9 micrograms/ml (35.6 approximately 99.0 micrograms/ml), respectively.","[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746857/),[μg] / [ml],31.8,205564,DB01597,Cilastatin
,2746857,peak serum levels,"In mature infants, peak serum levels of IPM and CS were 31.8 micrograms/ml (17.1 approximately 59.0 micrograms/ml) and 59.9 micrograms/ml (35.6 approximately 99.0 micrograms/ml), respectively.","[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746857/),[μg] / [ml],59.9,205565,DB01597,Cilastatin
,2746857,Half-lives,Half-lives of IPM and CS were 1.0 approximately 2.7 hrs.,"[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746857/),h,1.0 approximately 2.7,205566,DB01597,Cilastatin
,11876899,half-life,"Compared to those in control group, pharmacokinetic parameters of Imipenem exhibited evident difference, such as prolonged half-life [(1.56 plus minus 0.55) h vs (1.06 plus minus 0.24) h] and enlarged distributing volume (16.16 plus minus 4.26) vs (13.96 plus minus 7.10).",[Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876899/),h,1.56,208445,DB01597,Cilastatin
,11876899,half-life,"Compared to those in control group, pharmacokinetic parameters of Imipenem exhibited evident difference, such as prolonged half-life [(1.56 plus minus 0.55) h vs (1.06 plus minus 0.24) h] and enlarged distributing volume (16.16 plus minus 4.26) vs (13.96 plus minus 7.10).",[Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876899/),h,1.06,208446,DB01597,Cilastatin
,11876899,distributing volume,"Compared to those in control group, pharmacokinetic parameters of Imipenem exhibited evident difference, such as prolonged half-life [(1.56 plus minus 0.55) h vs (1.06 plus minus 0.24) h] and enlarged distributing volume (16.16 plus minus 4.26) vs (13.96 plus minus 7.10).",[Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876899/),,16.16,208447,DB01597,Cilastatin
,11876899,distributing volume,"Compared to those in control group, pharmacokinetic parameters of Imipenem exhibited evident difference, such as prolonged half-life [(1.56 plus minus 0.55) h vs (1.06 plus minus 0.24) h] and enlarged distributing volume (16.16 plus minus 4.26) vs (13.96 plus minus 7.10).",[Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876899/),,13.96,208448,DB01597,Cilastatin
,3483288,elimination half-life,The mean elimination half-life of imipenem was 0.87 h in children and 2.1 h in neonates.,Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3483288/),h,0.87,209309,DB01597,Cilastatin
,3483288,elimination half-life,The mean elimination half-life of imipenem was 0.87 h in children and 2.1 h in neonates.,Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3483288/),h,2.1,209310,DB01597,Cilastatin
,3483288,elimination half-life,The mean cilastatin elimination half-life was 0.73 h in children and 5.1 h in neonates.,Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3483288/),h,0.73,209311,DB01597,Cilastatin
,3483288,elimination half-life,The mean cilastatin elimination half-life was 0.73 h in children and 5.1 h in neonates.,Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3483288/),h,5.1,209312,DB01597,Cilastatin
,2055812,plasma half-life,"The mean plasma half-life of meropenem was 0.8 h, mean plasma clearance 277 ml/min and the mean volume of distribution 20.4 l.","Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055812/),h,0.8,221718,DB01597,Cilastatin
,2055812,plasma clearance,"The mean plasma half-life of meropenem was 0.8 h, mean plasma clearance 277 ml/min and the mean volume of distribution 20.4 l.","Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055812/),[ml] / [min],277,221719,DB01597,Cilastatin
,2055812,volume of distribution,"The mean plasma half-life of meropenem was 0.8 h, mean plasma clearance 277 ml/min and the mean volume of distribution 20.4 l.","Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055812/),l,20.4,221720,DB01597,Cilastatin
,2055812,peak plasma concentrations,The metabolite reached mean peak plasma concentrations of 1.5 mg/l.,"Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055812/),[mg] / [l],1.5,221721,DB01597,Cilastatin
,2055812,Renal clearance,Renal clearance of meropenem averaged 200 ml/min.,"Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055812/),[ml] / [min],200,221722,DB01597,Cilastatin
,2055812,urinary recovery,The mean urinary recovery of the metabolite was 20% and of unchanged drug 72% of the dose given.,"Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055812/),%,20,221723,DB01597,Cilastatin
,2055812,urinary recovery,The mean urinary recovery of the metabolite was 20% and of unchanged drug 72% of the dose given.,"Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055812/),%,72,221724,DB01597,Cilastatin
,2055812,recovery,"The recovery of meropenem ranged from 62.2% to 78.2% and was correlated to the urinary recovery of imipenem when given without cilastatin to the same subjects in previous studies (range 15.2-32.2%, rank correlation coefficient = 0.934).","Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055812/),%,62.2,221725,DB01597,Cilastatin
,2055812,recovery,"The recovery of meropenem ranged from 62.2% to 78.2% and was correlated to the urinary recovery of imipenem when given without cilastatin to the same subjects in previous studies (range 15.2-32.2%, rank correlation coefficient = 0.934).","Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2055812/),%,78.2,221726,DB01597,Cilastatin
,6573157,urinary recovery,"Thus, at an N-formimidoyl thienamycin/MK-791 ratio of 1:0.25 or higher, the urinary recovery was about 72% in all subjects, whereas it varied between 7.7 and 43% when N-formimidoyl thienamycin was given alone.",Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573157/),%,72,222880,DB01597,Cilastatin
,6573157,urinary recovery,"Thus, at an N-formimidoyl thienamycin/MK-791 ratio of 1:0.25 or higher, the urinary recovery was about 72% in all subjects, whereas it varied between 7.7 and 43% when N-formimidoyl thienamycin was given alone.",Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573157/),%,7,222881,DB01597,Cilastatin
,6573157,urinary recovery,"Thus, at an N-formimidoyl thienamycin/MK-791 ratio of 1:0.25 or higher, the urinary recovery was about 72% in all subjects, whereas it varied between 7.7 and 43% when N-formimidoyl thienamycin was given alone.",Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573157/),%,43,222882,DB01597,Cilastatin
,15871639,peak serum concentration,"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90.1 +/- 50.9 vs 46.6 +/- 14.6 mg/L, p < 0.01); the area under the serum concentration-time curve was significantly higher for imipenem than for meropenem (216.5 +/- 86.3 vs 99.5 +/- 23.9 mg . h/L, p < 0.01), while the mean volume of distribution and mean total clearance were significantly higher for meropenem than for imipenem (25 +/- 4.1 vs 17.4 +/- 4.5L, p < 0.01 and 191 +/- 52.2 vs 116.4 +/- 42.3 mL/min, p < 0.01, respectively).",Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871639/),[mg] / [l],90.1,223061,DB01597,Cilastatin
,15871639,peak serum concentration,"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90.1 +/- 50.9 vs 46.6 +/- 14.6 mg/L, p < 0.01); the area under the serum concentration-time curve was significantly higher for imipenem than for meropenem (216.5 +/- 86.3 vs 99.5 +/- 23.9 mg . h/L, p < 0.01), while the mean volume of distribution and mean total clearance were significantly higher for meropenem than for imipenem (25 +/- 4.1 vs 17.4 +/- 4.5L, p < 0.01 and 191 +/- 52.2 vs 116.4 +/- 42.3 mL/min, p < 0.01, respectively).",Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871639/),[mg] / [l],46.6,223062,DB01597,Cilastatin
,15871639,area under the serum concentration-time curve,"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90.1 +/- 50.9 vs 46.6 +/- 14.6 mg/L, p < 0.01); the area under the serum concentration-time curve was significantly higher for imipenem than for meropenem (216.5 +/- 86.3 vs 99.5 +/- 23.9 mg . h/L, p < 0.01), while the mean volume of distribution and mean total clearance were significantly higher for meropenem than for imipenem (25 +/- 4.1 vs 17.4 +/- 4.5L, p < 0.01 and 191 +/- 52.2 vs 116.4 +/- 42.3 mL/min, p < 0.01, respectively).",Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871639/),[h·mg] / [l],216.5,223063,DB01597,Cilastatin
,15871639,area under the serum concentration-time curve,"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90.1 +/- 50.9 vs 46.6 +/- 14.6 mg/L, p < 0.01); the area under the serum concentration-time curve was significantly higher for imipenem than for meropenem (216.5 +/- 86.3 vs 99.5 +/- 23.9 mg . h/L, p < 0.01), while the mean volume of distribution and mean total clearance were significantly higher for meropenem than for imipenem (25 +/- 4.1 vs 17.4 +/- 4.5L, p < 0.01 and 191 +/- 52.2 vs 116.4 +/- 42.3 mL/min, p < 0.01, respectively).",Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871639/),[h·mg] / [l],99.5,223064,DB01597,Cilastatin
,15871639,volume of distribution,"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90.1 +/- 50.9 vs 46.6 +/- 14.6 mg/L, p < 0.01); the area under the serum concentration-time curve was significantly higher for imipenem than for meropenem (216.5 +/- 86.3 vs 99.5 +/- 23.9 mg . h/L, p < 0.01), while the mean volume of distribution and mean total clearance were significantly higher for meropenem than for imipenem (25 +/- 4.1 vs 17.4 +/- 4.5L, p < 0.01 and 191 +/- 52.2 vs 116.4 +/- 42.3 mL/min, p < 0.01, respectively).",Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871639/),l,25,223065,DB01597,Cilastatin
,15871639,total clearance,"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90.1 +/- 50.9 vs 46.6 +/- 14.6 mg/L, p < 0.01); the area under the serum concentration-time curve was significantly higher for imipenem than for meropenem (216.5 +/- 86.3 vs 99.5 +/- 23.9 mg . h/L, p < 0.01), while the mean volume of distribution and mean total clearance were significantly higher for meropenem than for imipenem (25 +/- 4.1 vs 17.4 +/- 4.5L, p < 0.01 and 191 +/- 52.2 vs 116.4 +/- 42.3 mL/min, p < 0.01, respectively).",Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871639/),[ml] / [min],17.4,223066,DB01597,Cilastatin
,15871639,total clearance,"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90.1 +/- 50.9 vs 46.6 +/- 14.6 mg/L, p < 0.01); the area under the serum concentration-time curve was significantly higher for imipenem than for meropenem (216.5 +/- 86.3 vs 99.5 +/- 23.9 mg . h/L, p < 0.01), while the mean volume of distribution and mean total clearance were significantly higher for meropenem than for imipenem (25 +/- 4.1 vs 17.4 +/- 4.5L, p < 0.01 and 191 +/- 52.2 vs 116.4 +/- 42.3 mL/min, p < 0.01, respectively).",Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871639/),[ml] / [min],191,223067,DB01597,Cilastatin
,15871639,total clearance,"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90.1 +/- 50.9 vs 46.6 +/- 14.6 mg/L, p < 0.01); the area under the serum concentration-time curve was significantly higher for imipenem than for meropenem (216.5 +/- 86.3 vs 99.5 +/- 23.9 mg . h/L, p < 0.01), while the mean volume of distribution and mean total clearance were significantly higher for meropenem than for imipenem (25 +/- 4.1 vs 17.4 +/- 4.5L, p < 0.01 and 191 +/- 52.2 vs 116.4 +/- 42.3 mL/min, p < 0.01, respectively).",Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871639/),[ml] / [min],116.4,223068,DB01597,Cilastatin
,2338419,peak plasma concentrations,"The peak plasma concentrations (36.4 +/- 4.96 mg/l), plasma half-life (60 min), volume of distribution (0.28 +/- 0.02 l/kg) and plasma clearance (3.23 +/- 0.38 ml/min/kg) were comparable with those in normal healthy volunteers suggesting that the drug handling is not appreciably altered in this group of patients.",Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338419/),[mg] / [l],36.4,225202,DB01597,Cilastatin
,2338419,plasma half-life,"The peak plasma concentrations (36.4 +/- 4.96 mg/l), plasma half-life (60 min), volume of distribution (0.28 +/- 0.02 l/kg) and plasma clearance (3.23 +/- 0.38 ml/min/kg) were comparable with those in normal healthy volunteers suggesting that the drug handling is not appreciably altered in this group of patients.",Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338419/),min,60,225203,DB01597,Cilastatin
,2338419,volume of distribution,"The peak plasma concentrations (36.4 +/- 4.96 mg/l), plasma half-life (60 min), volume of distribution (0.28 +/- 0.02 l/kg) and plasma clearance (3.23 +/- 0.38 ml/min/kg) were comparable with those in normal healthy volunteers suggesting that the drug handling is not appreciably altered in this group of patients.",Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338419/),[l] / [kg],0.28,225204,DB01597,Cilastatin
,2338419,plasma clearance,"The peak plasma concentrations (36.4 +/- 4.96 mg/l), plasma half-life (60 min), volume of distribution (0.28 +/- 0.02 l/kg) and plasma clearance (3.23 +/- 0.38 ml/min/kg) were comparable with those in normal healthy volunteers suggesting that the drug handling is not appreciably altered in this group of patients.",Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338419/),[ml] / [kg·min],3.23,225205,DB01597,Cilastatin
,12168180,total amount,"The total amount of vancomycin released by the cements treated with vancomycin alone was 7.98 mg for CMW1, 7.74 mg for Palacos R, and 6.76 mg for Simplex P; with the addition of imipenem-cilastatin, the total amount of vancomycin released by the 3 cements increased by 30.58%, 50.52%, and 50.15%.",The in vitro elution characteristics of vancomycin combined with imipenem-cilastatin in acrylic bone-cements: a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12168180/),,7.98,227805,DB01597,Cilastatin
,12168180,total amount,"The total amount of vancomycin released by the cements treated with vancomycin alone was 7.98 mg for CMW1, 7.74 mg for Palacos R, and 6.76 mg for Simplex P; with the addition of imipenem-cilastatin, the total amount of vancomycin released by the 3 cements increased by 30.58%, 50.52%, and 50.15%.",The in vitro elution characteristics of vancomycin combined with imipenem-cilastatin in acrylic bone-cements: a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12168180/),mg,7.74,227806,DB01597,Cilastatin
,10722486,MICs,"The MICs of the beta-lactams with an inoculum of 5 log(10) CFU/ml were as follows for E. cloacae NOR-1 and its ceftazidime-resistant mutant, respectively: imipenem, 16 and 128 microg/ml, meropenem, 4 and 32 microg/ml, cefepime, <0.03 and 1 microg/ml, and ceftazidime, 1 and 512 microg/ml.","Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722486/),[μg] / [ml],16,228737,DB01597,Cilastatin
,10722486,MICs,"The MICs of the beta-lactams with an inoculum of 5 log(10) CFU/ml were as follows for E. cloacae NOR-1 and its ceftazidime-resistant mutant, respectively: imipenem, 16 and 128 microg/ml, meropenem, 4 and 32 microg/ml, cefepime, <0.03 and 1 microg/ml, and ceftazidime, 1 and 512 microg/ml.","Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722486/),[μg] / [ml],128,228738,DB01597,Cilastatin
,10722486,MICs,"The MICs of the beta-lactams with an inoculum of 5 log(10) CFU/ml were as follows for E. cloacae NOR-1 and its ceftazidime-resistant mutant, respectively: imipenem, 16 and 128 microg/ml, meropenem, 4 and 32 microg/ml, cefepime, <0.03 and 1 microg/ml, and ceftazidime, 1 and 512 microg/ml.","Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722486/),[μg] / [ml],4,228739,DB01597,Cilastatin
,10722486,MICs,"The MICs of the beta-lactams with an inoculum of 5 log(10) CFU/ml were as follows for E. cloacae NOR-1 and its ceftazidime-resistant mutant, respectively: imipenem, 16 and 128 microg/ml, meropenem, 4 and 32 microg/ml, cefepime, <0.03 and 1 microg/ml, and ceftazidime, 1 and 512 microg/ml.","Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722486/),[μg] / [ml],32,228740,DB01597,Cilastatin
<,10722486,MICs,"The MICs of the beta-lactams with an inoculum of 5 log(10) CFU/ml were as follows for E. cloacae NOR-1 and its ceftazidime-resistant mutant, respectively: imipenem, 16 and 128 microg/ml, meropenem, 4 and 32 microg/ml, cefepime, <0.03 and 1 microg/ml, and ceftazidime, 1 and 512 microg/ml.","Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722486/),[μg] / [ml],0.03,228741,DB01597,Cilastatin
<,10722486,MICs,"The MICs of the beta-lactams with an inoculum of 5 log(10) CFU/ml were as follows for E. cloacae NOR-1 and its ceftazidime-resistant mutant, respectively: imipenem, 16 and 128 microg/ml, meropenem, 4 and 32 microg/ml, cefepime, <0.03 and 1 microg/ml, and ceftazidime, 1 and 512 microg/ml.","Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722486/),[μg] / [ml],1,228742,DB01597,Cilastatin
,10722486,MICs,"The MICs of the beta-lactams with an inoculum of 5 log(10) CFU/ml were as follows for E. cloacae NOR-1 and its ceftazidime-resistant mutant, respectively: imipenem, 16 and 128 microg/ml, meropenem, 4 and 32 microg/ml, cefepime, <0.03 and 1 microg/ml, and ceftazidime, 1 and 512 microg/ml.","Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722486/),[μg] / [ml],1,228743,DB01597,Cilastatin
,10722486,MICs,"The MICs of the beta-lactams with an inoculum of 5 log(10) CFU/ml were as follows for E. cloacae NOR-1 and its ceftazidime-resistant mutant, respectively: imipenem, 16 and 128 microg/ml, meropenem, 4 and 32 microg/ml, cefepime, <0.03 and 1 microg/ml, and ceftazidime, 1 and 512 microg/ml.","Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722486/),[μg] / [ml],512,228744,DB01597,Cilastatin
,2393278,Elimination half-life,"Elimination half-life, steady-state volume of distribution, and body clearance averaged 2.5 h, 0.5 liter/kg, and 2.5 ml/min per kg, respectively, for imipenem and 9.1 h, 0.4 liter/kg, and 0.5 ml/min per kg, respectively, for cilastatin.",Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393278/),h,2.5,232900,DB01597,Cilastatin
,2393278,steady-state volume of distribution,"Elimination half-life, steady-state volume of distribution, and body clearance averaged 2.5 h, 0.5 liter/kg, and 2.5 ml/min per kg, respectively, for imipenem and 9.1 h, 0.4 liter/kg, and 0.5 ml/min per kg, respectively, for cilastatin.",Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393278/),[l] / [kg],0.5,232901,DB01597,Cilastatin
,2393278,body clearance,"Elimination half-life, steady-state volume of distribution, and body clearance averaged 2.5 h, 0.5 liter/kg, and 2.5 ml/min per kg, respectively, for imipenem and 9.1 h, 0.4 liter/kg, and 0.5 ml/min per kg, respectively, for cilastatin.",Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393278/),[ml] / [kg·min],2.5,232902,DB01597,Cilastatin
,2393278,body clearance,"Elimination half-life, steady-state volume of distribution, and body clearance averaged 2.5 h, 0.5 liter/kg, and 2.5 ml/min per kg, respectively, for imipenem and 9.1 h, 0.4 liter/kg, and 0.5 ml/min per kg, respectively, for cilastatin.",Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393278/),[l] / [kg],0.4,232903,DB01597,Cilastatin
,2393278,body clearance,"Elimination half-life, steady-state volume of distribution, and body clearance averaged 2.5 h, 0.5 liter/kg, and 2.5 ml/min per kg, respectively, for imipenem and 9.1 h, 0.4 liter/kg, and 0.5 ml/min per kg, respectively, for cilastatin.",Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393278/),[ml] / [kg·min],0.5,232904,DB01597,Cilastatin
,2393278,renal clearances,"Corresponding renal clearances averaged 0.4 and 0.2 ml/min per kg for imipenem and cilastatin, respectively.",Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393278/),[ml] / [kg·min],0.4,232905,DB01597,Cilastatin
,2393278,renal clearances,"Corresponding renal clearances averaged 0.4 and 0.2 ml/min per kg for imipenem and cilastatin, respectively.",Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393278/),[ml] / [kg·min],0.2,232906,DB01597,Cilastatin
,3464775,Clinical,Clinical cure rate was 93% and bacteriological efficacy rate was 88%.,[Clinical evaluation of imipenem/cilastatin sodium in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464775/),%,93,233749,DB01597,Cilastatin
,3464775,serum half-life,The serum half-life of MK-0787 was 0.892 hour in children with normal renal functions.,[Clinical evaluation of imipenem/cilastatin sodium in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464775/),h,0.892,233750,DB01597,Cilastatin
,3463803,Plasma concentrations,"Plasma concentrations of MK-0787 in antecubital vein and uterine artery were 18.2 micrograms/ml and 16.4 micrograms/ml, respectively, and of MK-0791 were 9.5 micrograms/ml and 10.3 micrograms/ml, respectively, at 1.28 hours after the end of a drip infusion of 0.5 g/0.5 g of MK-0787/MK-0791.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463803/),[μg] / [ml],18.2,235620,DB01597,Cilastatin
,3463803,Plasma concentrations,"Plasma concentrations of MK-0787 in antecubital vein and uterine artery were 18.2 micrograms/ml and 16.4 micrograms/ml, respectively, and of MK-0791 were 9.5 micrograms/ml and 10.3 micrograms/ml, respectively, at 1.28 hours after the end of a drip infusion of 0.5 g/0.5 g of MK-0787/MK-0791.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463803/),[μg] / [ml],16.4,235621,DB01597,Cilastatin
,3463803,Plasma concentrations,"Plasma concentrations of MK-0787 in antecubital vein and uterine artery were 18.2 micrograms/ml and 16.4 micrograms/ml, respectively, and of MK-0791 were 9.5 micrograms/ml and 10.3 micrograms/ml, respectively, at 1.28 hours after the end of a drip infusion of 0.5 g/0.5 g of MK-0787/MK-0791.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463803/),[μg] / [ml],9.5,235622,DB01597,Cilastatin
,3463803,Plasma concentrations,"Plasma concentrations of MK-0787 in antecubital vein and uterine artery were 18.2 micrograms/ml and 16.4 micrograms/ml, respectively, and of MK-0791 were 9.5 micrograms/ml and 10.3 micrograms/ml, respectively, at 1.28 hours after the end of a drip infusion of 0.5 g/0.5 g of MK-0787/MK-0791.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463803/),[μg] / [ml],10.3,235623,DB01597,Cilastatin
,2664254,Plasma,"1. Plasma concentrations of IPM and CS after 30-minute infusion of the drug reached their peaks at the end of administration, and obtained values were 22.4 to 29.0 micrograms/ml for IPM and 26.3 to 34.6 micrograms/ml for CS, thus peak plasma levels of CS were a little higher than IPM.",[Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2664254/),[μg] / [ml],22.4 to 29.0,242937,DB01597,Cilastatin
,2664254,Plasma,"1. Plasma concentrations of IPM and CS after 30-minute infusion of the drug reached their peaks at the end of administration, and obtained values were 22.4 to 29.0 micrograms/ml for IPM and 26.3 to 34.6 micrograms/ml for CS, thus peak plasma levels of CS were a little higher than IPM.",[Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2664254/),[μg] / [ml],26.3 to 34.6,242938,DB01597,Cilastatin
,2664254,Plasma half-lives,"Plasma half-lives of IPM were 1.05 to 2.43 hours, and those of CS were 1.24 to 4.76 hours, and the half-life of CS tended to be longer than that of IPM.",[Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2664254/),h,1.05 to 2.43,242939,DB01597,Cilastatin
,2664254,Plasma half-lives,"Plasma half-lives of IPM were 1.05 to 2.43 hours, and those of CS were 1.24 to 4.76 hours, and the half-life of CS tended to be longer than that of IPM.",[Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2664254/),h,1.24 to 4.76,242940,DB01597,Cilastatin
,2664254,Plasma half-lives,"Plasma half-lives of IPM were 1.40 to 1.63 hours, whereas those of CS were 1.51 to 2.90 hours.",[Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2664254/),h,1.40 to 1.63,242941,DB01597,Cilastatin
,2664254,Plasma half-lives,"Plasma half-lives of IPM were 1.40 to 1.63 hours, whereas those of CS were 1.51 to 2.90 hours.",[Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2664254/),h,1.51 to 2.90,242942,DB01597,Cilastatin
,9410067,apparent Vd,"Similar to other beta-lactamic drugs, it is mainly distributed in the extravascular space (apparent Vd, 21 I) with an half life of elimination of approximately one hour.",[Meropenem: pharmacologic advantages of clinical interest]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9410067/),i,21,247965,DB01597,Cilastatin
,9410067,half life of elimination,"Similar to other beta-lactamic drugs, it is mainly distributed in the extravascular space (apparent Vd, 21 I) with an half life of elimination of approximately one hour.",[Meropenem: pharmacologic advantages of clinical interest]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9410067/),h,one,247966,DB01597,Cilastatin
,9410067,(AUICo infinity),Administered at a doses of 1 g/8 hours meropenem presented a value of (AUICo infinity) 60-90 micrograms/h/ml.,[Meropenem: pharmacologic advantages of clinical interest]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9410067/),[μg] / [h·ml],60-90,247967,DB01597,Cilastatin
,9410067,(AUIC)24,The (AUIC)24 = 125 ensures that the serum concentrations are maintained above 3 micrograms/ml during a period greater than 80% of the dosage interval.,[Meropenem: pharmacologic advantages of clinical interest]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9410067/),,125,247968,DB01597,Cilastatin
,1854179,peak,"Mean peak and trough plasma imipenem concentrations were 5.28 +/- 1.78 and 1.43 +/- 0.76 micrograms/ml in group I, 6.25 +/- 0.78 and 2.50 +/- 0.00 micrograms/ml in group II, and 14.3 +/- 0.71 and 6.85 +/- 1.06 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],5.28,251284,DB01597,Cilastatin
,1854179,peak,"Mean peak and trough plasma imipenem concentrations were 5.28 +/- 1.78 and 1.43 +/- 0.76 micrograms/ml in group I, 6.25 +/- 0.78 and 2.50 +/- 0.00 micrograms/ml in group II, and 14.3 +/- 0.71 and 6.85 +/- 1.06 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],6.25,251285,DB01597,Cilastatin
,1854179,trough plasma imipenem concentrations,"Mean peak and trough plasma imipenem concentrations were 5.28 +/- 1.78 and 1.43 +/- 0.76 micrograms/ml in group I, 6.25 +/- 0.78 and 2.50 +/- 0.00 micrograms/ml in group II, and 14.3 +/- 0.71 and 6.85 +/- 1.06 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],1.43,251286,DB01597,Cilastatin
,1854179,trough plasma imipenem concentrations,"Mean peak and trough plasma imipenem concentrations were 5.28 +/- 1.78 and 1.43 +/- 0.76 micrograms/ml in group I, 6.25 +/- 0.78 and 2.50 +/- 0.00 micrograms/ml in group II, and 14.3 +/- 0.71 and 6.85 +/- 1.06 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],14.3,251287,DB01597,Cilastatin
,1854179,trough plasma imipenem concentrations,"Mean peak and trough plasma imipenem concentrations were 5.28 +/- 1.78 and 1.43 +/- 0.76 micrograms/ml in group I, 6.25 +/- 0.78 and 2.50 +/- 0.00 micrograms/ml in group II, and 14.3 +/- 0.71 and 6.85 +/- 1.06 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],6.85,251288,DB01597,Cilastatin
,1854179,peak,"Mean peak and trough plasma cilastatin concentrations were 11.8 +/- 2.85 and 0.31 +/- 0.43 microgram/ml in group I, 15.5 +/- 2.48 and 2.03 +/- 2.05 micrograms/ml in group II, and 24.5 +/- 6.72 and 10.7 +/- 5.94 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],11.8,251289,DB01597,Cilastatin
,1854179,peak,"Mean peak and trough plasma cilastatin concentrations were 11.8 +/- 2.85 and 0.31 +/- 0.43 microgram/ml in group I, 15.5 +/- 2.48 and 2.03 +/- 2.05 micrograms/ml in group II, and 24.5 +/- 6.72 and 10.7 +/- 5.94 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],15.5,251290,DB01597,Cilastatin
,1854179,trough plasma cilastatin concentrations,"Mean peak and trough plasma cilastatin concentrations were 11.8 +/- 2.85 and 0.31 +/- 0.43 microgram/ml in group I, 15.5 +/- 2.48 and 2.03 +/- 2.05 micrograms/ml in group II, and 24.5 +/- 6.72 and 10.7 +/- 5.94 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],0.31,251291,DB01597,Cilastatin
,1854179,trough plasma cilastatin concentrations,"Mean peak and trough plasma cilastatin concentrations were 11.8 +/- 2.85 and 0.31 +/- 0.43 microgram/ml in group I, 15.5 +/- 2.48 and 2.03 +/- 2.05 micrograms/ml in group II, and 24.5 +/- 6.72 and 10.7 +/- 5.94 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],24.5,251292,DB01597,Cilastatin
,1854179,trough plasma cilastatin concentrations,"Mean peak and trough plasma cilastatin concentrations were 11.8 +/- 2.85 and 0.31 +/- 0.43 microgram/ml in group I, 15.5 +/- 2.48 and 2.03 +/- 2.05 micrograms/ml in group II, and 24.5 +/- 6.72 and 10.7 +/- 5.94 micrograms/ml in group III, respectively.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[μg] / [ml],10.7,251293,DB01597,Cilastatin
,1854179,AUCss (area under the concentration-time curve over a dosage interval at steady state),"Mean imipenem AUCss (area under the concentration-time curve over a dosage interval at steady state) values were 38.7 +/- 7.9 micrograms.h/ml for group I, 52.3 +/- 7.3 micrograms.h/ml for group II, and 143.7 +/- 11.9 micrograms.h/ml for group III.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[h·μg] / [ml],38.7,251294,DB01597,Cilastatin
,1854179,AUCss (area under the concentration-time curve over a dosage interval at steady state),"Mean imipenem AUCss (area under the concentration-time curve over a dosage interval at steady state) values were 38.7 +/- 7.9 micrograms.h/ml for group I, 52.3 +/- 7.3 micrograms.h/ml for group II, and 143.7 +/- 11.9 micrograms.h/ml for group III.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[h·μg] / [ml],52.3,251295,DB01597,Cilastatin
,1854179,AUCss (area under the concentration-time curve over a dosage interval at steady state),"Mean imipenem AUCss (area under the concentration-time curve over a dosage interval at steady state) values were 38.7 +/- 7.9 micrograms.h/ml for group I, 52.3 +/- 7.3 micrograms.h/ml for group II, and 143.7 +/- 11.9 micrograms.h/ml for group III.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[h·μg] / [ml],143.7,251296,DB01597,Cilastatin
,1854179,AUCss,"Mean cilastatin AUCss values were 45.6 +/- 12.5 micrograms.h/ml for group I, 93.8 +/- 51.2 micrograms.h/ml for group II, and 217.5 +/- 57.8 micrograms.h/ml for group III.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[h·μg] / [ml],45.6,251297,DB01597,Cilastatin
,1854179,AUCss,"Mean cilastatin AUCss values were 45.6 +/- 12.5 micrograms.h/ml for group I, 93.8 +/- 51.2 micrograms.h/ml for group II, and 217.5 +/- 57.8 micrograms.h/ml for group III.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[h·μg] / [ml],93.8,251298,DB01597,Cilastatin
,1854179,AUCss,"Mean cilastatin AUCss values were 45.6 +/- 12.5 micrograms.h/ml for group I, 93.8 +/- 51.2 micrograms.h/ml for group II, and 217.5 +/- 57.8 micrograms.h/ml for group III.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[h·μg] / [ml],217.5,251299,DB01597,Cilastatin
,1854179,apparent body clearance,"Cilastatin mean apparent body clearance values (normalized to weight) were 2.78 +/- 0.67 ml/min for group I, 1.43 +/- 0.81 ml/min for group II, and 0.71 +/- 0.24 ml/min for group III.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[ml] / [min],2.78,251300,DB01597,Cilastatin
,1854179,apparent body clearance,"Cilastatin mean apparent body clearance values (normalized to weight) were 2.78 +/- 0.67 ml/min for group I, 1.43 +/- 0.81 ml/min for group II, and 0.71 +/- 0.24 ml/min for group III.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[ml] / [min],1.43,251301,DB01597,Cilastatin
,1854179,apparent body clearance,"Cilastatin mean apparent body clearance values (normalized to weight) were 2.78 +/- 0.67 ml/min for group I, 1.43 +/- 0.81 ml/min for group II, and 0.71 +/- 0.24 ml/min for group III.",Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854179/),[ml] / [min],0.71,251302,DB01597,Cilastatin
,3459389,peak concentrations,Mean peak concentrations in serum were 34.9 +/- 4.0 micrograms/ml for the 1-g dose and 26.6 +/- 2.5 micrograms/ml for the 500-mg dose.,Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459389/),[μg] / [ml],34.9,251527,DB01597,Cilastatin
,3459389,peak concentrations,Mean peak concentrations in serum were 34.9 +/- 4.0 micrograms/ml for the 1-g dose and 26.6 +/- 2.5 micrograms/ml for the 500-mg dose.,Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459389/),[μg] / [ml],26.6,251528,DB01597,Cilastatin
,3459389,Trough levels,"Trough levels were 3.1 and 1.0 micrograms/ml, respectively.",Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459389/),[μg] / [ml],3.1,251529,DB01597,Cilastatin
,3459389,Trough levels,"Trough levels were 3.1 and 1.0 micrograms/ml, respectively.",Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459389/),[μg] / [ml],1.0,251530,DB01597,Cilastatin
,3459389,serum half-life,"The mean serum half-life was 82.0 +/- 25.3 min, with a range of 50 to 138 min.",Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459389/),min,82.0,251531,DB01597,Cilastatin
,3459389,apparent volume of distribution,"The apparent volume of distribution was 0.35 +/- 0.13 liter/kg, and the mean total body clearance was 0.183 +/- 0.067 liter/kg per h.",Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459389/),[l] / [kg],0.35,251532,DB01597,Cilastatin
,3459389,total body clearance,"The apparent volume of distribution was 0.35 +/- 0.13 liter/kg, and the mean total body clearance was 0.183 +/- 0.067 liter/kg per h.",Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459389/),[l] / [h·kg],0.183,251533,DB01597,Cilastatin
,3459389,urinary recovery,"The mean urinary recovery was 39.1 +/- 12.8% (range, 15.0 to 59.2%) and did not correlate with creatinine clearance until it was below 15 ml/min.",Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459389/),%,39.1,251534,DB01597,Cilastatin
,15160299,T > MIC,"The values of T > MIC predictive of clinical efficacy against P. aeruginosa infection varied among antimicrobials and were >/=17%, >/=17%, >/=23%, and >/=33% for BIPM, IPM/CS, MEPM, and CAZ, respectively.",Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160299/),%,17,252703,DB01597,Cilastatin
>,15160299,T > MIC,"The values of T > MIC predictive of clinical efficacy against P. aeruginosa infection varied among antimicrobials and were >/=17%, >/=17%, >/=23%, and >/=33% for BIPM, IPM/CS, MEPM, and CAZ, respectively.",Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160299/),%,17,252704,DB01597,Cilastatin
>,15160299,T > MIC,"The values of T > MIC predictive of clinical efficacy against P. aeruginosa infection varied among antimicrobials and were >/=17%, >/=17%, >/=23%, and >/=33% for BIPM, IPM/CS, MEPM, and CAZ, respectively.",Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160299/),%,23,252705,DB01597,Cilastatin
,15160299,T > MIC,"The values of T > MIC predictive of clinical efficacy against P. aeruginosa infection varied among antimicrobials and were >/=17%, >/=17%, >/=23%, and >/=33% for BIPM, IPM/CS, MEPM, and CAZ, respectively.",Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160299/),%,33,252706,DB01597,Cilastatin
<,15160299,MIC,"From these values and the known plasma concentrations of the antimicrobials in humans after administration at the common clinical doses, the MIC for bacterial strains at which clinical efficacy can be expected was estimated to be </=4.4 microg/ml for BIPM, </=6.1 microg/ml for IPM/CS, </=2.2 microg/ml for MEPM, and </=13.6 microg/ml for CAZ.",Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160299/),[μg] / [ml],4.4,252707,DB01597,Cilastatin
<,15160299,MIC,"From these values and the known plasma concentrations of the antimicrobials in humans after administration at the common clinical doses, the MIC for bacterial strains at which clinical efficacy can be expected was estimated to be </=4.4 microg/ml for BIPM, </=6.1 microg/ml for IPM/CS, </=2.2 microg/ml for MEPM, and </=13.6 microg/ml for CAZ.",Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160299/),[μg] / [ml],6.1,252708,DB01597,Cilastatin
<,15160299,MIC,"From these values and the known plasma concentrations of the antimicrobials in humans after administration at the common clinical doses, the MIC for bacterial strains at which clinical efficacy can be expected was estimated to be </=4.4 microg/ml for BIPM, </=6.1 microg/ml for IPM/CS, </=2.2 microg/ml for MEPM, and </=13.6 microg/ml for CAZ.",Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160299/),[μg] / [ml],2.2,252709,DB01597,Cilastatin
<,15160299,MIC,"From these values and the known plasma concentrations of the antimicrobials in humans after administration at the common clinical doses, the MIC for bacterial strains at which clinical efficacy can be expected was estimated to be </=4.4 microg/ml for BIPM, </=6.1 microg/ml for IPM/CS, </=2.2 microg/ml for MEPM, and </=13.6 microg/ml for CAZ.",Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160299/),[μg] / [ml],13.6,252710,DB01597,Cilastatin
,2338416,peak plasma concentrations,Intravenously administered FCE 22101 at a dose of 250 mg gave peak plasma concentrations of about 12 mg/l and the plasma half-life was about 60 min.,"Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338416/),[mg] / [l],12,253731,DB01597,Cilastatin
,2338416,plasma half-life,Intravenously administered FCE 22101 at a dose of 250 mg gave peak plasma concentrations of about 12 mg/l and the plasma half-life was about 60 min.,"Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338416/),min,60,253732,DB01597,Cilastatin
,2338416,peak concentrations,"When FCE 22891 was given orally at a dose of 500 mg (corresponding to 400 mg of FCE 22101 free acid), peak concentrations of 2.2 to 6.1 mg/l were found.","Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338416/),[mg] / [l],2.2 to 6.1,253733,DB01597,Cilastatin
,1971581,pulmonary extraction,The pulmonary extraction was evaluated to be 0.033 by comparing the AUCs resulting from iv and intra-arterial administration of 10 mg/kg.,"Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971581/),,0.033,254085,DB01597,Cilastatin
,1971581,extraction ratios,"From the arterial-to-venous concentration differences under steady state conditions in rats, extraction ratios of SUN5555 across the kidney, hind leg, gut, and liver were determined to be 0.333, 0.104, 0.071 and 0.053, respectively, whereas no appreciable extraction across the brain was observed.","Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971581/),,0.333,254086,DB01597,Cilastatin
,1971581,extraction ratios,"From the arterial-to-venous concentration differences under steady state conditions in rats, extraction ratios of SUN5555 across the kidney, hind leg, gut, and liver were determined to be 0.333, 0.104, 0.071 and 0.053, respectively, whereas no appreciable extraction across the brain was observed.","Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971581/),,0.104,254087,DB01597,Cilastatin
,1971581,extraction ratios,"From the arterial-to-venous concentration differences under steady state conditions in rats, extraction ratios of SUN5555 across the kidney, hind leg, gut, and liver were determined to be 0.333, 0.104, 0.071 and 0.053, respectively, whereas no appreciable extraction across the brain was observed.","Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971581/),,0.071,254088,DB01597,Cilastatin
,1971581,extraction ratios,"From the arterial-to-venous concentration differences under steady state conditions in rats, extraction ratios of SUN5555 across the kidney, hind leg, gut, and liver were determined to be 0.333, 0.104, 0.071 and 0.053, respectively, whereas no appreciable extraction across the brain was observed.","Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971581/),,0.053,254089,DB01597,Cilastatin
,3210301,peak plasma concentrations,"1. Plasma concentrations and urinary recovery rates (1) The 1-hour intravenous drip infusion at 10 mg/10 mg/kg of IPM/CS IPM: Its peak plasma concentrations were obtained at the end of drip infusion of the test drug in all 3 groups, their values ranged from 18.18 to 19.90 micrograms/ml with no statistically significant variations.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),[μg] / [ml],18.18 to 19.90,258409,DB01597,Cilastatin
,3210301,half-lives,"The half-lives tended to be shorter in older neonates, with mean half-lives being 1.87, 1.55 and 1.40 hours, respectively.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),h,1.87,258410,DB01597,Cilastatin
,3210301,half-lives,"The half-lives tended to be shorter in older neonates, with mean half-lives being 1.87, 1.55 and 1.40 hours, respectively.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),h,1.55,258411,DB01597,Cilastatin
,3210301,half-lives,"The half-lives tended to be shorter in older neonates, with mean half-lives being 1.87, 1.55 and 1.40 hours, respectively.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),h,1.40,258412,DB01597,Cilastatin
,3210301,peak plasma concentrations,CS: Its peak plasma concentrations were obtained for all 3 groups at the end of drip infusion and were ranging from 28.23 to 30.00 micrograms/ml with no significant variations.,[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),[μg] / [ml],28.23 to 30.00,258413,DB01597,Cilastatin
,3210301,Plasma concentrations,"Plasma concentrations in the 0-3 day-age group and the 4-7 day-age group slowly decreased to 6.30 micrograms/ml and 4.58 micrograms/ml at 8 hours after administration of IPM/CS, respectively.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),,6.30,258414,DB01597,Cilastatin
,3210301,Plasma concentrations,"Plasma concentrations in the 0-3 day-age group and the 4-7 day-age group slowly decreased to 6.30 micrograms/ml and 4.58 micrograms/ml at 8 hours after administration of IPM/CS, respectively.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),,4.58,258415,DB01597,Cilastatin
,3210301,Half-lives,"Half-lives were 4.10 hours and 3.08 hours, respectively.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),h,4.10,258416,DB01597,Cilastatin
,3210301,Half-lives,"Half-lives were 4.10 hours and 3.08 hours, respectively.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),h,3.08,258417,DB01597,Cilastatin
,3210301,half-life,"On the other hand, those of the 8-day or older group rapidly decreased to below the detection limit in 8 hours after administration with a half-life of 1.6 hours.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),h,1.6,258418,DB01597,Cilastatin
,3210301,Peak plasma concentrations,(2) The 1-hour intravenous drip infusion at 20 mg/20 mg/kg of IPM/CS IPM: Peak plasma concentrations were obtained in all 3 groups at the end of drip infusion and were ranging from 31.1 to 38.24 micrograms/ml.,[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),[μg] / [ml],31.1 to 38.24,258419,DB01597,Cilastatin
,3210301,Plasma concentrations,"Plasma concentrations rapidly decreased, and were 0.95-2.08 micrograms/ml at 8 hours after administration with half-lives of 1.5-1.88 hours.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),[μg] / [ml],0.95-2.08,258420,DB01597,Cilastatin
,3210301,half-lives,"Plasma concentrations rapidly decreased, and were 0.95-2.08 micrograms/ml at 8 hours after administration with half-lives of 1.5-1.88 hours.",[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),h,1.5-1.88,258421,DB01597,Cilastatin
,3210301,Peak plasma concentrations,CS: Peak plasma concentrations were obtained in all 3 groups at the end of drip infusion and were ranging from 47.0 to 55.82 micrograms/ml.(ABSTRACT TRUNCATED AT 400 WORDS),[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210301/),[μg] / [ml],47.0 to 55.82,258422,DB01597,Cilastatin
,6594492,t1/2 lambda 1,The distribution phase was rapid (t1/2 lambda 1 = 0.18 hours) and was followed by a monoexponential elimination phase (t1/2 lambda 2 = 1.2 hours).,Single-dose pharmacokinetics of imipenem in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594492/),h,0.18,266772,DB01597,Cilastatin
,6594492,t1/2 lambda 2,The distribution phase was rapid (t1/2 lambda 1 = 0.18 hours) and was followed by a monoexponential elimination phase (t1/2 lambda 2 = 1.2 hours).,Single-dose pharmacokinetics of imipenem in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594492/),h,1.2,266773,DB01597,Cilastatin
,6594492,apparent volume of distribution,The calculated value for the apparent volume of distribution (0.66 L/kg) was similar to that of total body water.,Single-dose pharmacokinetics of imipenem in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594492/),[l] / [kg],0.66,266774,DB01597,Cilastatin
,6594492,total plasma clearance,The total plasma clearance was rapid (0.36 L/hr/kg).,Single-dose pharmacokinetics of imipenem in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6594492/),[l] / [h·kg],0.36,266775,DB01597,Cilastatin
,21177674,MICs,"MICs of imipenem, meropenem, ertapenem and aztreonam for the infecting isolate were 1, ≤0.25, 1.5 and ≤0.25 mg/L, respectively.",Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177674/),[mg] / [l],1,267584,DB01597,Cilastatin
≤,21177674,MICs,"MICs of imipenem, meropenem, ertapenem and aztreonam for the infecting isolate were 1, ≤0.25, 1.5 and ≤0.25 mg/L, respectively.",Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177674/),[mg] / [l],0.25,267585,DB01597,Cilastatin
,21177674,MICs,"MICs of imipenem, meropenem, ertapenem and aztreonam for the infecting isolate were 1, ≤0.25, 1.5 and ≤0.25 mg/L, respectively.",Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177674/),[mg] / [l],1.5,267586,DB01597,Cilastatin
less,3464778,peak MIC,"The peak MIC of MK-0787 was less than or equal to 0.024 micrograms/ml against S. aureus, which were sensitive or resistant to CEZ, 0.10 micrograms/ml against E. coli, P. mirabilis, or K. pneumoniae, 0.39 micrograms/ml against S. marcescens and 1.56 micrograms/ml against P. aeruginosa.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],0.024,268583,DB01597,Cilastatin
,3464778,peak MIC,"The peak MIC of MK-0787 was less than or equal to 0.024 micrograms/ml against S. aureus, which were sensitive or resistant to CEZ, 0.10 micrograms/ml against E. coli, P. mirabilis, or K. pneumoniae, 0.39 micrograms/ml against S. marcescens and 1.56 micrograms/ml against P. aeruginosa.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],0.10,268584,DB01597,Cilastatin
,3464778,peak MIC,"The peak MIC of MK-0787 was less than or equal to 0.024 micrograms/ml against S. aureus, which were sensitive or resistant to CEZ, 0.10 micrograms/ml against E. coli, P. mirabilis, or K. pneumoniae, 0.39 micrograms/ml against S. marcescens and 1.56 micrograms/ml against P. aeruginosa.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],0.39,268585,DB01597,Cilastatin
,3464778,peak MIC,"The peak MIC of MK-0787 was less than or equal to 0.024 micrograms/ml against S. aureus, which were sensitive or resistant to CEZ, 0.10 micrograms/ml against E. coli, P. mirabilis, or K. pneumoniae, 0.39 micrograms/ml against S. marcescens and 1.56 micrograms/ml against P. aeruginosa.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],1.56,268586,DB01597,Cilastatin
,3464778,Maximum serum levels,"Maximum serum levels of MK-0787, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg were 41.6 micrograms/ml and 72.9 micrograms/ml, respectively, at the end of infusion and 0.1 micrograms/ml at 6 hours, respectively, after drip infusion.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],41.6,268587,DB01597,Cilastatin
,3464778,Maximum serum levels,"Maximum serum levels of MK-0787, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg were 41.6 micrograms/ml and 72.9 micrograms/ml, respectively, at the end of infusion and 0.1 micrograms/ml at 6 hours, respectively, after drip infusion.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],72.9,268588,DB01597,Cilastatin
,3464778,Maximum serum levels,"Maximum serum levels of MK-0787, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg were 41.6 micrograms/ml and 72.9 micrograms/ml, respectively, at the end of infusion and 0.1 micrograms/ml at 6 hours, respectively, after drip infusion.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],0.1,268589,DB01597,Cilastatin
,3464778,half-life,The half-life of both dose levels was 0.9 hour.,[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),h,0.9,268590,DB01597,Cilastatin
,3464778,peak serum levels,"Mean peak serum levels of MK-0791, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 49.7 micrograms/ml and 87.0 micrograms/ml, respectively, with half-life of 1.1 and 0.6 hour, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],49.7,268591,DB01597,Cilastatin
,3464778,peak serum levels,"Mean peak serum levels of MK-0791, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 49.7 micrograms/ml and 87.0 micrograms/ml, respectively, with half-life of 1.1 and 0.6 hour, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],87.0,268592,DB01597,Cilastatin
,3464778,half-life,"Mean peak serum levels of MK-0791, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 49.7 micrograms/ml and 87.0 micrograms/ml, respectively, with half-life of 1.1 and 0.6 hour, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),h,1.1,268593,DB01597,Cilastatin
,3464778,half-life,"Mean peak serum levels of MK-0791, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 49.7 micrograms/ml and 87.0 micrograms/ml, respectively, with half-life of 1.1 and 0.6 hour, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),h,0.6,268594,DB01597,Cilastatin
,3464778,Urinary recovery rates,"Urinary recovery rates of MK-0787 for 6 hours at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 47.8-82.7% and 25.5-78.0%, respectively, and of MK-0791 for 6 hours were 51.7-93.4% and 40.3-94.4%, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),%,47.8-82.7,268595,DB01597,Cilastatin
,3464778,Urinary recovery rates,"Urinary recovery rates of MK-0787 for 6 hours at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 47.8-82.7% and 25.5-78.0%, respectively, and of MK-0791 for 6 hours were 51.7-93.4% and 40.3-94.4%, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),%,25.5-78.0,268596,DB01597,Cilastatin
,3464778,Urinary recovery rates,"Urinary recovery rates of MK-0787 for 6 hours at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 47.8-82.7% and 25.5-78.0%, respectively, and of MK-0791 for 6 hours were 51.7-93.4% and 40.3-94.4%, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),%,51.7-93.4,268597,DB01597,Cilastatin
,3464778,Urinary recovery rates,"Urinary recovery rates of MK-0787 for 6 hours at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 47.8-82.7% and 25.5-78.0%, respectively, and of MK-0791 for 6 hours were 51.7-93.4% and 40.3-94.4%, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),%,40.3-94.4,268598,DB01597,Cilastatin
,6593092,plasma half-life,The mean plasma half-life of imipenem varied from 52 min in subjects with normal renal function to 173 min in subjects with end-stage renal failure studied while off-dialysis.,The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6593092/),min,52,271544,DB01597,Cilastatin
,6593092,plasma half-life,The mean plasma half-life of imipenem varied from 52 min in subjects with normal renal function to 173 min in subjects with end-stage renal failure studied while off-dialysis.,The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6593092/),min,173,271545,DB01597,Cilastatin
,6593092,plasma half-life,The mean plasma half-life of cilastatin varied from 54 min in normals to 798 min in patients with end-stage renal failure.,The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6593092/),min,54,271546,DB01597,Cilastatin
,6593092,plasma half-life,The mean plasma half-life of cilastatin varied from 54 min in normals to 798 min in patients with end-stage renal failure.,The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6593092/),min,798,271547,DB01597,Cilastatin
,2510062,total clearance,"While the pharmacokinetics of both drugs are almost identical in patients with normal renal function, we found the following dissociation of pharmacokinetic parameters in our patients with renal failure: for imipenem the total clearance and elimination half-life was 104 +/- 12 ml/min and 2.2 +/- 0.1 h, respectively, and for cilastatin 29 +/- 10 ml/min and 13.8 +/- 4.5 h.",Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510062/),[ml] / [min],104,273156,DB01597,Cilastatin
,2510062,elimination half-life,"While the pharmacokinetics of both drugs are almost identical in patients with normal renal function, we found the following dissociation of pharmacokinetic parameters in our patients with renal failure: for imipenem the total clearance and elimination half-life was 104 +/- 12 ml/min and 2.2 +/- 0.1 h, respectively, and for cilastatin 29 +/- 10 ml/min and 13.8 +/- 4.5 h.",Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510062/),h,2.2,273157,DB01597,Cilastatin
,2510062,elimination half-life,"While the pharmacokinetics of both drugs are almost identical in patients with normal renal function, we found the following dissociation of pharmacokinetic parameters in our patients with renal failure: for imipenem the total clearance and elimination half-life was 104 +/- 12 ml/min and 2.2 +/- 0.1 h, respectively, and for cilastatin 29 +/- 10 ml/min and 13.8 +/- 4.5 h.",Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510062/),[ml] / [min],29,273158,DB01597,Cilastatin
,2510062,elimination half-life,"While the pharmacokinetics of both drugs are almost identical in patients with normal renal function, we found the following dissociation of pharmacokinetic parameters in our patients with renal failure: for imipenem the total clearance and elimination half-life was 104 +/- 12 ml/min and 2.2 +/- 0.1 h, respectively, and for cilastatin 29 +/- 10 ml/min and 13.8 +/- 4.5 h.",Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510062/),h,13.8,273159,DB01597,Cilastatin
